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ABSTRACT	  
HIV-­‐1	   protease	   (PR)	   is	   an	   important	   enzyme	   for	   the	  maturation	   of	   infectious	   virions	   and	   has	  
been	  an	  effective	  drug	  target	  for	  HIV/AIDS	  for	  about	  two	  decades.	  PR	  inhibitors	  (PIs)	  were	  successfully	  
designed	  based	  on	  the	  structural	  data	  for	  AIDS	  therapy.	  Nonetheless,	  the	  drug	  resistant	  PR	  variants	  are	  
selected	   rapidly	   during	   therapy.	   Crystal	   structures	   of	   HIV-­‐1	   PR	   variants	   and	   their	   complexes	   with	   PIs	  
have	  been	  studied	  so	  as	  to	  discover	  the	  mechanisms	  for	  drug	  resistance	  and	  assist	  in	  design	  of	  more	  ef-­‐
fective	   drugs	   for	  AIDS	   therapy.	  Mutation	   L76V	   is	   associated	  with	   drug	   resistance	   and	   shows	  opposite	  
effects	  on	  different	  protease	   inhibitors.	  Kinetics	  and	  stability	  of	  PRL76V	   containing	  L76V	  mutation	  were	  
studied	  and	  high-­‐resolution	  X-­‐ray	  crystal	  structures	  of	  complexes	  of	  PRL76V	  with	  inhibitors,	  darunvair	  and	  
saquinavir,	  were	  solved	  at	  resolutions	  of	  1.46-­‐1.45	  Å	  to	  identify	  structural	  changes.	  HIV-­‐1	  PRP51	  variant	  is	  
a	  multiple	  mutant	  selected	  for	  resistance	  to	  darunavir	  in	  the	  laboratory	  in	  vitro	  and	  it	  is	  of	  utility	  to	  in-­‐
vestigate	  the	  mechanisms	  of	  HIV-­‐1	  resistance	  to	  darunavir.	  The	  crystal	  structures	  of	  an	  inactive	  form	  of	  
PRP51	   have	  been	  determined	   at	   1.50-­‐1.66	  Å	   resolution:	   a	   darunavir	   bound	   structure	   and	   a	   ligand	   free	  
structure.	  The	  kinetics	  and	  crystal	  structures	  of	  these	  drug	  resistant	  mutants	  provide	  the	  information	  to	  
understand	  drug	  resistance	  mechanisms	  and	  give	  hints	  for	  design	  of	  novel	  inhibitors.	  
Ca2+	   plays	   an	   important	   role	   in	   the	   regulation	   of	   numerous	   biological	   functions	   in	   the	   human	  
body	   as	   a	   ubiquitous	   signaling	   molecule.	   Calcium	   biosensor	   CatchER	   was	   designed	   by	   site-­‐directed	  
mutagenesis	  in	  the	  fluorescent	  sensitive	  location	  of	  chromophore.	  CatchER	  was	  studied	  via	  X-­‐ray	  crystal-­‐
lography	  to	  investigate	  the	  calcium	  binding	  site	  and	  mechanisms	  of	  chromophore	  response	  to	  Ca2+.	  Crys-­‐
tal	  structures	  of	  CatchER	  in	  the	  absence	  of	  Ca2+	  (apo	  form),	  complexed	  with	  Ca2+	  and	  also	  with	  Gd3+	  were	  
determined	  at	  resolutions	  of	  1.78-­‐1.20	  Å.	  Metal	  ions	  were	  identified	  in	  the	  designed	  calcium-­‐binding	  site	  
and	   structures	   showed	   the	   metal	   ion	   induced	   changes	   related	   to	   changes	   in	   optical	   properties.	   The	  
structural	  information	  can	  be	  useful	  for	  the	  optimization	  of	  the	  sensor	  and	  assist	  the	  design	  of	  protein-­‐
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1.1 Overcoming	  Drug	  Resistance	  by	  Targeting	  HIV	  Protease	  Mutants	  
1.1.1 HIV	  Life	  Cycle	  
AIDS	  is	  a	  global	  pandemic	  and	  approximately	  35.3	  million	  people	  worldwide	  are	  living	  with	  HIV	  
as	  of	  2012	  according	  to	  the	  UNAIDS	  report	  2013	  (UNAIDS,	  2013).	  It	  has	  been	  well	  established	  that	  HIV	  
(Human	   Immunodeficiency	   Virus)	   is	   the	   cause	   of	   AIDS	   (Acquired	   Immunodeficiency	   Deficiency	   Syn-­‐
drome)	   for	  about	   three	  decades	   (Gallo	   et	  al.,	  1984).	  HIV	   is	  a	  member	  of	   retrovirus	   family	   (Levy	   et	  al.,	  
1985).	   Therefore,	   its	   genetic	   information	   carrier	   is	   RNA	   that	   is	   the	   characteristic	   of	   all	   retroviruses	  
(Barre-­‐Sinoussi	  et	  al.,	  1983,	  Levy	  et	  al.,	  1985).	  Figure	  1.1	  shows	  the	  general	  construction	  of	  the	  mature	  
HIV	  virion	  and	  ribbon	  representations	  of	  known	  structures	  of	   the	  viral	  proteins	  and	  protein	   fragments	  
(Turner	  et	  al.,	  1999).	  The	  surface	  of	  virus	  is	  a	  lipid	  bilayer	  in	  which	  envelope	  proteins	  derived	  from	  the	  
membrane	  of	   its	  host	   are	  embedded	  by	   surface	  unit	   glycoprotein	   (SU).	   In	   the	  middle	  of	   the	   spherical	  
viral	  particle	   is	  a	  matrix	   shell	   composed	  by	  matrix	  protein	   (MA)	  and	  a	  capsid	  core	   that	  consists	  of	   the	  
capsid	  protein	  (CA).	   Inside	  the	  capsid	  particle	  are	  two	  copies	  of	  the	  viral	  genome	  RNA	  and	  three	  most	  
essential	  viral	  enzymes:	  protease	  (PR),	  reverse	  transcriptase	  (RT)	  and	  integrase	  (IN).	  
HIV	  life	  cycle	  is	  a	  process	  of	  viral	  infection	  and	  replication	  in	  a	  host	  cell,	  which	  involves	  four	  ma-­‐
jor	  steps:	  cell	  fusion	  and	  entry,	  reverse	  transcription	  of	  the	  viral	  RNA	  to	  DNA,	  integration	  into	  the	  host	  
cell	  DNA	  and	  maturation	  of	  virus	  (Figure	  1.2).	  Currently,	  the	  four	  key	  steps	  in	  HIV	  replication	  have	  been	  
employed	  as	  anti-­‐HIV	  drug	  targets.	  The	  virus	  fuses	  and	  enters	  the	  host	  cell	  via	  the	  recognition	  of	  the	  vi-­‐
ral	   envelope	   glycoprotein	   gp120	   and	   gp41	   by	   CD4	   receptors	   and	   other	   coreceptors	   on	   the	   host	   cells	  
(Clapham	  et	  al.,	  1997,	  Maddon	  et	  al.,	  1986,	  Moore,	  1997).	  The	  viral	  genetic	  material,	  two	  copies	  of	  sin-­‐
gle-­‐strand	  RNA,	  and	  viral	  enzymes	  are	  released	  into	  the	  cytosol	  of	  the	  host	  cell.	  The	  viral	  RNA	  is	  first	  re-­‐
2 
verse	  transcribed	  into	  pro-­‐viral	  DNA	  by	  the	  catalysis	  of	  viral	  reverse	  transcriptase	  and	  then	  the	  pro-­‐viral	  
DNA	  is	  integrated	  into	  the	  genome	  of	  the	  host	  cell	  by	  the	  catalytic	  action	  of	  integrase.	  The	  host	  cell	  pro-­‐
vides	   the	  machine	   for	   the	   viral	   genome	   to	   replicate	   and	   to	   be	   translated	   into	   accessory	   proteins	   and	  
three	  major	  polyproteins	  (Figure	  1.3):	  Env,	  Gag,	  and	  Gag-­‐pol.	  Env	  contains	  two	  exterior	  proteins	  SU	  (sur-­‐
face	  unit	  glycoprotein)	  and	  TM	  (transmembrane	  envelope).	  Then,	  viral	  RNA	  and	  proteins	  accumulate	  at	  
the	  host	  cell	  surface	  to	  form	  an	  immature	  particle.	  Mature	  protease	  is	  formed	  by	  autoprocessing	  of	  Gag-­‐
Pol	   through	   folding	  and	  dimerization	   (Louis	   et	  al.,	  1999a,	   Louis	   et	  al.,	  2000).	  Finally,	  as	  protease	  cata-­‐
lyzes	  the	  cleavage	  of	  Gag	  and	  Gag-­‐Pol	  to	  produce	  structural	  proteins	  including	  MA,	  CA	  and	  NC	  and	  func-­‐



















Figure	  1.1	  Drawing	  of	  mature	  HIV	  virion	  surrounded	  by	  ribbon	  representation	  of	  HIV	  protein	  and	  pro-­‐





















Figure	  1.3	  Composition	  of	  Gag,	  Gag-­‐Pol	  and	  Env	  polyproteins.	  MA	  is	  matrix,	  CA	  is	  capsid,	  NC	  is	  nucleo-­‐
capsid,	  TF	  is	  transframe,	  RT	  is	  reverse	  transcriptase,	  RH	  is	  RNase	  H,	  IN	  is	  integrase,	  p1	  and	  p2	  are	  spacer	  


















1.1.2 HIV	  Protease	  and	  Structures	  
HIV	  protease	   (PR)	   is	  an	  enzyme	  that	   is	   responsible	   for	  catalyzing	   the	  cleavage	  of	   two	  polypro-­‐
teins-­‐Gag	  and	  Gag-­‐pol	  into	  structural	  and	  functional	  proteins	  for	  the	  maturation	  of	  virus.	  Thus,	  PR	  is	  es-­‐
sential	   for	   production	  of	   infectious	   virus	   (Weber	   et	   al.,	   2009b).	   It	   is	   encoded	   in	   the	  5’	   end	  of	   the	  Pol	  
gene,	  expressed	  as	  part	  of	  the	  Gag-­‐Pol	  polyprotein	  produced	  from	  a	  ribosomal	  frameshift	  (Louis	  et	  al.,	  
2000)	  and	  become	  active	  through	  autoprocessing	  (LouIs	  et	  al.,	  1994).	  Protease	  inhibitors	  can	  block	  the	  
proteolytic	  activity	  of	  PR	  and	  the	  cleavage	  of	  Gag	  and	  Gag-­‐Pol	  is	  interrupted,	  resulting	  in	  failure	  of	  viral	  
replication	  (Kohl	  et	  al.,	  1988,	  Seelmeier	  et	  al.,	  1988).	  The	  three	  dimensional	  structures	  of	  HIV	  PR	  in	  the	  
absence	  and	  presence	  of	  inhibitor	  have	  been	  determined	  by	  X-­‐ray	  crystallography	  (Lapatto	  et	  al.,	  1989,	  
Vondrasek	  et	  al.,	  1997,	  Wlodawer	  et	  al.,	  1989,	  Wlodawer	  et	  al.,	  1993).	  As	  shown	  in	  Figure	  1.4,	  HIV-­‐1	  PR	  
is	  a	  homodimer	  with	  99	  amino	  acid	  residues	  in	  each	  subunit,	  and	  the	  residues	  are	  numbered	  1-­‐99	  in	  one	  
subunit	   and	  1’-­‐99’	   in	   the	  other	   subunit.	   Folding	  of	   the	   two	   subunits	   forms	   the	   active	   site	  where	   sub-­‐
strates	  bind	  and	  hydrolysis	  occurs.	  PR	  is	  a	  member	  of	  the	  aspartic	  protease	  family,	  of	  which	  the	  active	  
site	  shares	  the	  catalytic	  triad	  Asp25-­‐Thr26-­‐Gly27.	  PR	  inhibitors	  are	  designed	  to	  competitively	  bind	  in	  the	  
active	   site	   to	   inhibit	   the	  binding	  and	  cleavage	  of	  natural	   substrates.	  The	   secondary	   structures	  of	  each	  
subunit	  of	  PR	  contain	  one	  short	  α-­‐helix	  near	  the	  C	  terminus	  and	  two	  β	  sheets,	  which	  are	  connected	  by	  
turns.	  Two	  antiparallel	  β-­‐strands	  composed	  by	  residues	  44-­‐57	  from	  one	  subunit	  create	  the	  flexible	  flap.	  
Residues	  8,	  23-­‐30,	  32,	  45-­‐50,	  53,	  56,	  76,	  80-­‐82	  and	  84	  form	  the	  substrate	  binding	  site.	  PR	  residues	  1-­‐3,	  5-­‐
9,	  23-­‐27,	  29,	  47-­‐52,	  54,	  67,	  81,	  87	  and	  90-­‐99	  are	  engaged	  in	  the	  dimer	  interface	  contacts,	  including	  non-­‐
covalent	  interactions,	  hydrophobic	  packing	  of	  side	  chains	  and	  interactions.	  Additionally,	  the	  stabilization	  
of	  each	  subunit	  is	  achieved	  by	  the	  contacts	  of	  aliphatic	  residues	  in	  a	  hydrophobic	  core.	  
The	  glycine-­‐rich	  loop	  from	  residues	  44-­‐57	  is	  known	  as	  the	  flaps.	  The	  two	  flaps	  in	  the	  dimer	  exist	  
in	  the	  dynamic	  equilibrium	  of	  fully	  open,	  semi-­‐open	  and	  closed	  conformations	  as	  analyzed	  by	  NMR	  and	  
molecular	  dynamic	  simulations	  (Hornak	  et	  al.,	  2006,	  Freedberg	  et	  al.,	  2002).	  The	  fully	  open	  flaps	  allow	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the	  entry	  of	  substrate	  and	  the	  closed	  conformation	  will	  occur	  upon	  binding	  inhibitors	  or	  peptides,	  while	  
the	  semi-­‐open	  form	  is	  observed	  in	  the	  structures	  of	  unliganded	  PR	  (Nicholson	  et	  al.,	  1995,	  Freedberg	  et	  
al.,	  2002).	  Mutation	  of	  residues	  on	  the	  flaps	  has	  been	  studied	  to	  identify	  the	  role	  of	  side	  chains	  for	  PR	  
activity	  (Shao	  et	  al.,	  1997).	  Based	  on	  the	  side	  chains,	  the	  residues	  on	  the	  flaps	  can	  be	  divided	  into	  three	  
groups:	  Met46,	  Phe53	  and	  Lys55	  with	  side	  chains	  directed	  into	  solvent	  show	  tolerance	  to	  substitutions;	  
Ile47,	  Ile50,	  Ile54	  and	  Val56	  with	  side	  chains	  directed	  into	  the	  protein	  interior	  and	  tolerate	  a	  few	  conser-­‐
vative	  substitutions;	  and	  Gly48,	  Gly49,	  Gly51	  and	  Gly52	  in	  the	  Gly-­‐rich	  region	  which	  is	  sensitive	  to	  substi-­‐
tutions	   (Shao	   et	   al.,	   1997).	   Different	   degrees	   of	   separation	   of	   the	   flaps	   have	   been	   observed	   in	  many	  
structures	  of	  wild	  type	  PR	  and	  PR	  variants,	  such	  as	  apo	  wild	  type	  PR,	  PR	  variants	  MDR769,	  PR20	  and	  in	  
solution	  studies	  using	  Double	  Electron-­‐Electron	  Resonance	  (DEER)	  spectroscopy	  (Martin	  et	  al.,	  2005,	  Liu	  
et	  al.,	  2006,	  Wlodawer	  et	  al.,	  1989,	  de	  Vera	  et	  al.,	  2012,	  Spinelli	  et	  al.,	  1991,	  Lapatto	  et	  al.,	  1989,	  Navia	  
et	  al.,	  1989,	  Heaslet	  et	  al.,	  2007,	  Logsdon	  et	  al.,	  2004,	  Agniswamy	  et	  al.,	  2012).	  The	  flexibility	  of	  flaps	  to	  
undergo	   movements	   is	   critical	   for	   the	   enzyme	   to	   bind	   and	   cleave	   substrate	   and	   disruption	   of	   these	  









Figure	  1.4	  Overall	  structure	  of	  HIV-­‐1	  PR/inhibitor	  complex	  in	  cartoon	  representation.	  The	  two	  subunits	  
are	   colored	   in	  grey	  and	  cyan,	   respectively.	   Flaps	  and	  80’s	   loops	  are	   colored	   in	   red	  and	  green,	   respec-­‐
tively.	  The	  Asp25/Asp25’	  are	  shown	  as	  balls	  and	  sticks	  in	  each	  subunit.	  The	  inhibitor	  darunavir	  (DRV)	  is	  
represented	   by	   spheres	   and	   yellow	   sticks.	   The	   double-­‐sided	   arrow	   indicates	   the	   dimer	   interface.	   The	  












1.1.3 Substrate	  Specificity	  of	  HIV	  PR	  
HIV	  PR	  hydrolyzes	   the	  peptide	  bond	   in	  several	  different	  cleavage	  sites	   in	   the	  Gag	  and	  Gag-­‐Pol	  
precursors	  (Figure	  1.3).	  It	  is	  important	  that	  knowing	  the	  substrate	  specificity	  of	  HIV	  PR	  can	  assist	  in	  the	  
design	  of	  new	  anti-­‐viral	  drugs.	  Despite	  the	  symmetric	  characteristic	  of	  PR	  dimer,	  the	  substrate	  binds	  in	  
an	  asymmetric	  manner	  (Figure	  1.5).	  The	  residues	  of	  substrate	  peptide	  at	  carbonyl	  side	  of	  peptide	  bond	  
are	  defined	  as	  P1,	  P2,	  P3	  and	  P4,	  and	  P1’,	  P2’,	  P3’	  and	  P4’	  in	  the	  amino	  side.	  To	  accommodate	  P4’-­‐P4,	  
the	   residues	  of	   PR	  are	   correspondingly	  defined	  as	   forming	   subsites	   S4’-­‐S4.	   The	   substrate	   specificity	   is	  
determined	  by	  the	  shape	  and	  chemical	  structure	  of	  side	  chains	  of	  amino	  acids	  around	  the	  cleavage	  site	  
(Konvalinka	   et	   al.,	   1990,	   Tozser	   et	   al.,	   1992,	   Tozser	   et	   al.,	   1991).	   Table	   1.1	   lists	   the	   cleavage	   site	   se-­‐
quences	  on	  Gag	  and	  Gag-­‐Pol	  polyproteins	  (Louis	  et	  al.,	  2000).	  The	  sequences	  are	  quite	  diverse,	  but	  still	  
show	  some	  common	  features	  (Pettit	  et	  al.,	  1991,	  Poorman	  et	  al.,	  1991,	  Tozser	  et	  al.,	  1992,	  Louis	  et	  al.,	  
2000).	  Two	  major	  types	  of	  cleavage	  sites	  at	  P1	  were	  proposed	  for	  HIV-­‐1	  PR:	  type	  1-­‐Tyr(Phe)-­‐Pro	  at	  P1-­‐
P1’;	   type	  2-­‐hydrophobic	   residues	   (excluding	  Pro)	  at	  P1	  and	  P1’.	  Hydrophobic	  and	   small	  polar	   residues	  
typically	  occupy	  P2	  and	  P2’,	  while	  P3	  is	  glutamine	  or	  basic	  amino	  acids	  and	  P4	  is	  normally	  a	  small	  amino	  
acid.	  Enzyme	  kinetics	  studies	  using	  oligopeptides	  have	  showed	  that	  PR	  cannot	  cleave	  peptides	  with	  β-­‐
branched	  amino	  acids	  and	  Pro,	  Ser	  or	  Gly	  substituted	  in	  the	  P1	  position	  (Tozser	  et	  al.,	  1992,	  Phylip	  et	  al.,	  
1990).	  And	  also	  charged	  amino	  acids	  at	  P1	  or	  P1’	  positions	  are	  not	  preferred	  in	  substrates	  (Konvalinka	  et	  
al.,	  1990,	  Cameron	  et	  al.,	  1993).	  P3	  and	  P3’	  can	  be	  occupied	  by	  various	  residues	  while	  the	  P2’	  preference	  
is	  dependent	  on	  the	  type	  of	  amino	  acid	  at	  P1	  and	  P1’	  positions	  (Cameron	  et	  al.,	  1993,	  Konvalinka	  et	  al.,	  







Figure	  1.5	  Schematic	  diagram	  of	  a	  substrate	  (P4-­‐P3’)	  bound	  to	  HIV-­‐1	  PR	  (S4-­‐S3’)	  subsites.	  The	  scissile	  
















Table	  1.1	  Protease	  cleavage	  sites	  in	  HIV-­‐1	  Gag	  and	  Gag-­‐Pol	  polyproteins.	  (Louis	  et	  al.,	  2000)	  
Location	  of	  the	  
cleavage	  site	  
P4	   P3	   P2	   P1	   P1’	   P2’	   P3’	  
In	  Gag	   	   	   	   	   	   	   	  
MA-­‐CA	   Ser	   Gln	   Asn	   Tyr	   Pro	   Ile	   Val	  
CA-­‐p2	   Ala	   Arg	   Val	   Leu	   Ala	   Glu	   Ala	  
p2-­‐NC	   Ala	   Thr	   Ile	   Met	   Met	   Gln	   Arg	  
NC-­‐p1	   Arg	   Gln	   Ala	   Phe	   Phe	   Leu	   Gly	  
p1-­‐p6	   Pro	   Gln	   Asn	   Leu	   Leu	   Gln	   Ser	  
in	  p6	   Lys	   Glu	   Leu	   Pro	   Pro	   Leu	   Thr	  
In	  Pol	   	   	   	   	   	   	   	  
TFP-­‐p6	   Asp	   Leu	   Ala	   Phe	   Leu	   Gln	   Gly	  
p6	   Ser	   Phe	   Asn	   Phe	   Pro	   Gln	   Ile	  
PR-­‐RT	   Thr	   Leu	   Asn	   Phe	   Pro	   Ile	   Ser	  
p66-­‐p51	   Ala	   Glu	   Thr	   Phe	   Tyr	   Val	   Asp	  

















1.1.4 Catalytic	  Mechanism	  of	  HIV-­‐1	  Protease	  
As	  a	  member	  of	  the	  aspartic	  protease	  family,	  the	  HIV-­‐1	  PR	  contains	  a	  conserved	  triplet,	  Asp25-­‐
Thr26-­‐Gly27	  at	  the	  active	  site.	  The	  mutation	  of	  Asp25	  results	  in	  the	  complete	  inactivation	  of	  the	  HIV-­‐1	  
PR	  and	  thus	  the	  Asp25	  is	  a	  critical	  residue	  in	  the	  reaction	  to	  hydrolyze	  the	  peptide	  bond	  (Seelmeier	  et	  
al.,	  1988,	  Kohl	  et	  al.,	  1988).	  Although	  several	  proteolytic	  mechanisms	  have	  been	  proposed	  for	  HIV	  PR,	  
the	  detailed	  catalytic	  mechanism	  is	  still	  not	  fully	  understood.	  A	  commonly	  accepted	  basic	  mechanism	  is	  
the	   general	   acid-­‐base	  mechanism	   for	   aspartic	   PR	   in	   despite	   of	   some	  difference	   on	   details	   among	   the	  
various	  possible	  mechanisms.	  As	  shown	  in	  Figure	  1.6,	  Hyland	  proposed	  the	  mechanism	  based	  on	  solvent	  
isotope	  effects	  and	  structure	  data	  (Hyland	  et	  al.,	  1991,	  Brik	  et	  al.,	  2003).	  In	  this	  mechanism,	  the	  water	  
molecule	  is	  activated	  by	  the	  unprotonated	  Asp25’	  and	  becomes	  nucleophilic.	  Then	  the	  hydroxyl	  of	  water	  
attacks	   the	  carbonyl	  C	  of	   the	  substrate	  and	   the	  proton	  of	  one	  of	   the	  carboxylate	  O	  of	  Asp25	   is	   trans-­‐
ferred	   to	   carbonyl	   O	   of	   the	   substrate	  while	   the	   photon	   of	   water	   is	   transferred	   to	   the	   Asp25’.	   A	   diol	  
tetrahydral	   intermediate	   is	   formed	  and	  then	  the	  newly	  gained	  proton	  of	  Asp25’	   then	   is	   transferred	  to	  
the	  amide	  N	  of	   the	  substrate;	   simultaneously	   (Hyland	  et	  al.,	  1991,	  Mitra	  et	  al.,	  1996)	  or	  subsequently	  
(Okimoto	  et	  al.,	  1999)	  a	  proton	  from	  hydroxyl	  group	  of	  the	  carbonyl	  C	  donates	  to	  the	  Asp25	  (Piana	  et	  al.,	  
2002).	  Among	  those	  mechanisms,	  the	  nucleophilic	  water	   is	  critical	  and	  should	  be	   located	  between	  the	  
two	  Asp25/25’.	  However,	  crystal	  structures	  of	  HIV	  PR	  complexed	  with	  inhibitors	  reveal	  that	  there	  is	  no	  
water	  molecule	  or	  other	  atoms	  bigger	  than	  a	  proton	  at	  this	  position	  due	  to	  the	  lack	  of	  space.	  
Three	   consecutive	   steps	   in	   the	  proteolytic	   reaction	  of	  HIV-­‐1	  PR	  have	  been	   captured	   in	   crystal	  
structures	  of	  PR	  and	  other	  mutants	  (Shen	  et	  al.,	  2012,	  Kumar	  et	  al.,	  2005,	  Kovalevsky	  et	  al.,	  2007).	  Struc-­‐
tural	  analysis	   reveals	   the	  gem-­‐diol	   tetrahedral	   intermediate,	  which	  has	  also	  been	  reported	   in	  previous	  
work	  on	  other	  aspartic	  proteinases	  (Veerapandian	  et	  al.,	  1992,	  Holladay	  et	  al.,	  1985).	  Besides	  the	  agree-­‐
ment	  with	  the	  general	  features	  of	  the	  reaction	  pathway	  with	  three	  stages,	  Gly27	  was	  proposed	  to	  have	  
a	   potential	   role	   in	   recycling	   from	   the	   product	   complex	   to	   the	   ligand-­‐free	   enzyme	   (Shen	   et	   al.,	   2012).	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2012).	  Despite	  variation	  in	  details	  of	  the	  proposed	  mechanisms,	  they	  agree	  with	  involvement	  of	  the	  nu-­‐



























1.1.5 Interactions	  between	  Protease	  and	  Substrates	  or	  Inhibitors	  
The	   substrate	   binding	   site	  mainly	   consists	   of	   two characteristic	   catalytic	   triplets,	   two	   flexible	  
flaps	   and	   80’s	   loop	   (Figure	   1.4).	  When	   substrates	   or	   inhibitors	   enter	   the	   active	   site,	   the	   flaps	   are	   ex-­‐
pected	  fold	  down	  to	  bind	  substrate	  and	  exclude	  water	  molecule	  from	  the	  active	  site,	  changing	  from	  the	  
open	  conformation	  to	  the	  closed	  form	  (Figure	  1.7)	  (Louis	  et	  al.,	  2000,	  Wlodawer	  et	  al.,	  1993).	  As	  shown	  
in	  Figure	  1.8A	  and	  B,	  one	  buried	  water	  molecule	  that	  connects	  the	  ligand	  and	  Ile50/50’	  NH	  groups	  of	  the	  
flaps	   is	   conserved	   in	   most	   PR-­‐inhibitor	   complexes	   including	   substrate	   analogs	   (Harrison	   et	   al.,	   1994,	  
Gustchina	  et	  al.,	  1990).	  Mutation	  of	  catalytic	  residues	  at	  the	  active	  site	  or	  disruption	  of	  the	  dimer	  infer-­‐
face	  contacts	  of	  active	  HIV-­‐1	  protease	  monomers	  will	  lead	  to	  the	  elimination	  of	  the	  catalytic	  activity	  of	  
the	  PR	  and	  thus	  block	  the	  viral	  maturation.	  Inhibitors	  or	  substrates	  are	  recognized	  in	  the	  active	  site	  of	  PR	  
by	  different	  types	  of	  interactions	  including	  hydrogen	  bonds,	  van	  der	  Waals	  contacts	  and	  CH...O	  interac-­‐
tions	  depending	  on	  the	  shape	  and	  chemistry	  of	  the	  groups	  or	  side	  chains	  at	  each	  position	  (Figure	  1.8A	  
and	  B).	  A	  set	  of	  hydrogen	  bonds	  interactions	  is	  conserved	  between	  the	  main	  chain	  amides	  and	  carbonyl	  
oxygens	  of	  PR,	  involving	  the	  amide	  and	  carboxylate	  oxygen	  of	  Asp29,	  the	  carbonyl	  oxygen	  of	  Gly27	  and	  
the	  amide	  and	  carbonyl	  of	  Gly48	  from	  both	  subunits.	  Clinical	  drugs	  have	  smaller	  chemical	  structure	  and	  











Figure	  1.7	  PR	  structures	  with/without	  inhibitor	  (or	  substrate).	  Red	  one	  presents	  PR	  dimer	  with	  bound	  






Figure	  1.8	  Hydrogen	  bond	   interactions	  between	  PR	  and	  substrates	  or	   inhibitors.	  A.	  PR	  and	  substrate	  
analog	  p2/NC.	  B.	  PR	  and	  inhibitor	  darunavir.	  PR	  and	  ligands	  are	  in	  stick	  representation;	  water	  molecules	  




1.1.6 Structure-­‐Guided	  Design	  of	  Protease	  Inhibitors	  
Protease	   inhibitors	   (PIs)	  have	  been	  successful	   in	   treating	  HIV	   infection	   to	  provide	  HIV-­‐infected	  
individuals	  with	  a	   longer	   life	   span	  and	   improve	   the	  quality	  of	   life	   (Wlodawer	   et	  al.,	  1998).	  Currently	  9	  
FDA	   (Food	   and	   Drugs	   Administration)	   approved	   drugs	   include	   the	   PIs:	   saquinavir,	   ritonavir,	   indinavir,	  
nelfinavir,	   lopinavir,	   atazanavir,	   fosamprenavir,	   tipranavir,	   and	   darunavir	   (Figure	   1.9).	   Except	   for	   ti-­‐
pranavir,	   the	  design	  of	  all	  other	  PIs	   is	  based	  on	  mimicking	   the	  substrate	  analog	  (Roberts	  et	  al.,	  1990).	  
Structure-­‐guided	  drug	  design	  is	  one	  of	  the	  powerful	  approaches	  in	  drug	  development	  if	  molecular	  struc-­‐
tures	  of	  targets	  are	  available	  or	  predicted	  accurately.	  The	  initial	  design	  of	  anti-­‐viral	  PIs	  was	  based	  on	  X-­‐
ray	  crystal	  structures	  of	  HIV-­‐1	  PR	  complexed	  with	  non-­‐hydrolysable	  substrate	  analogs	  in	  which	  the	  pep-­‐
tide	  bond	  at	  the	  cleavage	  site	  is	  reduced	  from	  carbonyl	  to	  methylene	  or	  hydroxymethylene	  group	  (Miller	  
et	  al.,	  1989).	  Structural	  analysis	  of	  crystal	  structures	  of	  HIV-­‐1	  PR	  with	  the	  peptidic	  inhibitors	  shows	  that	  
main	   chain-­‐main	   chain	   interactions	   including	   hydrogen	   bonds	   and	   hydrophobic	   interactions	   connect	  
peptide	  inhibitor	  with	  PR	  residues	  25-­‐29	  and	  48-­‐50	  (Figure	  1.8A)	  (Gustchina	  et	  al.,	  1990,	  Tie	  et	  al.,	  2005).	  
However,	  there	  are	  several	  disadvantages	  in	  applying	  the	  substrate	  analogs	  in	  the	  clinics,	  such	  as	  large	  
size,	  difficult	  penetration	  into	  cells,	  easy	  digestion	  by	  other	  proteinases.	  Therefore,	  the	  following	  design	  
of	  new	  inhibitors	  utilizes	  smaller	  and	  less	  peptidic	  organic	  molecules.	  	  
In	  1995,	  saquinavir,	  which	  was	  designed	  based	  on	  the	  crystal	  structures	  of	  HIV-­‐1	  PR	  complexed	  
with	   substrate	   analogs,	   was	   the	   first	   PR	   inhibitor	   approved	   for	   AIDS	   therapy.	   Saquinavir	   still	   retains	  
many	  peptide-­‐like	  features,	  such	  as	  the	  peptidic	  backbone	  (Figure	  1.7)	  maintaining	  the	  hydrogen	  bonds	  
with	  main	  chain	  of	  PR	  (Tie	  et	  al.,	  2007,	  Krohn	  et	  al.,	  1991).	  The	  first	  generation	  of	  clinical	  inhibitors	  also	  
contains	  large	  hydrophobic	  groups	  to	  achieve	  high	  affinity	  for	  PR.	  Nevertheless,	  drug	  resistant	  mutations	  
that	  can	  alter	  the	  interactions	  between	  PR	  and	  inhibitors	  can	  reduce	  the	  affinity	  for	  these	  drugs	  (Tie	  et	  
al.,	  2007,	  Liu	  et	  al.,	  2005).	  Structural	  comparison	  of	  PR	  and	  its	  variants	  demonstrated	  minimal	  deviation	  
in	  the	  backbone	  atoms	  around	  the	  active	  site	  and	  some	  conserved	  residues	  that	  are	  essential	  to	  main-­‐
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tain	   the	   critical	   PR	   function	   in	   the	   viral	   replication.	   Therefore,	   this	   structural	   information	  provided	   in-­‐
sights	  into	  the	  design	  strategy	  of	  maximizing	  inhibitor	  interactions	  with	  PR	  backbones	  in	  the	  S2–S2’	  sub-­‐
sites	  and	  conserved	  residues	  in	  the	  active	  site	  for	  the	  next	  generation	  of	  inhibitor	  (Ghosh	  et	  al.,	  2012).	  
The	  second	  generation	  of	  drugs	  was	  designed	  based	  on	  Dr.	  Ghosh’s	  backbone-­‐binding	  concept	  to	  target	  
drug	  resistant	  PR	  as	  exemplified	  by	  darunavir	  (Figure	  1.7),	  which	  is	  the	  latest	  PR	  inhibitor	  approved	  by	  
FDA.	  	  Darunavir	  shows	  exceptional	  performance	  in	  cells	  infected	  with	  HIV	  bearing	  drug	  resistant	  PR	  mu-­‐
tations	  (Koh	  et	  al.,	  2003).	  A	  bis-­‐tetrahydrofuran	  (THF)	  in	  the	  P2	  group	  was	  used	  to	  introduce	  more	  non-­‐
peptide	  hydrogen	  bonds	  with	  main	  chain	  atoms	  and	  conserved	  residues	  of	  PR	  (Tie	  et	  al.,	  2004).	  Not	  only	  
was	  DRV	  bound	  in	  the	  regular	  active	  site	  with	  key	  interactions	  with	  the	  backbone	  of	  PR	  in	  wild	  type	  and	  
resistant	  PR	  mutants	  but	  a	  unique	  second	  binding	  site	  on	  one	  flap	  region	  was	  observed	  in	  high	  resolu-­‐
tion	   X-­‐ray	   structures	   which	   agreed	   with	   its	   kinetic	   study	   result	   of	   a	   “mixed-­‐type	   competitive-­‐
uncompetitive	  inhibition”	  model	  (Tie	  et	  al.,	  2004,	  Liu	  et	  al.,	  2008,	  Kovalevsky	  et	  al.,	  2008).	  Since	  darun-­‐
avir	   has	   demonstrated	   remarkable	   anti-­‐viral	   efficiency	   in	   AIDS	   therapy	   for	   combating	   HIV	   drug	   resis-­‐
tance,	   further	  design	  based	  on	   the	  backbone	  scaffold	  of	  DRV	  provided	  a	   series	  of	  new	   inhibitors.	  The	  
design	  of	  new	  inhibitors	  varies	  the	  chemical	  groups	  at	  P2,	  P1’	  and	  P2’,	  most	  of	  which	  exhibit	  inhibition	  of	  
PR	   in	  picomolar	  enhanced	   interaction	  with	   the	  conserved	   residues	   (Ghosh	   et	  al.,	  2012).	  However,	   the	  
persistent	  emergence	  of	  drug	   resistance	  viral	   strains	  necessitates	   the	  design	  of	  another	  generation	  of	  
inhibitor	  as	  a	  long	  term	  challenge	  and	  the	  backbone-­‐binding	  strategy	  will	  be	  useful	  to	  guide	  future	  de-­‐
velopment	  of	  anti-­‐AIDS	  agents.	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1.1.7 Drug	  Resistance	  for	  Protease	  Inhibitors	  in	  AIDS	  Therapy	  	  
However,	   the	  most	   severe	   concern	   in	  AIDS	   therapy	   is	   the	   emergence	  of	   drug	   resistance	   after	  
drug	  administration	  even	  when	  the	  patients	  achieve	  the	  viral	  suppression	  initially	  (Johnson	  et	  al.,	  2013).	  
The	  rapid	  development	  of	  mutations	   in	  the	  virus	   is	  caused	  by	  multiple	  factors.	  Since	  the	  genetic	   infor-­‐
mation	  carrier	  of	  virus	  is	  RNA,	  reverse	  transcriptase	  (RT)	  is	  used	  to	  produce	  DNA	  from	  viral	  RNA	  and	  RT	  
lacks	  3’-­‐5’	  exonuclease	  proofreading	   function,	   therefore	  mutations	  during	  viral	   replication	  are	   intrinsi-­‐
cally	  prone	  to	  occur.	  During	  the	  reverse	  transcription,	  roughly	  one	  base	  mutation	  is	  introduced	  in	  each	  
viral	  life	  cycle	  with	  the	  high	  error	  rate	  of	  RT	  (Preston	  et	  al.,	  1988,	  Mansky,	  1998).	  Another	  factor	  is	  the	  
high	  rate	  of	  replication	  of	  the	  virus	  with	  as	  many	  as	  109	  virus	  particles	  produced	  daily	  in	  a	  fully	  infected	  
patient	  (Ho	  et	  al.,	  1995).	  Drug	  pressure	  causes	  the	  rapid	  selection	  of	  drug	  resistant	  strains	   in	  the	  anti-­‐
viral	  therapy.	  The	  RT	  errors	  and	  rapid	  replication	  make	  selection	  of	  resistant	  variants	  faster	  in	  HIV.	  In	  the	  
presence	   of	   antiretroviral	   drugs,	   drug	   resistant	   strains	   are	   selected	   and	   replace	   the	   wild-­‐type	   virus	  
(Drake,	  1993,	  Wei	  et	  al.,	  1995).	  
Due	  to	  the	  polymorphous	  gene	  of	  HIV-­‐1	  PR	  even	  in	  the	  absence	  of	  inhibitors,	  as	  many	  as	  50	  dif-­‐
ferent	   residues	  mutate	   even	   in	   the	   absence	   of	   PIs	   and	  mutations	   of	  more	   than	   30	   different	   residues	  
have	  been	  reported	  to	  be	  associated	  with	  resistance	  to	  PIs (Figure	  1.10)	  (Johnson	  et	  al.,	  2013).	  The	  mu-­‐
tations	  in	  PR	  upon	  long	  exposure	  to	  the	  drugs	  are	  selected	  to	  confer	  drug	  resistance	  to	  PIs.	  Multiple	  mu-­‐
tations	  in	  the	  PR	  emerged	  in	  ordered,	  stepwise	  fashion	  in	  response	  to	  PIs	  (Molla	  et	  al.,	  1996).	  Single	  or	  
multiple	  mutations	  can	  cause	  multidrug	  resistance	  and	  cross-­‐resistance	  (Figure	  1.10).	  Drug	  resistant	  mu-­‐
tations	  in	  PR	  can	  change	  the	  enzyme	  properties	  like	  lowering	  catalytic	  activity	  or	  stability,	  while	  different	  
combinations	  of	   single	  mutations	   in	   PR	  or	   the	   cleavage	   sites	   of	  Gag	   and	  Gag-­‐Pol	   substrates	  were	  ob-­‐
served	   in	   the	  resistant	  clinical	   isolates	  which	  can	  compensate	   for	   the	  changes	  caused	  by	   the	   initial	  PR	  
mutations	  (Zhang	  et	  al.,	  1997,	  Cote	  et	  al.,	  2001,	  Rhee	  et	  al.,	  2003,	  Shafer	  et	  al.,	  1999).	  Drug	  therapy	  se-­‐
lects	   for	   resistant	  mutations	   that	  may	   tend	   to	   compromise	  proper	  protein	   folding,	   structural	   stability,	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and	  catalytic	  activity	  on	  various	  substrates	  (Erickson	  et	  al.,	  1996,	  Weber	  et	  al.,	  2009a).	  To	  overcome	  the	  
problem	  of	  drug	  resistance	  and	  develop	  new	  antiviral	  therapies,	   it	   is	   important	  to	  investigate	  the	  drug	  
resistance	  mechanisms.	  
Many	  crystal	  structures	  of	  drug	  resistant	  PR	  variants	  have	  been	  solved	  in	  complex	  with	  the	  cor-­‐
responding	  PIs,	  such	  as	  darunavir,	  saquinavir,	  indinavir	  and	  nelfinavir.	  Resistance	  mechanisms	  could	  de-­‐
pend	  on	  the	  specific	  type	  of	  mutations	  and	  drugs	  in	  therapy.	  Drug	  resistant	  mutations	  can	  be	  simply	  di-­‐
vided	  into	  substitutions	  in	  the	  active	  site	  (inhibitor	  binding	  site),	  the	  dimer	  interface	  and	  other	  distal	  re-­‐
gions	  of	  PR	  (Figure	  1.11):	  mutations	  at	  the	  active	  site	  can	  lead	  to	  the	  reduced	  affinity	  of	  the	  mutated	  PR	  
to	  inhibitor;	  mutations	  at	  the	  dimer	  interface	  can	  cause	  altered	  structural	  stability	  of	  PR;	  and	  mutations	  
of	  distal	  mutations	  can	  show	  a	  variety	  of	  effects	  (Weber	  et	  al.,	  2009a).	  PR	  variants	  with	  a	  single	  drug	  re-­‐
sistant	  mutation	  were	  studied	  to	  better	  understand	  the	  effect	  of	  an	   individual	  mutation	  rather	   than	  a	  
multiply	  mutated	  variant.	  Substitution	  of	  residues	  in	  the	  active	  site	  can	  diminish	  direct	  interactions	  with	  
inhibitor.	  Mutations	  of	   residues	  Leu23,	  Asp30,	  Val32,	  Met46,	   Ile47,	  Gly48,	   Ile50,	  Val82,	  and	   Ile84	   that	  
form	  interactions	  with	  substrates	  or	  inhibitors	  in	  the	  active	  site	  cavity	  have	  been	  reported	  in	  drug	  resis-­‐
tance	  (Johnson	  et	  al.,	  2013).	  The	  loss	  of	  interactions	  is	  observed	  in	  the	  crystal	  structures	  of	  PR	  variants	  
with	  PIs.	  For	  example,	  in	  the	  complex	  of	  I84V	  variant	  with	  darunavir,	  the	  mutation	  resulted	  in	  loss	  of	  two	  
van	  der	  Waals	   contacts	   between	   the	   residue	  84	   and	   the	   inhibitor	   due	   to	   reduced	   size	   of	   valine	   com-­‐
pared	   to	   isoleucine	  and	   this	  agrees	  with	   the	  Ki	  value	  of	   this	  variant	   for	  darunavir	   showing	  a	  3-­‐fold	   in-­‐
crease	  compared	  with	  the	  value	  for	  wild	  type	  PR	  (Tie	  et	  al.,	  2004).	  The	  flap	  mutation	  G48V	  differs	  from	  
many	  other	  drug	  resistant	  mutations	  due	  to	  the	  increased	  size	  of	  the	  amino	  acid	  side	  chain.	  G48V	  is	  se-­‐
lected	  by	  saquinavir	  treatment	  and	  structural	  studies	  of	  a	  double	  mutant	  bearing	  G48V/L90M	  revealed	  
the	  loss	  of	  an	  important	  hydrogen	  bond	  between	  carbonyl	  oxygen	  of	  residue	  48	  and	  the	  amide	  of	  saqui-­‐
navir	  at	  P2	  (Mahalingam	  et	  al.,	  1999).	  Mutations	  of	  residues	  Leu24,	  Ile50	  and	  Phe53	  that	  lie	  at	  the	  inter-­‐
face	  between	   the	   two	  subunits	  have	  been	  shown	   to	  affect	   the	  PR	   stability	   (Liu	   et	  al.,	   2005,	   Liu	   et	  al.,	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2008,	  Liu	  et	  al.,	  2006).	  The	  dimer	  stability	  studies	  were	  based	  on	  the	  sensitivity	  to	  urea	  and	  the	  value	  of	  
dimer	  dissociation.	  PR	  with	  the	  single	  mutation	  of	  L24I,	  I50V or	  F53L	  has	  significantly	  decreased	  stability	  
as	  assessed	  by	  urea-­‐denaturation	  and	  increased	  dimer	  dissociation	  value	  compared	  to	  wild	  type	  PR.	  Re-­‐
duced	  subunit-­‐subunit	  interactions	  appear	  in	  structures	  of	  variants	  L24I	  and	  I50V	  with	  indinavir.	  I50V	  is	  
also	  a	  mutation	  within	  the	  active	  site	  and	  PR	  with	  I50V	  has	  lost	  four	  hydrophobic	  contacts	  with	  between	  
residues	  50	  from	  the	  two	  subunits	  and	  indinavir	  compared	  with	  the	  9	  hydrophobic	  contacts	  in	  wild	  type	  
PR.	  Mutations	  at	  the	  distal	  regions	  can	  alter	  residues	  outside	  of	  the	  active	  site	  cavity	  and	  they	  occur	  at	  
the	  PR	  locations	  that	  far	  from	  inhibitors	  or	  dimer	  interface.	  Although	  they	  do	  not	  directly	  interact	  with	  
inhibitors,	  the	  mutated	  side	  chains	  perturb	  interactions	  in	  the	  PR	  dimer	  through	  an	  extended	  structural	  
network	  and	  can	   indirectly	   interfere	  with	  the	  binding	  of	  the	   inhibitor.	  The	  distal	  mutations	  of	   I54M/V,	  
L90M,	  and	  G73S	  have	  shown	  diverse	  effects	  to	  contribute	  to	  the	  drug	  resistance:	  mutation	  of	  residue	  54	  
induces	  changes	   in	   residues	  80-­‐82	   (the	  80’s	   loop)	   that	   interact	  with	   inhibitors	   (Liu	   et	  al.,	  2008);	   L90M	  
perturbs	   the	   catalytic	   triplet	   (Asp25-­‐Thr26-­‐Gly27)	   and	   further	   alters	   the	   affinity	   for	   inhibitors	  
(Mahalingam	   et	   al.,	   2004,	   Kozisek	   et	   al.,	   2007);	   G73S	   altered	   specificity	   for	   substrate	   peptides	   and	  
caused	  the	  changes	  in	  internal	  network	  of	  hydrogen	  bonds	  (Liu	  et	  al.,	  2005).	  Based	  on	  these	  studies	  on	  
PR	  with	  single	  mutations,	  diverse	  drug	  resistance	  mechanisms	  have	  been	  proposed:	  the	  loss	  of	  interac-­‐
tions	  with	  inhibitors	  or	  peptides;	  loss	  of	  intersubunit	  contacts	  and	  stability	  (Weber	  et	  al.,	  2009a).	  	  
In	  clinical	  isolates,	  multiple	  mutations	  accumulate	  together	  in	  PR	  in	  response	  to	  PIs	  and	  combine	  
to	   contribute	   to	   drug	   resistance	   from	   all	   individual	  mutations	   (Ohtaka	   et	   al.,	   2003,	   Henderson	   et	   al.,	  
2012).A	  mutant	  protease	  PR20	  containing	  20	  substitutions	  of	  Q7K,	  L10F,	   I13V,	   I15V,	  D30N,	  V32I,	  L33F,	  
E35D,	  M36I,	  S37N,	  I47V,	  I54L,	  Q58E,	  I62V,	  L63P,	  A71V,	  I84V,	  N88D,	  L89T	  and	  L90M	  exhibits	  more	  than	  
1000-­‐fold	   reduced	   susceptibility	   compared	   to	   wild	   type	   PR	   for	   darunavir	   (DRV)	   and	   saquinavir	   (SQV)	  
(Louis	  et	  al.,	  2011a).	  Crystal	  structure	  of	  PR20	  with	  DRV	  and	  SQV	  revealed	  loss	  of	  hydrophobic	  contacts	  
between	  the	  mutant	  and	  inhibitors	  attributed	  to	  the	  mutations	  D30N,	  V32I,	  I47V,	  and	  I84V,	  which	  alter	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alter	  the	  size,	  shape	  and	  charge	  of	  the	  inhibitor	  binding	  site	  (Agniswamy	  et	  al.,	  2012).	  A	  larger	  separa-­‐
tion	  of	  3	  Å	  increase	  between	  the	  closest	  side	  chain	  atoms	  of	  residues	  47	  and	  84	  where	  the	  P2’	  of	  SQV	  
was	   bound	   expands	   the	   S2/S2’	   subsites.	   The	   open-­‐conformation	   flap	   of	   the	   unliganded	   PR20	   has	   a	  
separation	   of	   6	   Å	   between	   the	   tips	   of	   the	   two	   flaps.	   In	   another	   study,	   a	  multi	   drug	   resistant	   variant	  
MDR769	  with	  10	  mutations	  exhibits	  2000-­‐fold	  weaker	  inhibition	  by	  darunavir	  compared	  to	  wild	  type	  PR	  
in	  agreement	  with	  the	  structural	  data	  of	  an	  expanded	  active	  site	  at	  S1/S1’	  caused	  by	  V82I	  and	  I84V	  and	  
also	  at	  S3/S3’	  and	  the	  more	  separated	  flaps	  by	  ~12	  Å	  compared	  the	  number	  of	  ~4	  Å	  in	  the	  wild	  type	  en-­‐
zyme	  (Logsdon	  et	  al.,	  2004,	  Martin	  et	  al.,	  2005).	  Meanwhile,	   the	  relationship	  between	  changes	   in	   flap	  
closure	  and	  drug	  potency	   for	  PR	  variant	  MDR769	  was	   investigated	  through	  the	  solution	  method	  using	  
Double	  Electron-­‐Electron	  Resonance	  (DEER)	  spectroscopy	  (de	  Vera	  et	  al.,	  2012).	  However,	  since	  the	  inac-­‐
tivating	  catalytic	  mutation	  D25N	  was	   introduced	  to	  prevent	  self-­‐proteolysis	   in	  MDR769	  variant,	   it	  may	  
influence	  the	  expanded	  active	  site	  and	  the	  unusual	  separation	  of	  the	  flaps.	  Studies	  of	  multiple	  mutants	  
demonstrated	   that	   multiple	   mutations	   coordinate	   in	   highly	   drug	   resistant	   mutants	   like	   PR20,	   and	  
MDR769	  by	  causing	  widely	  separated	  flaps	  and	  reducing	  interactions	  with	  peptide	  or	  inhibitors	  with	  ex-­‐
panded	   inhibitor	   binding	   subsites,	   which	   is	   considered	   as	   the	   drug	   resistance	  mechanism	   of	  multiple	  
mutations,	  and	  thus	  provide	  the	  ideas	  for	  design	  of	  new	  inhibitors	  by	  adding	  interactions	  with	  flap	  resi-­‐
dues	   to	   stabilize	   the	  variable	   flaps	  or	   Introducing	   larger	  P2/P2’	  groups	   to	   fit	  better	   in	  enlarged	  S2/S2’	  
subsites	  of	  PR20.	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Figure	  1.10	  Mutations	  in	  the	  protease	  gene	  associated	  with	  resistance	  to	  protease	  inhibitors.	  (Johnson	  
et	  al.,	  2013)	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Figure	  1.11	  Sites	  of	  drug	  resistance	  mutations.	  The	  mutations	  located	  in	  the	  active	  site	  cavity	  are	  col-­‐
ored	  in	  red	  while	  the	  flap	  mutations	  are	  in	  orange	  and	  the	  mutations	  distal	  from	  the	  active	  site	  are	  indi-­‐














1.1.8 Specific	  Aims	  and	  Brief	  Results	  of	  Studying	  HIV-­‐1	  Drug	  Resistant	  Mutants	  PRL76V	  and	  
PRP51	  
The	  specific	  aims	  of	  studying	  HIV-­‐1	  drug	  resistant	  mutants	  PRL76V	  and	  PRP51	  is	  to	  investigate	  the	  
molecular	  basis	  of	  drug	  resistance	  and	  further	  assist	  in	  the	  design	  of	  new	  anti-­‐viral	  drugs	  for	  AIDS	  ther-­‐
apy.	  PRL76V	  and	  PRP51	  are	  two	  drug	  resistant	  variants	  with	  a	  single	  mutation	  and	  multiple	  mutations,	  re-­‐
spectively,	  and	  thus,	   it	   is	   important	  to	  study	  the	  effect	  of	  a	  single	  mutation	  and	  multiple	  mutations	   in	  
drug	  resistance.	  The	  L76V	  mutation	  is	  a	  drug	  resistant	  mutation	  selected,	  interestingly,	  with	  decreased	  
susceptibility	  to	  LPV,	  DRV,	  APV,	  and	  IDV	  but	  similar	  or	  increased	  susceptibility	  to	  ATV,	  NFV,	  SQV	  or	  TPV	  
(Nijhuis	   et	  al.,	   2009a,	  Mueller	   et	  al.,	   2004,	  Vermeiren	   et	  al.,	   2007,	  Tartaglia	   et	  al.,	   2009,	  Young	   et	  al.,	  
2010).	  The	  single	  L76V	  mutant	  has	  displayed	  reduced	  viral	  replication	  capacity	  severely.	  Therefore,	  in	  my	  
study	  of	  PRL76V,	  the	  stability,	  activity,	  structures	  with	  inhibitors	  of	  RPL76V,	  and	  the	  autocatalytic	  processing	  
of	  the	  precursor	  with	  the	  single	  mutation	  L76V	  were	  explored	  in	  order	  to	  study	  drug	  resistance	  mecha-­‐
nism	  of	  this	  mutation	  (Louis	  et	  al.,	  2011b).	  DRV	  and	  SQV	  are	  chosen	  to	  co-­‐crystallize	  with	  PRL76V	  due	  to	  
the	  opposite	  effects	  in	  susceptibility	  that	  L76V	  mutation	  produced.	  The	  residue	  76	  is	  located	  in	  a	  distal	  
region	  where	  the	  residues	  have	  no	  direct	  contacts	  with	  inhibitors	  or	  substrates	  (Figure	  1.11).	  Kinetic	  as-­‐
says	  of	  HIV-­‐1	  PRL76V	  revealed	  that	  PRL76V	  has	  similar	  catalytic	  activity	  as	  wild	  type	  PR.	  The	  experimental	  
result	   from	   thermal,	   urea-­‐induced	   denaturation	   and	   dimer	   dissociation	   indicate	   that	   PRL76V	   has	   lower	  
stability	  than	  wild	  type	  PR.	  Crystal	  structures	  at	  high	  resolution	  of	  PRL76V	  with	   inhibitors,	  DRV	  and	  SQV	  
show	  the	  loss	  of	  internal	  van	  der	  Waals	  contacts	  of	  Val76	  compared	  to	  Leu76	  in	  wild	  type	  PR	  within	  hy-­‐
drophobic	   core	   consistent	  with	   lower	   stability,	  which	   is	   considered	  as	  a	  unique	  molecular	  mechanism	  
due	   to	   absence	   of	   contact	  with	   inhibitor	   or	   other	   subunit.	   Analysis	   of	   crystal	   structures	   showed	   that	  
PRL76V	   has	   lost	   two	   hydrogen	   bonds	  with	  DRV	   in	   agreement	  with	   lower	   susceptibility	   to	   DRV	   and	   im-­‐
proved	  interactions	  with	  SQV	  consistent	  with	  increased	  susceptibility	  and	  thus	  helps	  explain	  the	  oppo-­‐
site	  effect	  of	  the	  L76V	  mutation	  on	  PR	  susceptibility	  to	  DRV	  and	  SQV.	  The	  unique	  molecular	  mechanism	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for	  drug	   resistance	  provides	   the	   insights	   into	   the	  design	  of	  new	  anti-­‐viral	  drugs	   to	   combat	  drug	   resis-­‐
tance.	  L76V	  is	  also	  studied	  with	  new	  inhibitor	  GRL02031	  designed	  based	  on	  DRV	  from	  structural	  and	  in-­‐
hibition	  aspects	  (Chang	  et	  al.,	  2012).	  Furthermore,	  the	  L76V	  mutation	  produces	  a	  severe	  defect	  in	  auto-­‐
processing.	  The	  detailed	  studies	  including	  experimental	  methods	  and	  results	  on	  PRL76V	  are	  described	  in	  
Chapter	  2	  of	  this	  dissertation	  and	  (Louis	  et	  al.,	  2011b).	  
PRP51	   is	  an	  example	  of	  drug	  resistant	  mutant	  that	  contains	  multiple	  mutations	  evolving	  to	  give	  
high	  level	  resistance	  as	  generally	  happens	  when	  HIV	  replicates	  in	  the	  presence	  of	  drugs	  (Condra	  et	  al.,	  
1999).	  It	  is	  of	  utility	  to	  explore	  the	  molecular	  basis	  of	  the	  multiple	  mutations	  and	  further	  aid	  the	  design	  
of	  new	  anti-­‐viral	   drugs.	   The	  highly	  DRV-­‐resistant	  HIV-­‐1	   variant	  HIV-­‐1MIX
P51	   (viral	   population	  at	  passage	  
51)	  was	  obtained	  by	   the	  propagation	   in	   the	   laboratory	  of	  a	  mixture	  of	  8	  highly	  DRV-­‐susceptible	  HIV-­‐1	  
clinical	   isolates.	  The	  mixture	  contains	  9	   to	  14	  PI-­‐resistant	  mutations	   in	   the	  presence	  of	  DRV	  and	  repli-­‐
cated	  well	  at	  the	  concentration	  of	  5	  μM	  DRV	  (Koh	  et	  al.,	  2010).	  The	  HIV-­‐1MIX
P51	  protease	  (PRP51)	  has	  14	  
amino	  acid	  substitutions	  (Koh	  et	  al.,	  2010).	  The	  studies	  of	  physical	  and	  biochemical	  properties	  of	  PRP51	  
showed	  that	  the	  affinity	  for	  DRV	  and	  SQV	  was	  about	  7400-­‐fold	  and	  135-­‐fold	  weaker,	  respectively,	  than	  
the	  corresponding	  values	  for	  wild-­‐type	  PR.	  The	  autoprocessing	  of	  the	  TFR-­‐PRP51	  precursor	  was	  uninhibi-­‐
ted	   by	  DRV	   and	  marginally	   inhibited	   by	   SQV,	   at	   150	   μM	  PI	   concentration	   (Louis	   et	   al.,	   2011a).	   These	  
properties	  of	  PRP51	  are	  consistent	  with	  the	  high	  antiviral	   resistance	  to	  DRV	  measured	  for	  virus	  bearing	  
this	  variant	  (>300-­‐fold	  increased	  EC50)	  relative	  to	  wild	  type	  (Koh	  et	  al.,	  2010).	  In	  my	  study	  of	  PRP51,	  crys-­‐
tallographic	  study	  was	  performed	  to	  investigate	  the	  DRV-­‐bound	  PRP51	  complex	  and	  unliganded	  PRP51	  so	  
as	  to	  understand	  the	  molecular	  basis	  of	  the	  high	  resistance	  to	  DRV	  of	  this	  mutant	  and	  how	  the	  multiple	  
mutations	  influence	  the	  overall	  structure	  and	  changes	  in	  specific	  region	  of	  PRP51	  and	  further	  aid	  the	  de-­‐
sign	  of	  an	  anti-­‐viral	  drug	  to	  target	  multiple	  drug	  resistant	  mutants.	  Two	  crystal	  structures	  of	  PRP51	  bear-­‐
ing	  the	   inactivating	  mutation	  D25N	  to	  avoid	  autoproteolysis	  were	  determined:	  a	  DRV	  bound	  structure	  
and	  a	  ligand	  free	  structure.	  The	  crystal	  structure	  shows	  that	  DRV	  was	  bound	  in	  an	  unusual	  position	  com-­‐
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pared	  to	  the	  position	  of	  DRV	  in	  wild	  type	  PR	  within	  the	  active	  site	  of	  the	  protein	  parallel	  to	  dimer	  inter-­‐
face	  and	  also	  interacts	  with	  residues	  from	  two	  symmetry	  related	  dimers.	  The	  interactions	  between	  the	  
variant	  and	  DRV	  mainly	  depend	  on	  van	  der	  Waals	  interaction	  and	  fewer	  hydrogen	  bonds	  compared	  with	  
DRV	  bound	  in	  wild	  type	  PR.	  In	  both	  the	  unliganded	  PRP51	  and	  DRV	  bound	  PRP51	  structures,	  the	  flaps	  are	  
more	  separated	  from	  each	  other	  than	  seen	  in	  wild	  type	  PR.	  The	  multiple	  mutations	  effect	  the	  structural	  
changes	   in	  PRP51/DRV.	  The	  structural	   information	  suggests	   that	   the	   large	  separation	  of	   flaps	  may	  be	  a	  
common	  mechanism	  for	  resistance	  to	  PIs	  and	  the	  unique	  binding	  site	  for	  DRV	  provides	  the	  hint	  for	  de-­‐
signing	  novel	  types	  of	  antiviral	  inhibitors	  that	  capture	  the	  open,	  inactive	  conformation	  of	  the	  protease.	  

















1.2 Design	  of	  Green	  Fluorescent	  Protein	  Based	  Calcium	  Sensor	  	  
1.2.1 The	  Green	  Fluorescent	  Protein	  
The	  green	  fluorescent	  protein	  (GFP)	  is	  a	  chemiluminescent	  protein	  first	  isolated	  from	  Aequorea	  
jellyfish	   (Shimomura	   et	   al.,	   1962).	   The	   absorbance	   spectrum	   and	   fluorescence	   quantum	   yield	   of	   GFP	  
were	  measured	   and	   the	   result	   showed	   that	   aequorin	   could	   transfer	   its	   luminescence	   energy	   to	   GFP	  
(Morise	  et	  al.,	  1974).	  Chromophore	  is	  the	  luminescence	  generator	  and	  is	  centrally	  located	  in	  the	  mole-­‐
cule	   of	   GFP	   (Shimomura	   et	   al.,	   1979).	   The	   chemical	   name	   of	   the	   chromophore	   is	   4-­‐(p-­‐
hydroxybenzylidene)imidazolidin-­‐5-­‐one	  and	  the	  chemical	  structure	  is	  shown	  in	  Figure	  1.12.	  The	  fact	  that	  
the	  GFP	  gene	  can	  be	  cloned	  and	  expressed	  in	  other	  organisms	  and	  shows	  absorbance	  changes	  demon-­‐
strated	   that	   the	   posttranslational	   synthesis	   of	   the	   chromophore	   is	   not	   jellfish-­‐specific	   (Prasher	   et	   al.,	  
1992,	   Inouye	  et	  al.,	  1994).	  Aequorea	  GFP	  and	  Renilla	  GFP	  have	  been	  biochemically	  well	  characterized.	  	  
The	  differences	  are	   that	  Renilla	  GFP	  has	  a	  higher	  extinction	  coefficient,	  and	   is	  more	   likely	   to	  dimerize	  
and	   is	   more	   resistant	   to	   pH-­‐induced	   conformational	   changes	   and	   denaturation	   than	   Aequorea	   GFP	  
(Ward	  et	  al.,	  1982).	  However,	   the	  Aequorea	  GFP	  genes	  are	  the	  only	  GFP	  genes	  that	  have	  been	  cloned	  
successfully	  (Tsien,	  1998).	  
There	  are	  at	  least	  five	  currently	  known	  isoforms	  of	  the	  gene	  sequence	  of	  Aequorea	  GFP	  and	  the	  
gene	  has	  been	  introduced	  with	  altered	  codons	  or	  sequences	  so	  as	  to	  improve	  the	  translational	  initiation	  
(Tsien,	  1998).	  The	  chromophore	  is	  formed	  from	  residues	  Ser65-­‐Tyr66-­‐Gly67	  in	  the	  protein	  through	  the	  
three	  steps	  of	  folding-­‐cyclization-­‐dehydration	  in	  the	  currently	  accepted	  mechanism	  (Figure	  1.12)	  (Heim	  
et	  al.,	  1994,	  Cubitt	  et	  al.,	  1995,	  Reid	  et	  al.,	  1997).	  First,	  the	  folding	  of	  GFP	  leads	  to	  a	  nearly	  native	  con-­‐
formation,	  then	  the	  amide	  of	  Gly67	  as	  nucleophile	  attacks	  the	  carbonyl	  of	  residue	  65	  to	  form	  the	  imida-­‐
zolinone,	  followed	  by	  dehydration.	  Finally,	  the	  α-­‐β	  bond	  of	  residue	  66	  is	  dehydrogenated	  resulting	  in	  the	  
conjugation	  of	  its	  aromatic	  group	  with	  the	  imidazolinone.	  The	  three	  dimensional	  structure	  of	  GFP,	  com-­‐
posed	  of	  238	  amino	  acids,	  was	  first	  solved	  in	  1996	  independently	  by	  Ormo	  (Ormo	  et	  al.,	  1996),	  with	  PDB	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accession	  number	  1EMA,	  and	  by	  Yang	  (Yang	  et	  al.,	  1996),	  with	  PDB	  ID	  1GFL.	  The	  secondary	  structure	  of	  
GFP	  has	  11	  β-­‐strands	  that	  create	  a	  cylindrical	  beta-­‐can	  structure	  and	  one	  α-­‐helix	  running	  up	  the	  axis	  of	  
the	  cylinder.	  The	  chromophore	  is	  deeply	  buried	  in	  the	  center	  of	  the	  hydrophobic	  core	  of	  GFP.	  
Based	  on	   the	   component	   of	   the	   chromophore	  derived	   from	   residue	  66,	  GFP	   can	  be	   classified	  
into	  seven	  classes:	  class	  1,	  a	  mixture	  of	  anionic	  phenolate	  and	  neutral	  phenol;	  class	  2,	  the	  phenolate	  an-­‐
ion;	   class	   3,	   neutral	   phenol;	   class	   4,	   phenolate	   anion	  with	   stacked	   π-­‐electron	   system;	   class	   5,	   indole;	  
class	  6,	  imidazole;	  and	  class	  7,	  phenyl	  (Tsien,	  1998)	  (Figure	  1.13).	  The	  chromophore	  of	  classes	  1-­‐4	  con-­‐
tains	  Tyr	  at	  position	  66,	  while	  the	  ones	  of	  classes	  5-­‐7	  include	  Trp,	  His,	  and	  Phe	  at	  that	  position,	  respec-­‐
tively	  (Table	  1.2).	  Class	  1	  is	  the	  wild	  type	  GFP	  with	  a	  major	  excitation	  peak	  at	  395	  nm	  and	  a	  minor	  peak	  
at	  475	  nm,	  where	  the	  amplitude	  of	  the	  major	  peak	  is	  three	  times	  higher	  than	  the	  minor	  one.	  Excitation	  
at	  395	  nm	  leads	  to	  an	  emission	  maximum	  at	  508	  nm,	  whereas	  excitation	  at	  475	  nm	  gives	  a	  peak	  at	  503	  
nm	  (Heim	  et	  al.,	  1994).	  The	  generally	  accepted	  interpretation	  is	  that	  the	  protonated	  or	  neutral	  chromo-­‐
phore	  is	  responsible	  for	  the	  395-­‐nm	  peak	  and	  the	  deprotonated	  or	  anionic	  chromophore	  is	  responsible	  
for	  the	  475-­‐nm	  peak	  (Heim	  et	  al.,	  1994,	  Cubitt	  et	  al.,	  1995).	  Since	  the	  coexistence	  of	  neutral	  and	  anion	  
chromophores	  produces	  two	  excitation	  peaks	  in	  the	  spectrum,	  wild	  type	  GFP	  has	  many	  disadvantages.	  
GFPs	  with	  phenolate	   anions	   in	   the	   chromphore	  have	  been	  widely	   used	   for	   cell	   biological	   applications	  
because	  they	  combine	  the	  simple	  excitation	  and	  emission	  peaking	  with	  the	  high	  brightness.	  The	  signifi-­‐
cant	  mutation	   causing	   ionization	  of	  phenol	   is	   Ser65	   to	   Thr65,	   and	   thus	   the	  395-­‐nm	  excitation	  peak	   is	  
suppressed	  and	  the	  470	  to	  475-­‐nm	  peak	  is	  enhanced	  and	  shifted	  to	  489-­‐490	  nm	  with	  five-­‐	  to	  six	  fold	  in-­‐
crease	   in	  amplitude	  (Cubitt	  et	  al.,	  1995,	  Cheng	  et	  al.,	  1996).	  To	  pursue	  an	  obvious	   interest	   for	  protein	  
expression	  at	  37	  °C,	  additional	  mutations	  like	  F64L	  and	  V163A	  have	  been	  commonly	  used	  to	  improve	  the	  
folding	   efficiency	   and	   have	   little	   effect	   on	   the	   brightness	   (fluorescence	   intensity)	   of	   properly	   folded	  
molecules	  (Cormack	  et	  al.,	  1996).	  
32 
Crystal	   structures	   of	   wild	   type	   GFP	   and	   GFP	  with	   the	   substitution	   of	   S65T	   have	   revealed	   the	  
probable	  mechanism	  for	  the	  preference	  of	  neutral	  or	  anionic	  chromophore	  (Yang	  et	  al.,	  1996,	  Ormo	  et	  
al.,	  1996,	  Brejc	  et	  al.,	  1997)	  (Figure	  1.13).	  Ser65	  can	  serve	  as	  a	  hydrogen	  bond	  donor	  to	  the	  buried	  side	  
chain	  of	  Glu222	  to	  induce	  the	  ionization	  of	  the	  carboxylate	  group.	  The	  carboxylate	  group	  is	  located	  with-­‐
in	   3.7	  Å	   away	   from	   the	   chromophore	   and	   creates	   an	   anionic	   environment,	   and	   thus	   the	   electrostatic	  
repulsion	  is	  unfavorable	  for	  the	  anionic	  state	  of	  the	  chromophore	  and	  favorable	  for	  the	  neutral	  state	  of	  
the	   chromophore.	  However,	  when	   threonine	   replaces	   the	   serine	   at	   position	   65,	   this	   larger	   side	   chain	  
cannot	  provide	  the	  correct	  conformation	  in	  the	  crowded	  interior	  of	  protein	  to	  maintain	  the	  protonated	  
form	  of	  the	  carboxylate	  group	  of	  Glu222	  (Ormo	  et	  al.,	  1996,	  Brejc	  et	  al.,	  1997).	  Therefore,	  the	  ionization	  
state	  of	  the	  Glu222	  side	  chain	  is	  important	  for	  the	  existence	  of	  different	  forms	  of	  the	  chromophore.	  The	  
effect	  of	  mutation	  E222G	  is	  the	  same	  as	  that	  of	  mutations	  of	  Ser65	  on	  changes	  in	  the	  spectral	  shape	  and	  
wavelengths	  (Ehrig	  et	  al.,	  1995).	  Thr203	  is	  another	  one	  of	  the	  most	  essential	  residues.	  The	  main	  chain	  
carbonyl	  oxygen	  of	  Thr203	  can	  form	  a	  hydrogen	  bond	  interaction	  with	  the	  phenol	  of	  the	  chromphore	  in	  
wild	  type	  GFP,	  and	  the	  side	  chain	  hydroxyl	  group	  can	  be	  hydrogen-­‐bonded	  to	  the	  phenolic	  oxygen	  of	  the	  
chromophore	  in	  both	  wild	  type	  GFP	  and	  the	  phenolate	  class	  of	  GFP	  such	  as	  EGFP	  (enhanced	  green	  fluo-­‐
rescent	  protein)	  with	  S65T	  and	  F64L.	  Mutation	  T203I	  in	  wild	  type	  GFP	  results	  in	  the	  lack	  of	  the	  475	  nm	  
absorbance	  peak	  attributed	  to	  the	  anionic	  chromophore,	  which	   is	  due	  to	  the	   loss	  of	  a	  hydrogen	  bond	  
between	  the	  threonine	  side	  chain	  and	  the	  phenolate	  (Heim	  et	  al.,	  1994,	  Ehrig	  et	  al.,	  1995).	  The	  replace-­‐
ment	  of	  Thr	  by	  Ile	  could	  prevent	  ionization	  of	  the	  chromophore.	   
Applications	  of	  GFPs	  in	  cell	  biology	  are	  mainly	  divided	  into	  tagging	  or	  labeling	  and	  indication	  of	  
the	  change	  of	  its	  environment.	  As	  a	  tag,	  GFP	  can	  be	  used	  to	  detect	  gene	  expression	  when	  it	  is	  fused	  into	  
the	  host	  protein	  (Cheng	  et	  al.,	  1996,	  Muldoon	  et	  al.,	  1997).	  For	  another	  use	  as	  a	  tag,	  GFP	  has	  been	  suc-­‐
cessfully	  applied	  to	  monitoring	  the	  localization	  and	  fate	  of	  host	  proteins	  without	  interfering	  in	  the	  func-­‐
tion	   (Tsien,	   1998).	   A	   series	   of	   fluorescent	   proteins	   with	   emission	   spectra	   peaks	   from	   UV	   to	   infrared	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wavelengths	  has	  been	  created	  randomly	  or	  by	  direct	  mutagenesis	  (Shaner	  et	  al.,	  2004).	  GFP	  can	  act	  as	  
an	   indicator	   in	   response	   to	   the	   change	   of	   the	   environment.	   Fluorescence	   resonance	   energy	   transfer	  
(FRET)	  is	  a	  general	  way	  to	  explore	  the	  environment	  by	  using	  linked	  GFPs	  of	  different	  colors	  (Miyawaki	  et	  
al.,	  1997).	  FRET	  is	  quantum-­‐mechanical	  phenomenon	  that	  is	  produced	  when	  one	  of	  two	  fluorophores,	  as	  
the	  donor,	  has	  an	  emission	  spectrum	  overlapping	  the	  excitation	  spectrum	  of	  the	  other	  fluorophore,	  the	  
acceptor,	  and	   they	   less	   than	  100	  Å	  apart.	  The	  efficiency	  of	  FRET	  can	  be	  modulated	  by	  changes	  of	   the	  
spatial	  relationship	  between	  the	  fluorophores.	  The	  change	  in	  ratio	  of	  acceptor	  to	  donor	  emissions	  is	  in-­‐
dicative	  of	  chemical	  signal.	  The	  first-­‐demonstrated	  application	  of	  FRET	  between	  two	  GFPs	  is	  to	  monitor	  
the	  protease	  action	  by	  inserting	  a	  protease-­‐sensitive	  spacer	  between	  blue-­‐emitting	  GFP	  mutant	  (i.e.	  BFP	  
short	  for	  blue	  fluorescent	  protein)	  and	  a	  phenolate-­‐containing	  GFP.	  Upon	  the	  addition	  of	  protease	  that	  
can	  cleave	  the	  spacer	  and	  cut	  the	  linkage	  of	  the	  two	  GFPs,	  FRET	  is	  disrupted	  with	  increased	  ratio	  of	  blue	  
to	  green	  emissions	  (Heim	  et	  al.,	  1996,	  Mitra	  et	  al.,	  1996).	  Currently,	  an	   interesting	  wide	  application	  of	  
FRET	   is	   to	  monitor	   Ca2+	   by	   incorporating	  Ca2+	   sensitive	   region	  between	   two	  GFPs	   and	   this	  will	   be	   de-­‐























Table	  1.2	  Selected	  major	  classes	  of	  GFPs.	  (Tsien,	  1998)	  





Class	  1,	  wild-­‐type	  
None	  or	  Q80R	  










Class	  2,	  phenolate	  anion	  
S65T	  
F64L,	  S65T	  
F64L,	  S65T,	  V163A	  
















Class	  3,	  neutral	  phenol	  
S202F,	  T203I	  










Class	  4,	  phenolate	  anion	  with	  π	  stacked	  
electron	  system	  
S65G,	  S72A,	  T203F	  
S65G,	  S72A,	  T203H	  
S65G,	  V68L,	  Q69K,	  S72A,	  T203Y	  
S65G,	  V68L,	  S72A,	  T203Y	  






















Class	  5,	  indole	  in	  chromophore	  	  
(cyan	  fluorescence	  proteins)	  
Y66W	  
Y66W,	  N146I,	  M153T,	  V163A	  
F64L,	  S65T,	  Y66W,	  N146I,	  M153T,	  V163A	  



















Class	  6,	  imidazole	  in	  chromphore	  	  
(blue	  fluorescence	  proteins)	  
Y66H	  
Y66H,	  Y145F	  



























Figure	   1.13	   Fluorescence	   excitation	   and	   emission	   spectra	  and	   the	   chromophore	   structures.	   (a)	  wild-­‐
type,	  (b)	  Emerald,	  (c)	  H9-­‐40,	  (d)	  Topaz,	  (e)	  W1B,	  and	  (f)	  P4-­‐3	  as	  described	  in	  Table	  1.2;	  solid	  and	  dashed	  
lines	  represent	  excitation	  and	  emission,	  respectively;	  spectra	  have	  been	  normalized	  to	  a	  maximum	  am-­‐






Figure	  1.14	  Schemes	  of	  the	  interactions	  between	  the	  chromophore	  and	  the	  neighboring	  residues	  and	  


















1.2.2 Role	  of	  Calcium	  in	  Biological	  System	  
Calcium	  acts	  as	  a	  second	  messenger	  in	  regulating	  many	  biological	  functions,	  such	  as	  heart	  beat,	  
neural	   function,	  muscle	   contraction	  and	  cell	  proliferation	  and	  apoptosis	   (Berridge,	  1998).	  Calcium	   is	   a	  
ubiquitous	  signaling	  molecule	  interacting	  with	  calcium	  binding	  proteins,	  and	  it	  can	  flux	  between	  intracel-­‐
lular	  and	  extracellular	  space	  and	  subcellular	  compartments	  (Berridge	  et	  al.,	  2003).	  The	  intracellular	  con-­‐
centration	  of	  calcium	  ranges	  from	  submicromolar	  to	  millimolar	  levels	  and	  the	  time	  scale	  of	  cytosolic	  cal-­‐
cium	   transients	   varies	   from	  microseconds	   for	   neuron	   transmitter	   release,	   0.1	  milliseconds	   for	  muscle	  
contraction	  to	  days	  for	  cell	  development.	  It	  has	  been	  reported	  that	  the	  periodic	  change	  of	  calcium	  con-­‐
centration	  can	  regulate	  the	  cardiac	  relaxation	  and	  contraction	  in	  cardiomyocytes	  (Dibb	  et	  al.,	  2007)	  and	  
heart	   failure	   can	  be	   caused	  by	   the	  abnormal	   calcium	  signaling	   (Kawase	   et	  al.,	   2008).	  Upon	  binding	   to	  
Ca2+,	  A	   variety	  of	   calcium	  binding	  proteins,	   such	  as	   calmodulin	   (CaM),	   troponin	  C	   (TnC)	   and	  other	   ion	  
channels	  will	  be	  induced	  with	  conformational	  change	  on	  binding	  calcium,	  and	  can	  further	  influence	  nu-­‐
merous	  cellular	  processes	  (Nelson	  et	  al.,	  1998).	  
The	  endo/sarcoplasmic	  reticulum	  (ER/SR)	  lumen	  is	  the	  main	  store	  for	  >90%	  of	  intracellular	  Ca2+	  
and	   is	   critical	   in	   controlling	  Ca2+	   signaling,	   although	   it	   occupies	   less	   than	  10%	  of	   the	   total	   cell	   volume	  
(Hogan	  et	  al.,	  2010,	  Clapham,	  2007,	  Berridge,	  2007).	  The	  ER/SR	  Ca2+	  store	  is	  pivotal	  for	  the	  regulation	  of	  
Ca2+	  signaling	  and	  maintenance	  of	  Ca2+	  gradients.	  The	  fluxing	  of	  Ca2+	  across	  the	  cellular	  compartments	  is	  
regulated	  by	  ion	  channels,	  receptors	  and	  Ca2+	  buffer	  proteins.	  The	  Ca2+	  receptors	  and	  pumps	  can	  be	  ac-­‐
tivated	  by	   the	  agonists	   such	  as	  ATP,	   ionomycin,	  histamine,	  and	  glutamine,	   resulting	   in	   the	  ER	  Ca2+	   re-­‐
lease	   from	  ER	   into	  cytosol	   (Bers,	  2003,	  Galione	   et	  al.,	   2002,	  Giovannucci	   et	  al.,	   2002).	  Changes	  of	   the	  
free	  [Ca2+]	  in	  the	  cytosol	  modulate	  the	  activity	  of	  these	  channels	  and	  receptors	  (Babu	  et	  al.,	  1989).	  Sar-­‐
coplasmic	   Reticulum	   Ca2+	   release	   is	   very	   important	   in	   regulating	   skeletal	   muscle	   contraction	   (Ebashi,	  
1961,	  Ebashi	  et	  al.,	  1962).	  Therefore,	  it	  is	  crucial	  to	  study	  Ca2+	  signaling	  in	  ER/SR	  for	  their	  importance	  in	  
Ca2+	  related	  biological	  functions.	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1.2.3 Calcium	  Measurement	  
Due	  to	  the	  importance	  of	  Ca2+	   in	  biological	  systems,	  the	  attempt	  to	  measure	  [Ca2+]	  has	  contin-­‐
ued	  since	  1920.	  Currently,	  numerous	  techniques	  or	  methods	  have	  been	  developed	  for	  analyzing	  cellular	  
or	  subcellular	  Ca2+	  activity.	  Currently	  used	  calcium	  sensors	  are	  mainly	  divided	  into	  two	  classes:	  chemical	  
fluorescent	  indicators	  generated	  by	  organic	  synthesis	  based	  on	  BAPTA	  [1,2-­‐bis(o-­‐aminophenoxy)ethane-­‐
N,N,N',N'-­‐tetraacetic	  acid]	  and	  bioluminescent	  calcium	  indicators	  containing	  photoproteins	  (Tsien	  et	  al.,	  
1985,	  McCombs	  et	  al.,	  2008).	  BAPTA	  is	  the	  first	  organically	  synthesized	  small	  molecule	  designed	  on	  the	  
basis	   of	   EGTA	   (ethylene	   glycol	   tetraacetic	   acid),	   which	   exhibits	   high	  metal	   selectivity	   for	   Ca2+	   (Tsien,	  
1980).	  BAPTA	  became	  the	  essential	  component	  of	  several	  calcium	  dyes	  such	  as	  Indo	  1,	  Fluo	  3	  and	  Ore-­‐
gon	  green	  BAPTA	  (Grynkiewicz	  et	  al.,	  1985,	  Minta	  et	  al.,	  1989).	  The	  chemical	  fluorescent	  indicators	  can	  
be	  excited	  at	  different	  wavelength	  ranges:	  UV	  wavelength	  excitation,	   such	  as	   Indo	  1,	  Fura	  2	  and	   their	  
derivatives	   (Grynkiewicz	   et	   al.,	   1985,	   Naraghi,	   1997,	   Etter	   et	   al.,	   1994,	   Etter	   et	   al.,	   1996),	   and	   visible	  
wavelength	   excitation,	   such	   as	   Fluo	   3,	   calcium	   green,	   dextran	   conjugates	   (Grynkiewicz	   et	   al.,	   1985,	  
Minta	  et	  al.,	  1989).	  Even	  though	  the	  UV-­‐excitable	  Ca2+	  indicators	  are	  still	  used	  due	  to	  their	  quantitative	  
ratiometric	  property,	  they	  are	  known	  to	  be	  more	  cytotoxic	   (Brakenhoff	  et	  al.,	  1996).	  Therefore,	  visible	  
wavelength	  Ca2+	  sensors	  have	  many	  advantages	  over	  UV-­‐based	  Ca2+	  indicators	  like	  less	  cytotoxicity,	  the	  
ability	  to	  monitor	  change	  of	  [Ca2+]	  with	  UV-­‐sensitive	  compounds	  and	  emitting	  light	  within	  the	  region	  of	  
the	  electromagnetic	  spectrum	  with	  less	  severe	  background	  scattering	  (Takahashi	  et	  al.,	  1999).	  The	  ma-­‐
jority	  of	  these	  indicators	  can	  produce	  greater	  dynamic	  range	  of	  signals	  like	  fluo	  3	  that	  can	  undergo	  40-­‐
200	  fold	  increase	  in	  fluorescence	  upon	  binding	  Ca2+	  (Minta	  et	  al.,	  1989,	  Harkins	  et	  al.,	  1993).	  However,	  
the	  big	  disadvantage	  of	  these	  synthesized	  Ca2+	  sensors	  is	  their	  non-­‐specific	  targeting	  of	  membrane	  and	  
easy	   leakage	  from	  cell	   (McCombs	  et	  al.,	  2008).	   In	  addition,	  Ca2+	   in	  denser	  or	  thicker	  tissues	  cannot	  be	  
detected	  due	  to	  the	  difficulty	  in	  loading	  these	  Ca2+	  dyes	  and	  also,	  the	  emitted	  light	  signal	  is	  attenuated	  
in	  denser	  material.	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Bioluminescent	  Ca2+	  indicators	  mainly	  include	  two	  types	  of	  Ca2+	  sensors:	  Ca2+-­‐binding	  photopro-­‐
teins	  and	  GFP-­‐based	  indicators.	  Ca2+-­‐binding	  photoproteins,	  such	  as	  aequorin	  and	  obelin	  etc,	  offer	  sim-­‐
plicity	  for	  instrumentation	  by	  emitting	  visible	  bioluminescence	  through	  an	  intramolecular	  reaction	  upon	  
binding	  Ca2+	  (Shimomura,	  1984,	  Campbell,	  1974).	  Aequorin	  is	  the	  most	  widely	  used	  bioluminescent	  Ca2+	  
sensor	  which	  is	  composed	  of	  three	  parts:	  apoaequorin	  protein	  of	  molecular	  mass	  of	  21	  kDa,	  the	  lumino-­‐
phore	  coeleterazine	  and	  molecular	  oxygen	  (Inouye	  et	  al.,	  1985,	   Inouye	  et	  al.,	  1989,	  Shimomura	  et	  al.,	  
1988).	   The	   aequorin	   contains	   three	   Ca2+-­‐binding	   sites	   and	   produces	   emission	  with	   Ca2+	   binding	   to	   at	  
least	   two	   sites	   (Shimomura	   et	  al.,	   1963).	  Upon	  binding	  Ca2+	   ions,	   the	  molecular	  oxygen	   in	  aequorin	   is	  
released	  and	  the	  luminophore	  coeleterazine	  is	  oxidized	  to	  coelenteramide,	  emitting	  blue	  light	  (465	  nm)	  
which	   increases	  as	  [Ca2+]	   increases	  between	  10-­‐7	  and	  10-­‐4	  M	  (Shimomura	  et	  al.,	  1963).	  However,	   its	   in-­‐
ability	  to	  get	   into	  organelles	   limits	  the	  distribution	  of	  aequorin	   in	  cell	   (Shimomura	  et	  al.,	  1962).	  There-­‐
fore,	  recombinant	  aequorins	  have	  become	  quite	  useful	  probes	  for	  calcium	  due	  to	  their	  ability	  to	  enter	  
into	  various	  kinds	  of	  organelles	  without	  interfering	  with	  the	  physiological	  condition	  (Rizzuto	  et	  al.,	  1992).	  
Obelin	   is	  a	  Ca2+-­‐activated	  photoprotein	   that	  binds	  at	   least	   three	  molecules	  of	  Ca2+	  to	  emit	  biolumines-­‐
cence	   (Campbell,	   1974).	  Compared	   to	  aequorin,	  obelin	  has	   faster	  onset	  of	   the	  bioluminescence	   in	   re-­‐
sponse	  to	  binding	  Ca2+	  (3	  ms	  by	  obelin	  vs.	  10	  ms	  by	  aequorin)	  but	  less	  [Ca2+]	  sensitivity	  (Moisescu	  et	  al.,	  
1975).	  The	  GFP-­‐based	  Ca2+	  biosensor	   is	  a	  promising	   indicator	   that	  exhibits	  high	   specificity	   for	   location	  
and	  provides	  high	  accuracy	  for	  the	  measurement	  of	  subcellular	  Ca2+	  signaling	  (Inouye	  et	  al.,	  1994).	  The	  
basic	  strategy	  for	  the	  design	  of	  GFP-­‐based	  Ca2+	  biosensor	  is	  the	  insertion	  or	  graft	  of	  a	  Ca2+	  sensitive	  pro-­‐
tein	  such	  as	  calmodulin,	  or	  Ca2+	  binding	  proteins	  like	  troponin	  C,	  into	  different	  mutated	  types	  of	  GFP	  to	  
create	  various	  kinds	  of	  Ca2+	  indicators.	  Therefore,	   fluorescence	  changes	  provide	  the	   information	  about	  
[Ca2+],	  which	   is	   produced	  by	  direct	   alteration	   in	  GFP	  or	   an	   increase	   in	   fluorescence	   resonance	  energy	  
transfer	   (FRET).	   Cameleons,	   as	   one	   kind	  of	   the	   successfully	   synthesized	  Ca2+	  indicators,	   consist	   of	   two	  
GFP	   mutants	   with	   overlapping	   excitation/emission	   spectra	   and	   the	   Ca2+-­‐sensitive	   protein	   calmodulin	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with	   M13,	   which	   is	   a	   calmodulin-­‐binding	   peptide	   with	   26-­‐residues	   from	   myosin	   light-­‐chain	   kinase	  
(Miyawaki	  et	  al.,	  1997).	  The	  calmodulin-­‐M13	  complex	  linked	  the	  two	  GFP	  mutants.	  When	  Ca2+	  binds	  to	  
calmodulin,	   it	   induces	   the	   conformational	   change	  of	   the	   complex,	   resulting	   in	  decreased	  distance	  be-­‐
tween	  the	  two	  GPF	  mutants	  accompanied	  by	  an	   increase	   in	  FRET.	  Two	  combinations	  of	  donor	  and	  ac-­‐
ceptor	  GFP	  mutants	  have	  been	  designed:	  blue	  fluorescent	  protein	  (BFP)-­‐GFP	  and	  cyan	  fluorescent	  pro-­‐
tein	   (CFP)-­‐yellow	   fluorescent	   protein	   (YFP)	   (Tsien,	   1998).	   Troponin	   C	   is	   another	   Ca2+	   binding	   protein	  
functioning	  only	   in	  muscle	  contraction	  (Heim	  et	  al.,	  2004).	  Troponin	  C	   is	   inserted	  between	  CFP	  and	  ci-­‐
trine	  that	   is	  a	  yellow	  fluorescent	  protein	  derivative,	  and	  this	   forms	  troponeons	  that	   is	  another	  type	  of	  
FRET-­‐based	  Ca2+	   indicators.	  Compared	  to	  cameleons,	  troponeons	  exhibit	  better	  performance	  in	  target-­‐
ing	  to	  a	  specific	  subcellular	  domains	  (Takahashi	  et	  al.,	  1999).	  GFP-­‐based	  Ca2+	  indicators	  have	  been	  widely	  
used	   for	   its	  many	  advantages	  over	   the	  chemical	   fluorescent	  probes,	   such	  as	   the	   ratiometric	  measure-­‐
ment	  of	   [Ca2+],	  brighter	   fluorescence,	  high	  sensitivity,	  precise	  expression	   in	  targeted	   intracellular	  com-­‐
partments	   and	   so	   forth,	   although	   they	   demonstrated	   fewer	   changes	   than	  most	   chemical	   fluorescent	  
Ca2+	  indicators	  and	  pH-­‐sensitivity	  seen	  in	  some	  GFP	  variants	  as	  the	  disadvantages	  (Takahashi	  et	  al.,	  1999,	  
Kneen	  et	  al.,	  1998).	  
Yang’s	   lab	  has	  been	  devoted	  to	  exploring	  site-­‐specific	  Ca2+	  binding	  affinity	  of	  designed	  calcium	  
sensors	   (Figure	   1.15).	   They	  have	   successfully	   created	   a	   Ca2+	   sensor	   by	   grafting	   an	   EF-­‐hand	  motif	  with	  
Ca2+	  binding	  site	  into	  EGFP	  (enhanced	  green	  fluorescent	  protein)	  that	  contains	  F64L	  and	  S65T	  (Zou	  et	  al.,	  
2007).	  The	  grafted	  Ca2+	   sensor	   (G1)	  emitted	  a	  dual	  510	  nm	  fluorescence	   intensity	   ratio	  metric	   change	  
when	  excited	  at	  398	  nm	  and	  490	  nm	  wavelengths.	  The	  fluorescent	  emission	  ratio	  (measured	  at	  510	  nm)	  
for	  385	  nm	  to	  480	  nm	  excitation	   is	   indicative	  of	   [Ca2+].	  However,	  the	  dynamic	  range	   is	  small	  with	  only	  
10-­‐15%	  change	  observed	  in	  mammalian	  cell	  imaging	  (Zou	  et	  al.,	  2007).	  The	  hypothesis	  for	  the	  design	  of	  
EGFP-­‐based	  Ca2+	  sensor	  is	  that	  alteration	  of	  chromophore	  is	  associated	  with	  the	  conformational	  change	  
induced	  binding	  of	  Ca2+.	   It	  has	  been	  reported	  that	  the	  fluorescent	  sensitive	  sites	  are	  on	  the	  surface	  of	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EGFP	  and	  site	  directed	  mutations	  at	  that	  area	  were	  designed	  to	  bind	  small	  molecules	  such	  as	  the	  GFP-­‐
based	  zinc	  sensors	  (Kikuchi	  et	  al.,	  2004).	  Therefore,	  a	  new	  Ca2+	  binding	  pocket	  was	  designed	  via	  site	  di-­‐
rected	  mutagenesis	  on	  the	  surface	  of	  EGFP.	  A	  series	  of	  different	  combinations	  of	  amino	  acid	  substitu-­‐
tions	  with	   negatively	   charged	   side	   chains	   that	   can	   coordinate	  with	   Ca2+	  was	   designed	   to	   (Tang	   et	   al.,	  
2011).	   This	   de	   novo	   design	   of	   Ca2+	   sensors	   can	   provide	   theoretical	   support	   for	   developing	  GFP-­‐based	  













Figure	  1.16	  Scheme	  of	  EGFP-­‐based	  Ca2+	  biosensor.	  EGFP	  is	  used	  as	  a	  scaffold	  protein	  and	  EF-­‐hand	  III	  of	  
calmodulin	   was	   grafted	   into	   the	   fluorescent	   sensitive	   location	   of	   EGFP	   to	   produce	   Ca-­‐G1;	   negatively	  
charged	  amino	  acids	  were	  introduced	  on	  the	  surface	  of	  three	  antiparallel	  beta	  sheets	  of	  EGFP	  forming	  a	  















1.2.4 Specific	  Aims	  and	  Brief	  Results	  of	  Studying	  GFP-­‐based	  Calcium	  Sensor	  CatchER	  
Due	  to	  the	  need	  of	  efficient	  Ca2+	  sensors	  to	  target	  cellular	  compartments	  with	  a	  high	  Ca2+	  con-­‐
centration,	  such	  as	  the	  ER/SR,	  a	  novel	  class	  of	  genetically	  encoded	  indicators	  was	  developed	  by	  design-­‐
ing	  a	  Ca2+	  binding	   site	   in	   the	  enhanced	  green	   fluorescent	  protein	   (EGFP).	  CatchER	   (Calcium	  sensor	   for	  
detecting	   high	   concentration	   in	   the	   ER)	   shows	   Ca2+	   release	   kinetics	   with	   a	   fast	   off-­‐rate	   estimated	   at	  
around	  700	  s-­‐1	  and	  dissociation	  constant	  Kd	  around	  1	  mM	  of	  Ca
2+	  binding	  affinity	  (Tang	  et	  al.,	  2011).	  In	  
my	  study	  of	  CatchER,	  crystallographic	  study	  was	  performed	  of	  CatchER	  in	  the	  absence	  of	  Ca2+	  (apo	  form)	  
and	  complexed	  with	  Ca2+	  to	  identify	  where	  the	  calcium	  ion	  bound	  and	  to	  reveal	  the	  mechanisms	  of	  fluo-­‐
rescent	  change	  triggered	  by	  calcium	  (Zhang	  et	  al.,	  2013b).	  Analysis	  of	  these	  structures	  will	  help	  to	  fur-­‐
ther	  optimize	  the	  design	  of	  current	  calcium	  biosensors.	  In	  addition,	  to	  assist	  in	  locating	  the	  bound	  Ca2+	  
due	  to	  the	  weak	  Ca2+	  binding	  affinity,	  high	  off-­‐rate	  and	  difficulty	  in	  distinguishing	  calcium	  from	  water	  in	  
the	  crystal	  structure,	  the	  heavy	  metal	  ion	  Gd3+	  with	  similar	  metal	  binding	  coordination	  properties	  to	  cal-­‐
cium	  was	  soaked	  into	  apo	  CatchER	  crystals.	  The	  crystal	  structure	  of	  CatchER	  with	  Gd3+	  ion	  demonstrated	  
clearly	  the	  position	  of	  the	  bound	  metal	  ion.	  Analysis	  of	  these	  three	  structures	  shows	  that	  T203	  has	  lost	  
its	  direct	  hydrogen	  bond	  with	  the	  anionic	  form	  of	  chromophore	  and	  gained	  a	  water-­‐mediated	  hydrogen	  
bond	  with	  the	  chemically	  exchanged	  neutral	  chromophore	  in	  all	  three	  structures.	  Two	  partially	  occupied	  
Ca2+	   or	   Gd3+	   ions	   were	   observed	   and	   refined	   within	   the	   designed	   calcium-­‐binding	   site.	   In	   the	   crystal	  
structures	  of	  CatchER	  with	  Ca2+	  and	  Gd3+,	  the	  side	  chain	  of	  E222	  has	  two	  alternative	  conformations	  and	  
regains	  water-­‐mediated	  hydrogen	  bonding	  interaction	  with	  Gln69	  as	  in	  EGFP	  and	  main	  chain	  of	  residues	  
from	  202	  to	  206	  has	  maximum	  shift	  of	  0.8	  Å.	  The	  binding	  of	  the	  metal	  ion	  induced	  structural	  changes	  of	  
T203	   and	   E222	   around	   the	   chromophore	   corresponding	   to	   a	   concurrent	   increased	   intensity	   in	   absor-­‐
bance	   around	  490	  nm	   (increase	  of	   deprotonated	   chromophore)	   and	  a	  decreased	  absorption	   intensity	  
around	   398	   nm	   (decrease	   of	   protonated	   chromophore	   state)	   with	   the	   addition	   of	   Ca2+	   or	   Gd3+.	   This	  
structural	  information	  is	  of	  utility	  for	  optimizing	  the	  sensor.	  The	  detailed	  studies	  including	  experimental	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methods	  and	  results	  on	  CatchER	  are	  described	   in	  Chapter	  4	  of	  this	  dissertation	  and	  Zhang	  et	  al.,	  2013	  








































2 THE	  L76V	  DRUG	  RESISTANCE	  MUTATION	  DECREASES	  THE	  DIMER	  STABILITY	  AND	  RATE	  OF	  
AUTOPROCESSING	  OF	  HIV-­‐1	  PROTEASE	  BY	  REDUCING	  INTERNAL	  HYDROPHOBIC	  CONTACTS	  
(Published:	  Louis,	  J.M.,	  Zhang,	  Y.,	  Sayer,	  J.M.,	  Wang,	  Y.-­‐F.,	  Harrison,	  R.W.,	  Weber,	  I.T.,	  Biochemistry,	  
2011,	  50:	  4786-­‐4795)	  
2.1 Abstract	  
The	  mature	  HIV-­‐1	  protease	   (PR)	  bearing	  drug-­‐resistance	  mutation	   L76V	   (PRL76V)	   is	   significantly	  
less	  stable,	  with	  >7-­‐fold	  higher	  dimer	  dissociation	  constant	  (Kd)	  of	  71	  ±	  24	  nM	  and	  twice	  the	  sensitivity	  
to	  urea	  denaturation	  (UC50	  =	  0.85	  M)	  relative	  to	  PR.	  Differential	  scanning	  calorimetry	  showed	  a	  decrease	  
in	  Tm	  of	  12	  °C	  for	  PRL76V	   in	  the	  absence	  of	   inhibitors,	  and	  5-­‐7	  °C	  in	  the	  presence	  of	   inhibitors	  darunavir	  
(DRV),	  saquinavir	  (SQV)	  and	  lopinavir	  (LPV),	  relative	  to	  PR.	  Isothermal	  titration	  calorimetry	  gave	  a	  ligand	  
dissociation	   constant	   of	   0.8	   nM	   for	  DRV,	   ~160-­‐fold	   larger	   than	   that	   of	   PR,	   consistent	  with	  DRV	   resis-­‐
tance.	  Crystal	  structures	  of	  PRL76V	  complexed	  with	  DRV	  and	  SQV	  were	  determined	  at	  resolutions	  of	  1.45-­‐
1.46	  Å.	   Compared	   to	   the	   corresponding	   PR	   complexes,	   the	  mutated	  Val76	   lacks	   hydrophobic	   interac-­‐
tions	  with	   Asp30,	   Lys45,	   Ile47,	   and	   Thr74,	   and	   exhibits	   closer	   interactions	  with	   Val32	   and	   Val56.	   The	  
bound	  DRV	   lacks	   a	   hydrogen	  bond	  with	   the	  main	   chain	  of	  Asp30	   in	   PRL76V	   relative	   to	  PR,	   possibly	   ac-­‐
counting	  for	  resistance	  to	  DRV.	  SQV	  shows	  slightly	  improved	  polar	  interactions	  with	  PRL76V	  compared	  to	  
PR.	  Although	  the	  L76V	  mutation	  significantly	  slows	  the	  N-­‐terminal	  autoprocessing	  of	  the	  precursor	  TFR-­‐
PRL76V	   to	   give	   rise	   to	   the	  mature	  PRL76V,	   the	   co-­‐selected	  M46I	  mutation	   counteracts	  by	  enhancing	   this	  
rate	  but	  renders	  the	  TFR-­‐PRM46I/L76V	  precursor	  less	  responsive	  to	  inhibition	  by	  6	  µM	  LPV	  while	  retaining	  
inhibition	  by	  SQV	  and	  DRV.	  The	  correlation	  of	  lowered	  stability,	  higher	  Kd	  and	  impaired	  autoprocessing,	  
with	  reduced	  internal	  hydrophobic	  contacts	  suggests	  a	  novel	  molecular	  mechanism	  for	  drug	  resistance.	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2.2 Introduction	  
Human	  immunodeficiency	  HIV-­‐1	  protease	  (PR)	  is	  a	  major	  drug	  target	  for	  treatment	  of	  AIDS.	  PR	  
functions	  in	  the	  last	  step	  of	  the	  HIV-­‐1	  life	  cycle	  by	  catalyzing	  the	  cleavage	  of	  viral	  polyproteins	  produced	  
in	  the	  host	  cell	  (Turner	  et	  al.,	  1999).	  Hydrolysis	  of	  polyproteins	  into	  functional	  products	  is	  important	  for	  
the	  maturation	  and	  production	  of	  infectious	  progeny	  virions.	  Protease	  inhibitors	  (PIs)	  act	  to	  prevent	  the	  
maturation	  process.	  Currently,	  nine	  PIs	  are	  approved	  by	  the	  FDA	  as	  anti-­‐viral	  drugs.	  However,	  the	  lack	  of	  
a	  proofreading	  step	  of	  the	  viral	  reverse	  transcription	  leads	  to	  a	  high	  frequency	  of	  mutations,	  and	  under	  
drug	  pressure,	  rapid	  selection	  of	  a	  combination	  of	  mutations	  confers	  drug	  resistance	  thus	  presenting	  a	  
severe	  challenge	  in	  current	  anti-­‐HIV	  treatment	  (Emini,	  2002).	  	  
PR	   is	   a	   homodimer	  with	   99	   amino	   acids	   in	   each	   subunit	   (Figure	   2.1)	   (Louis	   et	   al.,	   2000).	   The	  
Asp25-­‐Thr26-­‐Gly27	   triplets	   of	   both	   monomers	   form	   the	   catalytic	   site,	   where	   Asp25	   and	   Asp25’	   (the	  
prime	   indicates	   the	   second	   subunit	   of	   the	   dimer)	   serve	   as	   general	   acid-­‐base	   catalysts	   of	   polyprotein	  
cleavage	   in	   the	   proposed	   reaction	   mechanism	   (Brik	   et	   al.,	   2003).	   Two	   flexible	   interacting	   flaps	   are	  
formed	  by	  residues	  44-­‐57	  of	  both	  subunits.	  The	  two	  characteristic	  triplets	  and	  two	  flaps	  make	  important	  
contributions	  to	  the	  active	  site	  cavity	   for	   the	  binding	  of	  substrates	  or	   inhibitors	   (Weber	  et	  al.,	  2009a).	  
The	  PR	  dimer	  is	  stabilized	  via	  noncovalent	  interactions	  of	  the	  residues	  at	  the	  dimer	  interface.	  Important	  
intersubunit	  hydrogen	  bonds	  connect	  the	  catalytic	  triplets,	  flaps	  and	  beta	  sheet	  formed	  by	  the	  4	  termi-­‐
nal	  strands	  (Gustchina	  et	  al.,	  1990).	  The	  tertiary	  fold	  of	  each	  monomer	  is	  stabilized	  by	  hydrophobic	  in-­‐
teractions	  among	  the	  aliphatic	  residues	  in	  an	  internal	  hydrophobic	  core.	  Mutations	  occurring	  in	  over	  30	  
of	  the	  99	  residues	  in	  each	  subunit	  are	  associated	  with	  drug	  resistance	  (Johnson	  et	  al.,	  2008).	  Two	  major	  
types	  of	   PI-­‐resistance	  mutations	   are	  proposed	   to	   influence	   the	  PR	  activity	   (Weber	   et	   al.,	   2009a).	  One	  
type	  located	  near	  the	  active	  site	  can	  change	  the	  binding	  affinity	  and/or	  specificity	  of	  PR	  with	  the	  inhibi-­‐
tor	  by	  altering	  direct	   interactions	   (Tie	   et	  al.,	  2007).	  Other	  mutations	  do	  not	  change	   the	  binding	  cavity	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directly;	  however,	  they	  may	  affect	  PR	  stability	  and	  indirectly	  influence	  the	  binding	  of	  inhibitors	  via	  long-­‐
range	  structural	  perturbations	  (Liu	  et	  al.,	  2005).	  
The	   L76V	  mutation	  has	  become	  more	  prevalent	   in	  datasets	  of	  HIV-­‐1	  mutants	  observed	   in	  pa-­‐
tients	  (Johnson	  et	  al.,	  2008).	  Presence	  of	  L76V	  as	  a	  single	  mutation	  was	  shown	  to	  hamper	  viral	  replica-­‐
tion	   severely	   (Nijhuis	   et	  al.,	   2009a).	   L76V,	   generally	   accompanied	  by	  other	  mutations,	   is	   considered	  a	  
major	  mutation	  providing	  2-­‐6-­‐fold	  decreased	  susceptibility	  to	  darunavir	  (DRV),	  fosamprenavir,	  indinavir	  
(IDV),	  and	  lopinavir	  (LPV)	  (Young	  et	  al.,	  2010,	  Rhee	  et	  al.,	  2010).	  It	   is	  also	  selected	  as	  a	  drug	  resistance	  
mutation	  in	  patients	  receiving	  LPV	  therapy	  (Nijhuis	  et	  al.,	  2009a).	  This	  mutation,	  however,	  is	  not	  associ-­‐
ated	  with	  resistance	  to	  atazanavir	  (ATV),	  nelfinavir	  (NFV),	  saquinavir	  (SQV)	  or	  tipranavir	  (TPV).	  Instead,	  
mutants	  containing	  L76V	  exhibit	  increased	  susceptibility	  to	  these	  drugs	  (Mueller	  et	  al.,	  2004,	  Vermeiren	  
et	  al.,	  2007,	  Young	  et	  al.,	  2010).	  Hence,	  this	  mutation	  shows	  opposing	  roles	  in	  drug	  resistance,	  acting	  to	  
increase	  susceptibility	  to	  some	  drugs	  and	  decrease	  susceptibility	  to	  others	  (Tartaglia	  et	  al.,	  2009).	  	  
We	   constructed	   PR	  with	   the	   single	  mutation	   of	   L76V	   in	   order	   to	   investigate	   its	   effect	   on	   the	  
structure,	  stability	  and	  activity	  of	   the	  enzyme.	  Crystal	  structures	  of	  PRL76V	  with	  DRV	  and	  SQV	  were	  de-­‐
termined	  to	   investigate	  the	  molecular	  basis	   for	  the	  responses	  of	  this	  mutant	  to	   inhibitors.	  Leu76	   is	   lo-­‐
cated	  in	  the	  hydrophobic	  core	  of	  PR	  close	  to	  the	  active	  site	  cavity,	  although	  its	  side	  chain	  has	  no	  van	  der	  
Waals	  contacts	  with	  most	  substrates	  or	  inhibitors.	  Additionally,	  the	  effect	  of	  the	  mutation	  on	  the	  auto-­‐
catalytic	  processing	  of	  the	  precursor,	  which	  is	  required	  for	  onset	  of	  the	  catalytic	  activity	  characteristic	  of	  
the	  mature,	  dimeric	  enzyme,	  was	  assessed	  in	  vitro,	  and	  the	  effect	  of	  a	  second	  mutation,	  M46I,	  was	  ex-­‐
amined	  in	  the	  precursor	  containing	  both	  mutations.	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2.3 	  Experimental	  Procedures	  
2.3.1 Protein	  Expression	  and	  Purification	  
The	  HIV-­‐1	  PR	  (Genbank	  HIVHXB2CG)	  clone	  optimized	  for	  structural	  and	  biochemical	  studies	  con-­‐
tains	  mutations	  Q7K,	  L33I	  and	  L63I	  to	  minimize	  autoproteolysis,	  and	  C67A	  and	  C95A	  to	  prevent	  cysteine-­‐
thiol	  oxidation	  (Louis	  et	  al.,	  1999a).	  The	  L76V	  mutation	  was	  introduced	  in	  this	  PR	  template	  as	  well	  as	  the	  
template	  encoding	  a	  PR	  precursor	  mimetic	   in	  which	  the	  full-­‐length	  transframe	  region	  (TFR)	   is	   fused	  to	  
the	  N-­‐terminus	  of	  PR	  (TFR-­‐PR)	  by	  use	  of	  the	  appropriate	  oligonucleotide	  primers	  using	  the	  QuikChange	  
protocol	  (Stratagene,	  La	  Jolla,	  CA)	  and	  verified	  by	  DNA	  sequencing.	  A	  second	  construct,	  containing	  two	  
mutations,	  M46I	  and	  L76V,	  in	  the	  PR	  domain	  of	  TFR-­‐PR	  was	  also	  made	  using	  TFR-­‐PRL76V	  as	  the	  template.	  
Proteins	  were	  expressed	  using	  pET11a	  vector	  and	  E.	  coli	  BL21(DE3),	  purified	  and	  refolded	  using	  estab-­‐
lished	  protocols	  (Wondrak	  et	  al.,	  1996,	  Ishima	  et	  al.,	  2007,	  Sayer	  et	  al.,	  2010),	  and	  the	  identities	  of	  the	  
products	  verified	  by	  ESI-­‐MS.	  
2.3.2 Enzyme	  Assays	  
The	  kinetic	  parameters	  were	  measured	  using	  a	  fluorescence	  assay	  as	  described	  (Liu	  et	  al.,	  2008)	  
with	   the	   substrate	   Abz-­‐Thr-­‐Ile-­‐Nle-­‐pNO2Phe-­‐Gln-­‐Arg-­‐NH2	   (where	   pNO2Phe	   is	   para-­‐nitro-­‐phenylalanine,	  
Nle	  is	  norleucine	  and	  Abz	  is	  anthranilic	  acid)	  (Bachem	  Bioscience	  Inc.,	  King	  of	  Prussia,	  PA),	  which	  is	  based	  
on	  the	  p2/NC	  cleavage	  site	  of	  the	  viral	  polyprotein.	  10	  μl	  PR	  L76V	  at	  a	  final	  concentration	  of	  34	  nM	  from	  
active	   site	   titration	   with	   SQV	   was	   mixed	   with	   100	   μl	   of	   reaction	   buffer	   [100	   mM	   MES	   (4-­‐
morpholineethanesulfonic	  acid),	  pH	  5.6,	  400	  mM	  NaCl,	  1	  mM	  ethylenediaminetetraacetic	  acid,	  and	  5%	  
glycerol]	  at	  26	  ˚C.	  The	  reaction	  was	  initiated	  by	  adding	  substrate	  from	  a	  stock	  solution	  of	  186	  μM	  to	  give	  
a	  final	  concentration	  of	  12-­‐84	  μM.	  PR	  activity	  was	  measured	  by	  monitoring	  the	  increase	  in	  fluorescence	  
over	  5	  min	  using	  an	  excitation	  wavelength	  of	  340	  nm	  and	  emission	  wavelength	  of	  420	  nm	  (pNO2Phe	  as	  
quencher-­‐fluorescent	  acceptor;	  Abz	  as	  fluorescent	  donor)	  with	  a	  POLARstar	  OPTIMA	  96-­‐well	  microplate	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instrument	  (BMC	  Labtech).	  Values	  for	  kcat	  and	  Km	  were	  obtained	  by	  fitting	  the	  curves	  to	  the	  Michaelis-­‐
Menten	  equation	  using	  the	  program	  SigmaPlot	  (SPSS	  Inc.,	  Chicago,	  IL).	  	  
For	  dimer	  dissociation	  and	  urea	  denaturation	  studies,	  enzyme	  activity	  was	  measured	  by	  follow-­‐
ing	  the	  initial	  rates	  of	  hydrolysis	  of	  the	  chromogenic	  peptide	  substrate	  IV	  that	  mimics	  the	  CA/p2	  cleav-­‐
age	   site	   (Lys-­‐Ala-­‐Arg-­‐Val-­‐Nle-­‐pNO2Phe-­‐Glu-­‐Ala-­‐Nle-­‐NH2,	   California	   Peptide	   Research,	   Napa,	   CA)	   at	   310	  
nm	  (Δε	  =	  1797	  M-­‐1cm-­‐1)	  in	  50	  mM	  sodium	  acetate	  buffer,	  pH	  5.0,	  in	  120	  mL	  cuvettes	  at	  28	  °C.	  Substrate	  
concentration	  (390	  μM	  in	  the	  assay	  mixtures)	  was	  determined	  from	  the	  UV	  spectrum	  of	  substrate	  stock	  
solutions	   (ε280	   =	   12,000	  M
-­‐1	   cm-­‐1).	   The	   dimer	   dissociation	   constant,	  Kd,	  was	   determined	   by	   fitting	   the	  
curve	  of	  activity	  (initial	  rate/protease	  concentration)	  vs.	  protease	  concentration	  (40-­‐1200	  nM	  as	  mono-­‐
mers)	   to	   an	  equation	  described	  previously	   (Sayer	   et	   al.,	   2010).	   For	  urea	  denaturation	   studies,	   activity	  
was	  measured	  at	  urea	  concentrations	  of	  0-­‐3.5	  M	  (Mahalingam	  et	  al.,	  1999)	  and	  a	  enzyme	  concentration	  
of	  0.3-­‐1.15	  μM.	  The	  UC50	  value	  is	  the	  urea	  concentration	  at	  which	  the	  PR	  activity	  is	  half	  of	  the	  maximum	  
activity	  in	  the	  absence	  of	  urea.	  	  
2.3.3 Calorimetry	  
Inhibitor	   concentrations	   were	   determined	   kinetically	   by	   active	   site	   titration	   against	   the	   wild-­‐
type	  PR.	  Samples	  for	  differential	  scanning	  calorimetry	  (DSC)	  were	  prepared	  by	  the	  quench	  protocol	  from	  
stock	  solutions	  in	  HCl	  as	  previously	  described	  (Ishima	  et	  al.,	  2007)	  to	  give	  a	  final	  enzyme	  concentration	  
of	  14-­‐15	  μM	  (as	  dimer)	  in	  50	  mM	  sodium	  acetate	  buffer,	  pH	  5.0.	  Final	  concentrations	  of	  inhibitors	  DRV,	  
SQV	  and	  LPV	  were	  28-­‐29	  μM	  (~2-­‐fold	  molar	  excess	  relative	  to	  dimeric	  enzyme).	  DSC	  scans	  were	  run	  on	  a	  
MicroCal	  VP-­‐DSC	  microcalorimeter	  (GE	  Healthcare)	  at	  90	  °C/h	  from	  a	  starting	  temperature	  of	  20	  ºC	  and	  
terminated	  at	  70-­‐90	  °C	  depending	  on	  the	  position	  of	  the	  transition.	  Data	  were	  processed	  using	  the	   in-­‐
strument’s	  Origin	  software	  as	  described	  (Sayer	  et	  al.,	  2008).	  SDS-­‐PAGE	  of	  the	  inhibitor-­‐free	  enzyme	  on	  a	  
20%	  homogeneous	  PhastGel	  (GE	  Healthcare)	  before	  and	  after	  DSC	  showed	  no	  evidence	  for	  autoprote-­‐
olysis	  during	  the	  course	  of	  the	  DSC	  experiment.	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For	  isothermal	  titration	  calorimetry,	  PRL76V	  (1.9	  mg/ml	  in	  12	  mM	  HCl)	  was	  folded	  by	  the	  quench	  
protocol	  (Ishima	  et	  al.,	  2007)	  to	  give	  final	  concentrations	  of	  8-­‐13.5	  μM	  in	  50	  mM	  sodium	  acetate	  buffer,	  
pH	  5,	  and	  titrated	  with	  16	   injections	  of	  DRV	   in	  the	  same	  buffer	   (60-­‐140	  μM	  depending	  on	  the	  protein	  
concentration)	  by	  use	  of	  a	  MicroCal	  iTC200	  microcalorimeter	  (GE	  Healthcare)	  at	  28	  °C.	  Stock	  160-­‐200	  µM	  
inhibitor	   solutions	  were	   prepared	   in	   low	   ionic	   strength	   buffers	   at	   a	   final	   concentration	   of	   0.5%	   (v/v)	  
DMSO,	  diluted	  from	  a	  stock	  solution	  of	  inhibitor	  in	  100%	  DMSO.	  All	  ITC	  experiments	  were	  performed	  at	  
0.5%	  or	   lower	  DMSO	  concentration.	  DMSO	  equivalent	   to	   that	   in	   the	   titrant	  was	  added	   to	   the	  protein	  
solution	  in	  the	  cell	  to	  minimize	  thermal	  effects	  of	  changing	  DMSO	  concentration	  during	  the	  titration.	  As	  
reduced	  autoproteolysis	  is	   intrinsic	  to	  the	  optimized	  PRs	  after	  folding	  at	  pH	  5,	  concentrations	  of	  active	  
PRL76V	  were	  verified	  from	  the	  known	  stoichiometry	  of	  inhibitor	  binding	  to	  the	  active	  site	  (N	  =	  1)	  on	  titra-­‐
tion.	  Data	  were	  processed	  using	  the	  instrument’s	  Origin	  software.	  Three	  separate	  experiments	  at	  differ-­‐
ent	  concentrations	  of	  PRL76V	  and	  DRV	  were	  consistent	  with	  an	  upper	  limit	  of	  ~10	  nM	  for	  the	  dissociation	  
constant	  (KL).	  A	  displacement	  titration	  with	  50	  μM	  DRV	  in	  the	  presence	  of	  16	  μM	  RPB	  inhibitor	  (H-­‐Arg-­‐
Val-­‐Leu-­‐(r)-­‐Phe-­‐Glu-­‐Ala-­‐Nle-­‐NH2;	  Bachem	  Americas,	  Inc.,	  Torrance,	  CA)	  added	  to	  the	  sample	  cell	  contain-­‐
ing	  4	  μM	  PRL76V	  provided	  a	  more	  accurate	  value.	  Analogous	  displacement	  titrations	  under	  the	  same	  con-­‐
ditions	  with	  SQV	  or	  LPV	  did	  not	  give	  adequate	  thermal	  effect	  for	  reliable	  quantitation.	  
2.3.4 Autoprocessing	  of	  TFR-­‐PRL76V	  Precursor	  
Isolation	  of	  PR	  precursors	  in	  significant	  quantities	  presents	  a	  substantial	  challenge	  because	  the	  
intrinsic	  autoprocessing	  of	   the	  precursors	   to	  mature	  protease	   results	   in	   their	  depletion	  during	  expres-­‐
sion.	  However,	  amounts	  of	   the	   full	   length	  precursors	   sufficient	   for	   small	   scale	  experiments	  can	  be	   re-­‐
covered.	   Thus,	   remnants	   of	   the	   unprocessed	   precursor	   TFR-­‐PRL76V	   and	   TFR-­‐PRM46I/L76V	  were	   purified	   as	  
described	  (Louis	  et	  al.,	  1999a,	  Sayer	  et	  al.,	  2010).	  The	  precursor	  was	  folded	  by	  addition	  of	  5.66	  volumes	  
of	  5	  mM	  sodium	  acetate	  buffer,	  pH	  5.3,	  with	  or	  without	  added	  DRV,	  to	  TFR-­‐PRL76V	  in	  12	  mM	  HCl,	  to	  give	  
a	  final	  pH	  of	  4.5.	  Samples	  (5	  µl)	  were	  removed	  at	  times	  from	  0-­‐26	  hours,	  mixed	  with	  3	  µl	  SDS-­‐PAGE	  sam-­‐
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ple	   buffer	   and	   frozen	   immediately.	   Samples	  were	   subjected	   to	   electrophoresis	   on	   20%	  homogeneous	  
PhastGels	  (GE	  Healthcare),	  and	  visualized	  by	  staining	  with	  PhastGel	  Blue	  R.	  
2.3.5 Crystallographic	  Analysis	  
PRL76V	  at	  a	  concentration	  of	  7	  mg·∙ml
-­‐1	  was	  mixed	  with	  the	  inhibitors	  DRV	  or	  SQV	  at	  5-­‐fold	  molar	  
excess.	  Crystals	  were	  grown	  by	  the	  hanging-­‐drop	  vapor-­‐diffusion	  method	  at	  room	  temperature	  using	  24	  
well	  VDX	  plates	  (Hampton	  Research,	  Aliso	  Viejo,	  CA).	  The	  crystallization	  drops	  had	  equal	  volumes	  of	  the	  
protein	  and	  reservoir	  solutions.	  Crystals	  of	  PRL76V	  with	  DRV	  grew	  in	  solutions	  of	  30	  mM	  NaOAc	  buffer	  (pH	  
4.6-­‐5.0),	  1.4-­‐1.8	  M	  NaCl	  and	  3%	  (v/v)	  DMSO.	  Crystals	  of	  PRL76V	  with	  SQV	  grew	   in	  solutions	  of	  100	  mM	  
Tris-­‐HCl	  buffer	  (pH	  6.0-­‐9.0)	  and	  1.3	  M	  NaCl	  with	  3%	  (v/v)	  DMSO.	  The	  crystals	  were	  frozen	  in	  liquid	  nitro-­‐
gen	  with	   the	   cryoprotectant	   of	   20-­‐30%	   (v/v)	   glycerol.	   X-­‐ray	   diffraction	   data	   for	   the	   crystals	  were	   col-­‐
lected	  on	   the	  SER-­‐CAT	  beamline	  of	   the	  Advanced	  Photon	  Source,	  Argonne	  National	  Laboratory	   in	  Chi-­‐
cago.	  	  
X-­‐ray	  data	  were	  processed	  with	  HKL2000	  (Otwinowski	  et	  al.,	  1997).	  The	  structures	  were	  solved	  
by	  molecular	  replacement	  using	  MolRep	  in	  the	  CPP4i	  suite	  of	  programs	  (Vagin	  et	  al.,	  1997)	  and	  the	  start-­‐
ing	  model	  was	  the	  wild	  type	  PR	  complex	  with	  DRV	  (PDB	  code	  2IEN)	  (Tie	  et	  al.,	  2004)	  in	  the	  same	  space	  
group	  as	  the	  new	  structures.	  The	  structures	  were	  refined	  with	  SHELXL	  (Sheldrick	  et	  al.,	  1997)	  and	  refit-­‐
ted	  using	  Coot	  0.3.3	   (Emsley	   et	  al.,	  2004).	  Alternate	  conformations	  were	  modeled	   for	  PR	   residues,	   in-­‐
hibitors	  and	  solvent	  molecules	  based	  on	  the	  observed	  electron	  density	  maps.	  The	  solvent	  was	  modeled	  
with	   over	   200	  water	  molecules,	   ions	   and	   other	   solvent	   present	   in	   the	   crystallization	   solutions,	   as	   de-­‐
scribed	  (Tie	  et	  al.,	  2004).	  Anisotropic	  B	  factors	  were	  applied	  for	  all	  the	  structures.	  Hydrogen	  atom	  posi-­‐
tions	  were	  calculated	  in	  the	  last	  stage	  of	  refinement,	  using	  all	  data	  once	  all	  other	  parameters,	  including	  
disorder,	  had	  been	  modeled.	  The	  mutant	  crystal	  structures	  were	  compared	  with	  the	  wild	  type	  PR	  by	  su-­‐
perimposing	   their	   Cα	   atoms	   as	   described	   (Tie	   et	   al.,	   2004).	   Structural	   figures	  were	  made	  using	   PyMol	  
(DeLano,	  2002).	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2.3.6 Protein	  Data	  Bank	  Entries	  
The	  structure	  coordinates	  and	  factors	  have	  been	  deposited	  in	  the	  RCSB	  Protein	  Data	  Bank	  with	  
access	  number	  3PWM	  for	  PRL76V-­‐DRV	  and	  3PWR	  for	  PRL76V-­‐SQV.	  
2.4 Results	  and	  Discussion	  
2.4.1 Properties	  and	  Stability	  of	  Mature	  PRL76V	  
Purified	  mature	  PRL76V	  showed	  a	  Km	  of	  37	  ±	  6	  µM	  and	  kcat	  of	  334	  ±	  23	  min
-­‐1	  at	  pH	  5.6	  and	  200	  
mM	  NaCl.	  The	  catalytic	  efficiency,	  kcat/Km,	  of	  9.0	  mM	  
-­‐1	  min-­‐1	  for	  hydrolysis	  of	  the	  fluorogenic	  substrate	  
based	  on	  the	  p2/NC	  cleavage	  site	  is	  essentially	  the	  same	  (1.2-­‐fold)	  as	  the	  value	  of	  7.2	  mM	  -­‐1	  min-­‐1	  deter-­‐
mined	  for	  PR	  under	  the	  same	  conditions	  (Liu	  et	  al.,	  2008).	  A	  plot	  of	  the	  dependence	  of	  activity	  on	  urea	  
concentration	   (Figure	  2.2A)	   shows	  a	   transition	  midpoint	   (UC50)	  of	  0.85	  M	  urea	   for	  PRL76V,	  which	   is	   ap-­‐
proximately	  half	  the	  value	  of	  1.78	  M	  for	  PR	  (Table	  2.1).	   Increased	  susceptibility	  to	  urea	  denaturation	  is	  
consistent	  with	  the	   lower	  stability	  of	  the	  PRL76V	  dimer	  relative	  to	  the	  wild	  type	  enzyme	  as	  reflected	  by	  
the	  Kd	  of	  71	  ±	  24	  nM	  for	  the	  PRL76V	  (Figure	  2.2B),	  which	  is	  at	  least	  7-­‐fold	  higher	  than	  that	  of	  PR	  (Ishima	  et	  
al.,	  2007).	  	  
2.4.2 Inhibitor	  Binding	  
Differential	  scanning	  calorimetry	   (Figure	  2.3A)	  was	  used	  to	  assess	  the	  thermal	  denaturation	  of	  
PRL76V	  in	  the	  absence	  and	  presence	  of	  inhibitors.	  The	  observed	  Tm	  values	  for	  PRL76V	  in	  Table	  2.1	  are	  com-­‐
pared	  with	  those	  previously	  reported	  for	  PR	  under	  the	  same	  conditions	  (Sayer	  et	  al.,	  2009).	   In	  the	  ab-­‐
sence	  of	  inhibitors	  PRL76V	  is	  markedly	  less	  stable	  to	  thermal	  denaturation	  than	  is	  PR,	  with	  a	  Tm	  that	  is	  12	  
°C	   lower	   than	   that	   of	   PR.	  Although	   the	  mechanisms	  of	   heat-­‐	   and	  urea-­‐induced	  denaturations	   are	  not	  
necessarily	   the	   same,	   the	   low	  Tm	  value	   for	  PRL76V	   is	   consistent	  with	   the	  observed	  effect	  of	  urea	  on	   its	  
catalytic	  activity,	  as	  both	  heat-­‐	  and	  urea-­‐	  denaturations	   involve	  changes	   in	   the	  stability	  of	   the	  protein	  
fold,	  which	  may	  precede	  and/or	  accompany	  dimer	  dissociation.	  Even	  when	  complexed	  with	   inhibitors,	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which	  should	  stabilize	  the	  proteases	  as	  dimers,	  the	  Tm	  value	  for	  PRL76V	  is	  about	  7	  °C	  lower	  than	  that	  for	  
PR.	   The	  decreased	   thermal	   stability	  of	  PRL76V	   contrasts	  with	   results	   reported	   for	   several	  other	  PR	  mu-­‐
tants	   associated	   with	   drug	   resistance.	   For	   example,	   Tm	   values	   for	   ATV	   resistant	   mutant	   I50L/A71V	  
(Yanchunas	   Jr	   et	   al.,	   2005)	   and	  multi-­‐drug	   resistant	  mutant	   V82F/I84V	   (Todd	   et	   al.,	   2000)	  were	   both	  
higher	  than	  the	  values	  observed	  for	  PR	  by	  2.2	  and	  4	  °C,	  respectively.	  A	  multi-­‐drug	  resistant	  mutant	  bear-­‐
ing	  11	  mutations	  also	  exhibited	  a	  slightly	  higher	  Tm	  than	  the	  wild	  type	  enzyme	  (Muzammil	  et	  al.,	  2007).	  	  	  
An	  upper	   limit	  of	  ~10	  nM	   for	   the	  dissociation	   constant	   (KL)	  of	   the	  PRL76V-­‐DRV	  complex,	  with	  a	  
range	   between	   6.6	   and	   18	   nM,	  was	   obtained	   by	   direct	   ITC	   titrations	   with	   the	   inhibitor.	   A	   substrate-­‐
analog	  inhibitor	  (RPB)	  with	  a	  reduced	  peptide	  bond	  exhibits	  a	  good	  negative	  thermal	  response	  (ΔH	  =	  -­‐4.3	  
kcal/mol)	  on	  binding	  to	  PRL76V	  and	  a	  KL	  of	  61	  ±	  13	  nM	  (Figure	  2.3B).	  A	  displacement	  titration	  with	  DRV	  in	  
the	  presence	  of	  RPB	  gave	  a	  value	  of	  0.79	  ±	  0.29	  nM	  (Figure	  2.3C),	  approximately	  160–fold	  larger	  than	  KL	  
for	  the	  PR-­‐DRV	  complex	  (King	  et	  al.,	  2004,	  Brower	  et	  al.,	  2008).	  Lack	  of	  an	  adequate	  thermal	  response	  
under	  the	  same	  conditions,	  either	  on	  direct	  titration	  or	  displacement	  of	  RPB	  (10-­‐15	  mM),	  precluded	  KL	  
measurements	  with	  SQV	  and	  LPV.	  Alternatively,	  a	  qualitative	  indication	  of	  the	  relative	  binding	  affinity	  of	  
different	  inhibitors	  to	  the	  same	  protein	  can	  be	  obtained	  from	  the	  increase	  in	  thermal	  denaturation	  tem-­‐
perature	   (ΔTm)	   in	   the	  presence	  of	   inhibitor	   (Sayer	   et	   al.,	   2009,	   Sayer	   et	   al.,	   2008,	   Yanchunas	   Jr	   et	   al.,	  
2005).	  The	  values	  of	  ΔTm	  for	  DRV,	  SQV	  and	  LPV	  binding	  to	  PRL76V	  are	  significantly	  larger	  (by	  5-­‐7	  °C)	  than	  
for	  PR,	  reflecting	  both	  the	  low	  thermal	  stability	  of	  the	  free	  PRL76V	  and	  significant	  stabilization	  of	  the	  pro-­‐
tein-­‐inhibitor	  complexes.	  ΔTm	  values	  for	  DRV,	  SQV	  and	  LPV	  binding	  to	  the	  PRL76V	   (Figure	  2.3A)	  differ	  by	  
less	  than	  2°	  C	   in	  the	  order	  DRV>SQV>LPV	  are	  consistent	  with	  large	  binding	  constants	  (small	  KL	  values),	  
although	  the	  magnitude	  of	  their	  enthalpy	  values	  for	  thermal	  denaturation	  decrease	  significantly	   in	  the	  
same	  order.	  The	  effects	  of	  these	  three	  inhibitors	  on	  autoprocessing	  of	  the	  TFR-­‐PRL76V	  precursor	  (cf.	  Fig-­‐
ure	  2.4	  and	  following	  section)	  suggest	  that	  KL	  for	  SQV	  and	  LPV	  will	  be	  larger	  than	  the	  0.8	  nM	  observed	  
by	  ITC	  for	  DRV.	  By	  contrast,	  in	  vitro	  phenotype	  assays	  found	  the	  mutation	  L76V	  in	  PR	  derived	  from	  clini-­‐
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cal	   samples	   to	   be	   associated	   with	   enhanced	   susceptibility	   to	   SQV	   and	   resistance	   to	   DRV	   and	   LPV	  
(Vermeiren	   et	  al.,	  2007,	  Young	   et	  al.,	  2010).	  However,	   in	  many,	   if	  not	  most,	  DRV	  resistant	  clinical	   iso-­‐
lates,	  a	  single	  resistance	  mutation	  does	  not	  occur	  alone	  but	  is	  associated	  with	  other	  mutations	  such	  as	  
M46I	  and	  L90M	  (Mueller	  et	  al.,	  2004,	  Mitsuya	  et	  al.,	  2007),	  which	  are	  selected	  along	  with	  L76V	  in	  clinical	  
settings.	  It	  is	  possible	  that	  the	  relative	  responses	  to	  these	  inhibitors	  as	  well	  as	  the	  dimer	  stability	  may	  be	  
altered	  by	  the	  presence	  of	  such	  additional	  mutations.	  
2.4.3 Autoprocessing	  of	  PRL76V	  and	  PRM46I/L76V	  Precursors	  
During	   viral	   replication,	   the	   autocatalytic	   processing	   (autoprocessing)	   of	   PR	   from	   its	   Gag-­‐Pol	  
polyprotein	  precursor	   is	  essential	   to	  generate	   the	  active	  mature	  PR	  and	   requisite	   structural	   and	   func-­‐
tional	  proteins	  of	  the	  infective	  virion	  (Louis	  et	  al.,	  2000).	  Cleavage	  between	  the	  transframe	  region	  (TFR),	  
encoded	  in	  the	  Pol	  open	  reading	  frame,	  and	  the	  N	  terminus	  of	  PR	  domain	  (TFR/PR	  site)	  is	  crucial	  for	  the	  
formation	   of	   stable	   PR	   dimers	   with	   full	   catalytic	   activity	   from	   the	  monomeric	   TFR-­‐PR.	   Consequently,	  
compromising	  this	  process	  will	  adversely	  affect	  the	  viability	  of	  the	  virus.	  Previous	  studies	  with	  the	  wild	  
type	  precursor,	  TFR-­‐PR,	  have	  identified	  the	  pathways	  for	  its	  maturation	  (Louis	  et	  al.,	  2000,	  Louis	  et	  al.,	  
2007).	  The	  time	  course	  of	  autoprocessing	  in	  the	  absence	  of	  inhibitors	  and	  in	  the	  presence	  of	  LPV,	  SQV	  
and	  DRV	  is	  shown	  in	  Figure	  2.4.	  At	  low	  pH	  an	  initial	  cleavage	  of	  TFR-­‐PR	  (a)	  occurs	  between	  F8/L9	  of	  the	  
TFR	  to	  give	  an	  intermediate	  (b)	  with	  low	  catalytic	  activity	  similar	  to	  the	  full-­‐length	  precursor.	  Subsequent	  
cleavage	  at	  the	  TFR/PR	  site	  releases	  the	  fully	  active,	  mature	  PR	  (c)	  and	  the	  fragment	  TFR9-­‐56	   (d).	  Auto-­‐
processing	  was	   assessed	   in	   vitro	   with	   a	   precursor	   comprising	   the	   56-­‐amino	   acid	   TFR	   fused	   to	   the	   N-­‐
terminus	  of	   the	  PR	  domain	   containing	   the	   L76V	  mutation	   (TFR-­‐PRL76V).	  Reactions	   conducted	  at	  ~6	  µM	  
protein	  concentration	  permit	  monitoring	  the	  autoprocessing	  of	  the	  precursor	  in	  small	  volumes	  suitable	  
for	   SDS-­‐PAGE	  on	  PhastGels.	   In	   the	   absence	  of	   inhibitors,	   only	   ~50%	  of	   the	   autoprocessing	   reaction	   is	  
complete	  at	  6	  h	  (Figure	  2.4A),	  in	  contrast	  to	  that	  of	  	  wild	  type	  TFR-­‐PR,	  which	  is	  complete	  in	  <	  1	  h	  (Louis	  
et	  al.,	  2000,	  Louis	  et	  al.,	  1999b).	  Thus,	  the	  slower	  rate	  of	  autoprocessing	  of	  TFR-­‐PRL76V	  seems	  to	  correlate	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with	   the	   lower	   stability	   of	   the	   mature	   PRL76V,	   namely	   the	   higher	   Kd	   and	   increased	   susceptibility	   to	  
denaturation	   by	   urea.	   Processing	   was	   only	   partially	   inhibited	   by	   LPV	   (Figure	   2.4B),	   but	   completely	  
inhibited	  by	  DRV	  (Figure	  2.4D),	  using	  both	  inhibitors	  at	  a	  concentration	  of	  	  6	  µM.	  SQV	  is	  intermediate	  in	  
its	   inhibition	  of	   TFR-­‐PRL76V	   autoprocessing	   being	   slightly	   better	   than	   LPV	   and	  poorer	   than	  DRV.	   In	   the	  
presence	  of	  LPV	  and	  SQV	  some	  cleavage	  occurred	  at	  F8/L9	  to	  give	  the	   intermediate	  TFR9-­‐56-­‐PRL76V,	  but	  
very	   little	  or	  no	   subsequent	   cleavage	  was	  detected	  at	   the	  N-­‐terminus	  of	   the	  protease	  domain	   to	  give	  
mature	  PRL76V.	  
The	  single	  mutation	  L76V	  severely	  compromises	  viral	  replication	  in	  cell	  cultures,	  whereas	  coexis-­‐
tence	  of	  another	  mutation,	  M46I,	  was	  found	  to	  increase	  resistance	  to	  LPV	  while	  also	  partially	  restoring	  
the	  ability	  of	  the	  virus	  to	  replicate	  (Nijhuis	  et	  al.,	  2009a).	  This	  presumably	  occurs	  by	  increasing	  the	  stabil-­‐
ity	  and/or	  catalytic	  efficiency	  of	  the	  protease	  or	  its	  precursor.	  Unfortunately,	  it	  was	  not	  possible	  to	  iso-­‐
late	   the	  mature	   PRM46I/L76V	   because	  of	   its	   rapid	   autoproteolysis	   and	   very	   poor	   accumulation	  during	   its	  
expression.	  However,	  limited	  quantities	  of	  the	  precursor	  TFR-­‐PR	  M46I/L76V	  could	  be	  obtained	  for	  compari-­‐
son	  with	  TFR-­‐PRL76V	  under	  the	  same	  conditions.	   In	  the	  absence	  of	   inhibitors,	  TFR-­‐PR	  M46I/L76V	  undergoes	  
autoprocessing	   significantly	   faster	   (Figure	  2.4E)	   than	  TFR-­‐PRL76V.	   The	  additional	  M46I	  mutation	  has	  no	  
effect	  on	  inhibition	  by	  6	  µM	  SQV	  or	  DRV	  (Figure	  2.4G	  and	  2.4H).	  Interestingly,	  however,	  TFR-­‐PR	  M46I/L76V	  
almost	  completely	  evades	  inhibition	  (Figure	  2.4F)	  under	  conditions	  where	  LPV	  inhibits	  processing	  of	  the	  
single	  mutant	  TFR-­‐PRL76V.	  These	  results	  are	  consistent	  with	  the	  observations	  of	  Nijhuis	  et	  al.	  (Nijhuis	  et	  
al.,	  2009a),	  and	  underscore	  the	  potential	  importance	  of	  secondary	  mutations	  for	  precursor	  processing,	  
both	  by	  improving	  the	  intrinsic	  autoprocessing	  activity	  of	  an	  otherwise	  compromised	  precursor,	  and	  by	  
decreasing	  its	  susceptibility	  to	  inhibition.	  	  
2.4.4 PRL76V-­‐Inhibitor	  Crystal	  Structures	  
Crystal	   structures	   of	   PRL76V	   in	   complexes	  with	   DRV	   and	   SQV	  were	   determined	   to	   identify	   any	  
structural	  changes	  caused	  by	  the	  mutation.	  The	  crystallographic	  data	  collection	  and	  refinement	  statistics	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are	  displayed	  in	  Table	  2.2.	  The	  crystal	  structures	  of	  PRL76V-­‐DRV	  and	  PRL76V-­‐SQV	  were	  refined	  to	  R-­‐factors	  
of	  0.14	  at	  the	  resolutions	  of	  1.45	  and	  1.46	  Å.	  The	  crystal	  structures	  had	  one	  PR	  dimer	  with	  residues	  la-­‐
beled	  1-­‐99	  and	  1’-­‐99’	   in	  each	  crystallographic	  asymmetric	  unit	   in	   the	  space	  group	  of	  P21212.	  DRV	  and	  
SQV	  were	  observed	  in	  two	  alternate	  conformations	  in	  the	  active	  site	  cavity	  of	  the	  dimer	  of	  PRL76V	  with	  
relative	  occupancies	   of	   0.63/0.37	   and	  0.73/0.27,	   respectively.	   Alternate	   conformations	  were	  modeled	  
for	  10	  and	  17	  residues	  in	  the	  PRL76V-­‐SQV	  and	  PRL76V-­‐DRV	  structures,	  respectively.	  The	  flap	  residues	  46,	  50	  
and	   51	   exhibited	   alternative	   conformations	   in	   both	   subunits	   of	   the	   two	   structures.	   The	  DRV	   complex	  
also	  showed	  alternative	  conformations	  of	  the	  side	  chains	  for	  Val82,	  Pro81’,	  Val82’	  and	  I84’	  in	  the	  inhibi-­‐
tor	  binding	  site;	  however,	  these	  residues	  showed	  a	  single	  conformation	  in	  the	  SQV	  complex.	  The	  struc-­‐
tures	  were	  refined	  with	  more	  than	  200	  water	  molecules.	  The	  solvent	  included	  one	  sodium	  ion,	  two	  chlo-­‐
ride	  and	  3	  acetate	  molecules	  in	  the	  DRV	  complex,	  while	  the	  SQV	  complex	  showed	  8	  glycerol	  molecules.	  
2.4.5 Structural	  Changes	  at	  the	  Site	  of	  Mutation	  
The	   PRL76V	   complexes	  with	  DRV	   and	   SQV	  were	   compared	  with	   the	   corresponding	   PR-­‐inhibitor	  
complexes.	  The	  PR-­‐DRV	  (2IEN)	  (Tie	  et	  al.,	  2004)	  structure	  was	  solved	  in	  the	  same	  space	  group	  P21212	  at	  
1.30	  Å	  resolution.	  The	  DRV	  complexes	  shared	  very	  similar	  backbone	  conformations	  with	  a	  low	  RMSD	  of	  
0.11	  Å	  on	  Cα	  atoms.	  The	  PR-­‐SQV	  (2NMW)	  (Tie	  et	  al.,	  2007)	  structure	  was	  refined	  at	  1.16	  Å	  resolution	  in	  
the	  same	  space	  group,	  although	  the	  unit	  cell	  dimensions	  differed.	  Hence,	  the	  SQV	  complexes	  with	  PRL76V	  
and	  PR	  superimposed	  with	  the	   larger	  RMSD	  value	  of	  0.65	  Å	  resulting	  from	  variations	  of	  up	  to	  2.3	  Å	   in	  
residues	  37-­‐41	  and	  36’-­‐45’,	  as	  typically	  seen	  for	  PR	  complexes	  in	  different	  space	  groups.	  
Leu76	  lies	  in	  the	  inner	  hydrophobic	  cluster	  in	  each	  subunit	  of	  the	  PR	  dimer	  (Ishima	  et	  al.,	  2001),	  
and	  its	  side	  chain	  makes	  hydrophobic	  contacts	  with	  the	  side	  chains	  of	  Asp30,	  Val32,	  Lys45,	  Ile47,	  Val56,	  
Gln58	  and	  Thr74.	  The	  mutation	  of	  leucine	  76	  to	  valine	  gives	  a	  shorter	  side	  chain,	  which	  results	  in	  the	  loss	  
of	  several	  van	  der	  Waals	  contacts.	  In	  the	  PRL76V-­‐DRV	  complex,	  hydrophobic	  contacts	  with	  the	  side	  chains	  
of	  Asp30,	  Lys45,	  and	  Thr74	  and	  one	  contact	  with	  Ile47	  are	  lacking	  in	  both	  subunits,	  as	  shown	  by	  an	  in-­‐
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teratomic	  distance	  of	  more	  than	  4.2	  Å	  (Figure	  2.5A).	  Instead,	  the	  mutated	  Val76	  forms	  more	  and	  closer	  
hydrophobic	   interactions	  with	   the	   side	   chain	   of	   Val32,	  with	   interatomic	   distances	   of	   3.8-­‐4.0	   Å	   rather	  
than	  the	  longer	  4.2	  Å	  separation	  seen	  in	  the	  PR	  structure.	  Similar	  changes	  are	  observed	  in	  the	  PRL76V-­‐SQV	  
complex,	  with	  the	  exception	  of	  contacts	  with	  Val32	  and	  Val56.	  The	  side	  chains	  of	  Val56	  and	  residue	  76	  
exhibit	  multiple	  hydrophobic	   contacts	   in	   the	  PRL76V	   complexes	  with	  both	   inhibitors	   and	   in	   the	  PR-­‐DRV	  
structure;	  however,	  the	  PR-­‐SQV	  structure	  shows	  only	  a	  single	  van	  der	  Waals	  interaction	  between	  these	  
residues	  (Figure	  2.5B	  and	  C).	  Similarly,	  the	  side	  chains	  of	  Leu76	  and	  Val32	  show	  no	  hydrophobic	  contacts	  
in	  PR-­‐SQV,	  while	  multiple	  contacts	  are	  seen	  in	  the	  PRL76V-­‐SQV	  complex	  and	  both	  DRV	  complexes.	  Thus,	  
PR-­‐SQV	  shows	   fewer	   internal	   contacts	  around	  Leu76	  compared	   to	   those	  of	  Val76	   in	   the	  mutant	   com-­‐
plex,	  whereas	  similar	  contacts	  of	  residues	  32,	  56	  and	  76	  are	  maintained	  in	  both	  DRV	  complexes.	  	  
The	  decrease	  in	  internal	  van	  der	  Waals	  interactions	  is	  correlated	  with	  the	  lower	  stability	  of	  the	  
mutant	  relative	  to	  the	  wild	  type	  enzyme	  described	  in	  the	  previous	  section.	  In	  contrast	  to	  other	  mutants	  
exhibiting	   lower	  stability	  such	  as	  PRL24I,	  PRI50V	  and	  PRF53L	  (Liu	  et	  al.,	  2005,	  Liu	  et	  al.,	  2006),	  however,	  no	  
significant	  changes	  were	  seen	  at	  the	  dimer	  interface	  of	  the	  mutant	  structures.	  Therefore,	  the	  major	  mo-­‐
lecular	  change	  associated	  with	  the	  significantly	  lower	  stability	  of	  PRL76V	  is	  the	  loss	  of	  internal	  hydropho-­‐
bic	  contacts	  characteristic	  of	  Leu76.	  This	  loss	  of	  hydrophobic	  contacts	  at	  the	  mutated	  residue	  stands	  in	  
strong	   contrast	   to	   the	  minimal	   changes	   reported	   for	   the	  majority	   of	   single	  mutants	   (Liu	   et	   al.,	   2005,	  
Shen	  et	  al.,	  2010).	  For	  example,	  our	  recent	  analysis	  of	  6	  mutants	  with	  single	  substitutions	  of	  residues	  in	  
the	  hydrophobic	  clusters	  showed	  small	  structural	  adjustments	  that	  tended	  to	  conserve	  the	  hydrophobic	  
interactions	   (Shen	   et	   al.,	   2010).	   Hence,	   the	  major	   loss	   of	   internal	   hydrophobic	   contacts	   for	   Val76	   in	  
PRL76V,	   coupled	   with	   reduced	   stability	   that	   is	   offset	   by	   secondary	   mutations,	   exemplifies	   a	   distinct	  
mechanism	  for	  drug	  resistance.	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2.4.6 Protease-­‐Inhibitor	  Interactions	  
In	  the	  crystal	  structure	  of	  PRL76V-­‐DRV,	  the	  inhibitor	  is	  observed	  in	  two	  orientations	  bound	  within	  
the	  active	  site	  cavity	  by	  a	  set	  of	  hydrogen	  bonds,	  which	  are	  similar	  to	  those	  in	  the	  PR-­‐DRV	  structure	  (Tie	  
et	  al.,	  2004).	  Both	  orientations	  of	  DRV	  show	  similar	  hydrogen	  bond	  interactions	  with	  PRL76V.	  DRV	  formed	  
4	  hydrogen	  bonds	  with	  the	  main	  chain	  atoms	  of	  Gly27’,	  Asp29’,	  and	  Asp30’,	  and	  5	  hydrogen	  bonds	  with	  
the	  side	  chain	  atoms	  of	  Asp25/Asp25’	  and	  Asp30	  of	  PRL76V	  (Figure	  2.6A).	  The	  water-­‐mediated	  hydrogen	  
bonds	  between	  Ile50/50’	  and	  DRV	  are	  conserved	  in	  the	  majority	  of	  crystal	  structures	  of	  PR	  and	  its	  mu-­‐
tants	  with	  inhibitors	  and	  substrates.	  Compared	  with	  the	  wild	  type	  complex,	  DRV	  shows	  weaker	  interac-­‐
tions	  with	  the	  main	  chain	  of	  Asp30,	  which	  is	  associated	  with	  the	  shift	  of	  the	  aniline	  group	  of	  DRV	  away	  
from	  the	  Asp30	  of	  PRL76V	  (Figure	  2.6B).	  The	  interatomic	  distance	  representing	  a	  hydrogen	  bond	  between	  
the	  aniline	  amino	  group	  of	  DRV	  and	  the	  amide	  of	  Asp30	  in	  PR-­‐DRV	  is	  elongated	  from	  3.2	  to	  3.6	  Å	  in	  the	  A	  
subunit	  of	  PRL76V-­‐DRV,	  while	  the	   interatomic	  distance	  between	  the	  DRV	  amino	  group	  and	  the	  carbonyl	  
oxygen	  of	  Asp30	  has	  lengthened	  from	  3.3	  to	  4.4	  Å	  showing	  loss	  of	  a	  hydrogen	  bond	  in	  the	  PRL76V	  mutant.	  
These	  changes	  may	  correlate	  with	  the	  loss	  of	  internal	  van	  der	  Waals	  contacts	  of	  Val76,	  especially	  those	  
with	  Asp30,	  relative	  to	  those	  of	  the	  wild	  type	  Leu76.	  	  
SQV	   is	  bound	  at	   the	  active	  site	   in	   two	  pseudosymmetric	  orientations	   in	  PRL76V-­‐SQV.	  The	  major	  
conformation	   of	   SQV	   forms	   9	   direct	   hydrogen	   bond	   interactions	   and	   four	   water-­‐mediated	   hydrogen	  
bonds	  with	  PRL76V	  (Figure	  2.6C).	  The	  mutant	  exhibits	  one	  improved	  direct	  and	  one	  more	  water-­‐mediated	  
interaction	  with	  SQV	  as	  compared	  with	  those	  in	  the	  wild	  type	  complex.	  Notably,	  a	  hydrogen	  bond	  inter-­‐
action	   is	   formed	  between	  the	  carbonyl	  oxygen	  of	  Gly27	  and	  the	  amide	  of	  SQV	  at	  3.3	  Å	  distance	  com-­‐
pared	  to	  the	  very	  weak	  3.6	  Å-­‐long	  interaction	  observed	  in	  the	  wild	  type	  complex	  (Figure	  2.6D).	  The	  con-­‐
served	   water-­‐mediated	   hydrogen	   bonds	   are	   seen	   between	   Ile50/50’	   and	   SQV,	   and	   another	   water-­‐
mediated	   interaction	   is	   conserved	   in	   reported	  high	   resolution	  crystal	   structures	  of	  PR	  and	   its	  mutants	  
with	  SQV	  (Tie	  et	  al.,	  2007).	  Compared	  with	  the	  PR-­‐SQV	  crystal	  structure,	  one	  more	  water-­‐mediated	  hy-­‐
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drogen	  bond	   is	  observed	  between	  SQV	  and	   the	  amide	  of	  Asp29	   in	  PRL76V.	  No	  water	  was	  visible	  at	   the	  
equivalent	  position	   in	   the	  wild	   type	  structure;	  however,	   the	  observation	  of	  ordered	  solvent	  molecules	  
partly	  depends	  on	  the	  crystallization	  conditions,	  quality	  and	  resolution	  of	  the	  diffraction	  data.	  Overall,	  
SQV	  has	  slightly	  improved	  hydrogen	  bond	  interactions	  with	  PRL76V	  relative	  to	  the	  wild	  type	  PR	  suggesting	  
that	  the	  mutant	  may	  retain	  high	  binding	  affinity	  for	  this	  inhibitor.	  
2.4.7 Implications	  for	  Drug	  Resistance	  
The	   structural	   changes	   in	   the	   PRL76V-­‐inhibitor	   complexes	   suggest	   the	   molecular	   basis	   for	   the	  
lowered	  stability	  of	   this	  mutant	  and	  slower	  autoprocessing	  of	   its	  precursor.	  The	   reduced	  hydrophobic	  
interactions	  of	  Val76	  can	  directly	  perturb	  the	  interactions	  of	  DRV	  with	  Asp30,	  although	  no	  direct	  effect	  
on	  the	  SQV	  interactions	  was	  seen.	  Also,	  the	  mutation	  is	   likely	  to	  perturb	  the	  flaps	  through	  loss	  of	  con-­‐
tacts	  between	  residue	  76	  and	  flap	  residues	  Lys45	  and	  Ile47.	  Movement	  of	  the	  flaps	  is	  required	  for	  bind-­‐
ing	  of	  substrate	  and	  release	  of	  products	  (Liu	  et	  al.,	  2006).	  Inter-­‐flap	  contacts	  also	  contribute	  to	  the	  dimer	  
interface,	  so	  that	  destabilization	  of	  the	  flaps	  will	   likely	  contribute	  to	  the	  higher	  dimer	  dissociation	  con-­‐
stant	  of	  PRL76V	  and	  its	  increased	  susceptibility	  to	  thermal	  and	  urea-­‐induced	  denaturations.	  Consequently,	  
precursor	   processing,	   formation	  of	   the	  mature	  dimer	   and	  drug	   resistance	  depend	  on	  maintaining	   the	  
correct	  flap	  conformations	  and	  their	  contacts	  with	  internal	  hydrophobic	  residues	  like	  Leu76.	  
The	  properties	  of	  this	  mutant	  are	  discussed	  in	  relation	  to	  the	  interactions	  of	  the	  nine	  clinical	  in-­‐
hibitors	  in	  order	  to	  understand	  why	  the	  L76V	  mutation	  is	  associated	  with	  increased	  resistance	  to	  some	  
drugs	  while	  retaining	  effective	  binding	  affinity	  for	  other	  clinical	  inhibitors.	  DRV	  forms	  no	  direct	  hydrogen	  
bonds	   with	   flap	   residues	   suggesting	   that	   its	   binding	  may	   allow	   changes	   in	   flap	   conformation	   (Figure	  
2.6A).	  In	  contrast,	  SQV	  forms	  a	  hydrogen	  bond	  with	  the	  carbonyl	  oxygen	  of	  Gly48	  in	  the	  flap,	  which	  sug-­‐
gests	   SQV	   binding	  may	   restrict	   such	   conformational	   changes	   (Figure	   2.6C).	   This	   analysis	   of	   the	   PRL76V	  
crystal	  structures	  and	  other	  PR	  complexes	  sheds	  light	  on	  the	  opposing	  clinical	  responses	  of	  this	  mutant	  
to	  different	  drugs	  (Nijhuis	  et	  al.,	  2009a,	  Young	  et	  al.,	  2010,	  Mueller	  et	  al.,	  2004).	  L76V	  is	  associated	  with	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resistance	  to	  the	  inhibitors	  LPV,	  DRV,	  APV,	  and	  IDV,	  which	  form	  hydrogen	  bond	  interactions	  with	  Gly27,	  
Asp29	  and/or	  Asp30	  near	  the	  catalytic	  Asp25,	  as	  well	  as	  the	  conserved	  water-­‐mediated	  interactions	  with	  
Ile50/50’	   (Tie	  et	  al.,	  2004,	  Mahalingam	  et	  al.,	  2004,	  Muzammil	  et	  al.,	  2007,	  Shen	  et	  al.,	  2010).	  On	  the	  
other	  hand,	  inhibitors	  ATV,	  SQV	  and	  TPV,	  for	  which	  mutants	  containing	  L76V	  show	  increased	  susceptibil-­‐
ity,	   all	   form	  direct	   or	  water-­‐mediated	   hydrogen	   bond	   interactions	  with	  Gly48,	  while	   TPV	   is	   unique	   in	  
forming	  direct,	  instead	  of	  water-­‐mediated,	  hydrogen	  bonds	  with	  the	  amides	  of	  Ile50	  and	  50’	  (Muzammil	  
et	  al.,	  2007).	  NFV	   is	   the	  only	  exception	  with	  no	  direct	   flap	   interactions	   (Kaldor	   et	  al.,	  1997),	  however,	  
susceptibility	  to	  NFV	  is	  less	  strongly	  associated	  with	  the	  L76V	  mutation	  compared	  to	  other	  drugs	  (Young	  
et	  al.,	  2010,	  Rhee	  et	  al.,	  2010).	  	  
The	   observed	   structural	   changes	   provide	   insight	   into	   the	   effects	   of	   combining	  mutation	   L76V	  
with	  M46I,	  which	  has	  been	  reported	  to	  contribute	  strongly	  to	  competence	  of	  the	  virus	  to	  replicate	  and	  
its	   clinical	   resistance	   to	  LPV	   (Nijhuis	   et	  al.,	  2009b).	  Analysis	  of	   the	  wild	   type	  PR	  crystal	   structures	   sug-­‐
gests	   that	   the	   P2	   group	   of	   LPV	   is	   unusual	   in	   forming	  multiple	   close	   hydrophobic	   contacts	  with	   Ile47,	  
whereas	  DRV	  and	  SQV	  show	  only	  1	  or	  2	  hydrophobic	  contacts	  with	  Ile47.	  Thus,	  altered	  contacts	  with	  flap	  
residues	  45	  and	  47	  associated	  with	  mutation	  L76V	  may	  partially	  diminish	  the	  binding	  affinity	  of	  LPV	  and	  
contribute	   to	   resistance	   to	   this	   drug	  while	   having	   less	   effect	   on	   the	   other	   drugs.	   Residues	   46	   and	   76	  
have	  no	  direct	  contacts	  in	  the	  dimer	  structure,	  since	  residue	  76	  is	  part	  of	  the	  internal	  hydrophobic	  clus-­‐
ter,	  while	  the	  side	  chain	  of	  residue	  46	  points	  away	  from	  the	  protein	  surface	  of	  the	  flexible	  flap.	  Instead,	  
Leu76	   contacts	   the	   side	   chains	   of	   Lys45	   and	   Ile47	   on	   either	   side	   of	  Met46.	   In	   PRL76V,	   Lys45	   and	   Ile47	  
show	  reduced	  interactions	  with	  Val76,	  suggesting	  that	  M46I	  may	  indirectly	  compensate	  for	  the	  destabi-­‐
lizing	  effects	  of	  L76V.	  Notably,	  although	  PRL76V	  shows	  a	  much	  slower	  rate	  of	  autoprocessing	  of	  its	  precur-­‐
sor	   relative	   to	   the	   wild	   type,	   in	   agreement	   with	   reported	   defective	   viral	   replication	   (Nijhuis	   et	   al.,	  
2009a),	   the	   rate	   is	   increased	   upon	   introduction	   of	  M46I	   (Figure	   2.4D).	   Furthermore,	   the	   presence	   of	  
both	  mutations	  significantly	  restores	  autoprocessing	  capability	   in	  the	  presence	  of	  LPV,	  although	  inhibi-­‐
63 
tion	  by	  DRV	   is	   retained.	  These	  results	  are	  consistent	  with	  previous	  data	  on	  viral	   replication	   in	  cell	  cul-­‐
tures	  (Nijhuis	  et	  al.,	  2009a)	  and	  suggest	  that	  investigating	  effects	  on	  precursor	  processing	  and	  its	  inhibi-­‐
tion	  will	  provide	  a	  useful	  approach,	  which	  is	  complementary	  to	  studies	  of	  inhibitor	  interactions	  with	  the	  
mature	  protease,	  for	  understanding	  the	  role	  and	  interactions	  of	  multiple	  mutations	  in	  drug	  resistance.	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Table	  2.1	  Dimer	  dissociation,	  urea	  and	  thermal	  denaturation	  of	  PRL76V	  
Protease	   UC50	  (M)	   Kd	  (nM)	  
Tm	  	  (°C)	  
no	  inhibitor	  
Tm	  (ΔTm)	  (°C)	  
DRV	  
Tm	  (ΔTm)	  (°C)	  
SQV	  
Tm	  (ΔTm)	  (°C)	  
LPV	  
PRL76V	   0.85	   71	  ±	  24	   53.7	   80.9	  (27.2)	   79.5	  (25.8)	   79.1	  (26.1)	  
PR	   1.78	   <10a	   65.7b	   88.1b	  (22.4)	   85.0b	  (19.3)	   nd	  	  	  (20.4)c	  
nd	  –	  not	  determined	  by	  DSC	  
aData	  from	  (Louis	  et	  al.,	  1999a)	  	  
bData	  from	  (Sayer	  et	  al.,	  2009)	  	  








































Table	  2.2	  Crystallographic	  data	  collection	  and	  refinement	  statistics	  
Protease	   PRL76V	   PRL76V	  
Inhibitor	   DRV	   SQV	  
Space	  group	   P21212	   P21212	  












Resolution	  range	  (Å)	   50-­‐1.46	   50-­‐1.45	  
Unique	  reflections	   37895	   38308	  
Rmerge	  (%)	  overall




<I/σ>	  overalla	   34.9	  (2.1)	   27.3	  (2.2)	  
Data	  range	  for	  refinement	  (Å)	   10-­‐1.46	   10-­‐1.45	  
Completeness	  (%)	  overalla	   91.9%	  (54.9%)	   90.1%	  (56.4%)	  
Rwork	  	   0.1404	   0.1449	  
Rfree	   0.1891	   0.1971	  
No.	  of	  solvent	  (total	  occupancies)b	   278	  (209.9)	   191	  (151.7)	  
RMS	  Deviation	  from	  Ideality	  
Bonds	  (Å)	   0.011	   0.011	  
Angle	  distance	  (Å)	   0.032	   0.029	  
Average	  B-­‐factors	  (Å2)	  
Main	  chain	  atoms	  













Relative	  occupancy	  of	  inhibitor	   0.64/0.36	   0.73/0.27	  
aValues	  in	  parentheses	  are	  given	  for	  the	  highest	  resolution	  shell	  




Figure	  2.1	  HIV-­‐1	  PR	  dimer	   structure	   (grey	  and	  yellow	  ribbons	   represent	   the	   two	  subunits)	  bound	   to	  
darunavir	  (red	  sticks).	  The	  site	  of	  mutation	  is	  indicated	  by	  magenta	  sticks	  for	  Leu76	  on	  one	  subunit.	  Po-­‐
sitions	  of	  residues	  interacting	  with	  Leu76	  are	  indicated	  and	  colored	  in	  green. 
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Figure	   2.2	   Urea	   denaturation	   of	   PRL76V	   and	  wild-­‐type	   PR	   and	   kinetic	   determination	   of	   PRL76V	   dimer	  
dissociation.	  A.	  UC50	  =	  0.85	  M	  and	  1.78	  M,	  for	  PRL76V	  and	  PRWT,	  respectively,	  dashed	  intersect	  on	  X-­‐axis).	  
B.	  A	  Dissociation	  constant,	  Kd	  =	  71	  ±	  24	  nM	  for	  PRL76V,	  indicated	  by	  the	  dashed	  vertical	  line	  at	  50%	  activ-­‐
ity,	  was	  determined	  as	  described	  (see	  Materials	  and	  Methods).	  	  For	  the	  wild	  type	  PR,	  Kd	  is	  <	  10	  nM	  [not	  
shown,	  (Louis	  et	  al.,	  2007)].	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Figure	  2.3	  Thermochemical	  data	  for	  interactions	  of	  inhibitors	  with	  PRL76V.	  A.	  DSC	  thermograms	  of	  PRL76V	  
in	  the	  presence	  and	  absence	  of	  inhibitors	  in	  50	  mM	  sodium	  acetate	  buffer,	  pH	  5.0.	  The	  thermal	  transi-­‐
tion	  temperatures	  (curve	  maxima)	  are	  in	  parentheses.	  	  Inhibitors	  were	  in	  a	  twofold	  molar	  excess	  relative	  
to	  dimeric	  PRL76V.	  B.	   ITC	  trace	  of	  5	  mM	  PRL76V
	  titrated	  with	  80	  mM	  RPB	  (KL	  =	  61	  nM)	   in	  50	  mM	  sodium	  
acetate	  buffer,	  pH	  5.	  	  C.	  Displacement	  of	  RPB	  (total	  concentration	  of	  16	  mM)	  bound	  to	  4.2	  mM	  PRL76V	  by	  
titration	  with	  DRV	  (50	  mM;	  KL	  =	  0.79	  nM).	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Figure	   2.4	   Autocatalytic	   maturation	   of	   precursors	   (TFR-­‐PRL76V	  and	   TFR-­‐PRM46I/L76V)	   at	   pH	   4.5	   and	   its	  
inhibition.	   Inhibitors	  were	   present	   at	   a	   1:1	  molar	   ratio	   (6	  mM)	   to	   precursors	   (as	   dimers).	   	   (A	   and	   E)	  
Controls	  without	  inhibitor.	  	  (B	  and	  F)	  In	  the	  presence	  of	  LPV.	  	  (C	  and	  G)	  In	  the	  presence	  of	  	  SQV.	  (D	  and	  
H)	  In	  the	  presence	  of	  	  DRV.	  	  Numbers	  indicated	  on	  top	  of	  the	  gels	  denote	  autoprocessing	  reaction	  times	  
in	  hours.	   	  Lane	  M	  corresponds	  to	  molecular	  weight	  markers	  of	  97,	  66,	  45,	  30,	  20	  and	  14	  kDa	  from	  the	  
top.	  Letter	  designations	  for	  the	  bands	  are:	  a,	  full	  length	  precursor;	  b,	  TFR9-­‐56-­‐PR;	  c,	  mature,	  active	  PR;	  d,	  




Figure	  2.5	  Hydrophobic	   interactions	  of	   residue	  76	   in	   the	  crystal	   structures	  of	  PRL76V	   (cyan),	  and	  wild	  
type	  PR	  (grey).	  A.	  Interactions	  of	  residue	  76	  in	  subunit	  A	  of	  PRL76V-­‐DRV	  and	  PR-­‐DRV.	  Leu76	  forms	  van	  der	  
Waals	   contacts	   (3.6-­‐4.2	  Å)	  with	   the	   side	  chains	  of	  Asp30,	  Val32	  Lys45,	   Ile47,	  and	  Thr74	   (black	  dashed	  
lines),	   while	   Val76	   in	   PRL76V	   only	   has	   hydrophobic	   contacts	   with	   Val32	   and	   Ile47	   (red	   dashed	   lines).	  
Neighboring	   residue	  Gln58	   is	   not	   shown	   since	   it	   forms	   similar	   interactions	  with	   residue	   76	   in	   PR	   and	  
PRL76V.	  Val56	  is	  omitted	  for	  clarity.	  B.	  Interactions	  of	  residue	  76	  with	  Val32	  and	  Val56	  in	  PRL76V-­‐DRV	  and	  
PR-­‐DRV.	  C.	   Interactions	  of	   residue	  76	  with	  Val32	  and	  Val56	   in	  PRL76V-­‐SQV	  and	  PR-­‐SQV.	   In	  B	  and	  C	   the	  
number	   of	   hydrophobic	   contacts	   between	   the	   side	   chains	   is	   indicated	   by	   black	   (with	   Leu76)	   and	   red	  
(with	  Val76)	  dashed	  arrows. 
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Figure	   2.6	   Protease-­‐inhibitor	   hydrogen	   bond	   interactions.	   Hydrogen	   bonds	   are	   indicated	   by	   dotted	  
lines.	  Water	  molecules	  are	   represented	  as	   red	  spheres.	  A.	  PRL76V	  hydrogen	  bond	   interactions	  with	   the	  
major	  conformation	  of	  DRV	  (in	  yellow).	  B.	  Superposition	  of	  PRL76V-­‐DRV	  (cyan	  bonds)	  and	  PR-­‐DRV	  (grey	  
bonds)	   showing	  PRL76V	  has	   fewer	  hydrogen	  bond	   interactions	  with	   the	  aniline	  group	  of	  DRV.	   	  The	  side	  
chain	   of	   Asp30	   has	   two	   alternate	   conformations	   in	   the	   PR-­‐DRV	   structure.	   Interatomic	   distances	   are	  
shown	   in	  Å	  with	   red	  dotted	   lines	   indicating	   the	  hydrogen	  bond	   interactions	   in	   the	  wild	   type	  complex,	  
and	  black	  broken	   lines	  show	  the	   larger	   interatomic	  separation	   in	  the	  mutant.	  C.	  PRL76V	  hydrogen	  bond	  
interactions	  with	  the	  major	  conformation	  of	  SQV	  (in	  green).	  The	  red	  dotted	   lines	   indicate	  the	  new	  hy-­‐
drogen	   bond	   interactions	   formed	   by	   SQV	   in	   PRL76V	   relative	   to	   PR-­‐SQV.	  D.	   Superposition	   of	   PRL76V-­‐SQV	  
(cyan	  bonds)	  and	  PR-­‐SQV	  (grey	  bonds)	  showing	  the	  improved	  interaction	  of	  SQV	  with	  PRL76V	  arising	  from	  
only	  slight	  structural	  changes.	  Red	  dotted	  lines	  indicate	  the	  new	  hydrogen	  bond	  interaction	  in	  the	  mu-­‐
tant,	  and	  black	  broken	  lines	  show	  the	  larger	  interatomic	  separation	  in	  the	  wild	  type	  SQV	  complex. 
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3 STRUCTURES	  OF	  HIGHLY	  DARUNAVIR-­‐RESISTANT	  HIV-­‐1	  PROTEASE	  MUTANT	  REVEAL	  WIDE	  OPEN	  
FLAPS	  AND	  ATYPICAL	  BINDING	  SITE	  FOR	  DARUNAVIR	  
(In	  preparation:	  Zhang,	  Y.,	  Chang,	  Y.	  E.,	  Louis,	  J.	  M.,	  Wang,	  Y.-­‐F.,	  Harrison,	  R.	  W.,	  Weber,	  I.	  T.)	  
3.1 Abstract	  
The	  molecular	  basis	  for	  high	  resistance	  to	  clinical	  inhibitors	  of	  HIV-­‐1	  protease	  (PR)	  was	  examined	  
for	  the	  variant	  designated	  PRP51	  that	  was	  selected	  for	  resistance	  to	  darunavir	  (DRV).	  High	  resolution	  crys-­‐
tal	  structures	  of	  PRP51	  with	  the	  active	  site	  D25N	  mutation	  revealed	  a	  ligand	  free	  form	  and	  an	  inhibitor-­‐
bound	  form	  showing	  a	  unique	  binding	  site	  and	  orientation	  for	  DRV.	  This	  inactivating	  mutation	  is	  known	  
to	   increase	  the	  dimer	  dissociation	  constant	  and	  DRV	  affinity	  of	  PR.	  The	  PRP51	  dimers	  were	   in	  the	  open	  
conformation	  with	  widely	   separated	   flaps,	   as	   reported	   for	   other	   highly	   resistant	   variants.	   PRP51	   dimer	  
bound	  to	  two	  DRV	  molecules	  showed	  larger	  separation	  of	  8.7	  Å	  between	  the	  closest	  atoms	  of	  the	  two	  
flaps	   compared	  with	  4.4	  Å	   for	   the	   ligand-­‐free	   structure	  of	  PRP51.	  Unlike	   the	  majority	  of	  PR	   structures,	  
however,	   the	   ligand-­‐free	  conformation	   lacked	  van	  der	  Waals	   contacts	  between	   Ile50	  and	  Pro81’	   from	  
the	  other	  subunit.	  DRV	  binds	  inside	  the	  active	  site	  cavity,	  however,	  the	  inhibitor	  is	  oriented	  almost	  per-­‐
pendicular	  to	  the	  typical	  position	  and	  exhibits	  mostly	  hydrophobic	  interactions	  with	  only	  2	  direct	  hydro-­‐
gen	  bond	  and	  two	  water-­‐mediated	   interactions	  with	  atoms	  of	  PRP51	  compared	  with	  11	  hydrogen	  bond	  
interactions	  seen	  for	  DRV	  bound	  in	  the	  typical	  position	  in	  wild-­‐type	  enzyme.	  However,	  the	  involvement	  
of	  crystal	   lattice	  contacts	  cannot	  be	  ruled	  out	  due	  to	  DRV	  interactions	  with	  a	  symmetry-­‐related	  dimer.	  
The	  atypical	  location	  of	  darunavir	  may	  provide	  opportunities	  for	  design	  of	  novel	  inhibitors	  targeting	  the	  
open	  conformation	  of	  PR	  drug	  resistant	  mutants.	  
3.2 Introduction	  
HIV-­‐1	  protease	  (PR)	  has	  been	  a	  successful	  target	   in	  AIDS	  therapy	  due	  to	   its	  critical	  role	   in	  viral	  
maturation	  by	  hydrolyzing	  the	  Gag	  and	  Gag-­‐Pol	  precursor	  polyproteins	  into	  mature	  structural	  and	  func-­‐
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tional	  proteins	  (Louis	  et	  al.,	  2000,	  Weber	  et	  al.,	  2009a).	  A	  series	  of	  clinical	  HIV-­‐1	  protease	  inhibitors	  (PIs)	  
has	  improved	  the	  survival	  of	  AIDS	  patients.	  One	  such	  inhibitor,	  darunavir	  (DRV),	  which	  was	  designed	  to	  
target	   drug	   resistance	   by	   introducing	   strong	   polar	   interactions	   with	   the	  main	   chain	   atoms	   of	   the	   PR	  
(Ghosh	  et	  al.,	  2012,	  Koh	  et	  al.,	  2003,	  Tie	  et	  al.,	  2004),	  has	  been	  widely	  used	  for	  the	  treatment	  of	  drug-­‐
naïve	  patients	  and	  those	  infected	  with	  multidrug-­‐resistant	  HIV-­‐1	  (de	  Meyer	  et	  al.,	  2008).	  DRV	  effectively	  
inhibits	  PR	  enzymatic	  activity	  with	  picomolar	  binding	  affinity	  assessed	  by	  isothermal	  titration	  calorimetry	  
(ITC)	  (King	  et	  al.,	  2004).	  However,	  HIV	  evolves	  resistance	  to	  DRV	  by	  selecting	  a	  combination	  of	  mutations	  
(de	  Meyer	  et	  al.,	  2008).	  
Highly	  DRV-­‐resistant	  HIV-­‐1	  variants	  were	  selected	  in	  the	  laboratory	  to	  elucidate	  the	  mechanism	  
for	  resistance	  (Koh	  et	  al.,	  2010).	  A	  mixture	  of	  8	  highly	  DRV-­‐susceptible	  HIV-­‐1	  clinical	   isolates	  (HIV-­‐1MIX)	  
containing	  9	  to	  14	  PI-­‐resistant	  mutations	  was	  propagated	  in	  the	  presence	  of	  DRV.	  The	  viral	  population	  at	  
passage	  51	  (HIV-­‐1MIX
P51)	  replicated	  well	  at	  the	  concentration	  of	  5	  μM	  DRV	  and	  sequencing	  revealed	  14	  
amino	  acid	   substitutions	   in	   the	  PR	  gene	   (Figure	  3.1)	   (Koh	   et	  al.,	  2010).	  The	  viral	   strain	  HIV-­‐1MIX
P51	  was	  
highly	   resistant,	   with	   half	   maximal	   effective	   concentration	   (EC50)	   for	   inhibition	   of	   viral	   replication	   in-­‐
creased	  to	  more	  than	  1	  μM	  for	  DRV	  and	  most	  other	  PIs,	  and	  showed	  moderate	  resistance	  to	  saquinavir	  
(SQV)	  (0.3	  μM	  EC50)	  (Koh	  et	  al.,	  2010).	  
We	  have	   investigated	   the	  physical	  and	  biochemical	  properties	  of	   several	   resistant	  variants,	   in-­‐
cluding	   the	  HIV-­‐1MIX
P51	  protease	   (PRP51)	   (Louis	   et	  al.,	  2011a).	  PRP51	  and	  another	  highly	   resistant	  variant	  
with	  20	  mutations	  (PR20)	  showed	  several	  extreme	  properties	  contributing	  to	  resistance.	  The	  affinity	  of	  
DRV	  and	  SQV	  for	  PRP51	  as	  measured	  by	  isothermal	  titration	  calorimetry	  (ITC)	  gave	  KL	  values	  of	  37	  and	  54	  
nM,	  respectively,	  or	  about	  7400-­‐fold	  and	  135-­‐fold	  weaker	  than	  the	  corresponding	  values	  for	  wild-­‐type	  
PR.	  Autocatalytic	  cleavage	  (autoprocessing)	  of	  precursor	  Gag-­‐Pol	  polyprotein	  is	  essential	  to	  produce	  ma-­‐
ture	  and	  fully	  active	  PR	  (Louis	  et	  al.,	  1999a).	  Autoprocessing	  of	  the	  precursor	  comprising	  the	  56-­‐amino	  
acid	  transframe	  region	  (TFR)	  fused	  to	  PR	  (TFR-­‐PR)	  was	  inhibited	  the	  best	  by	  DRV	  and	  SQV	  as	  compared	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to	  other	  clinical	  inhibitors,	  although	  in	  the	  low	  µM	  range.	  However,	  autoprocessing	  of	  the	  TFR-­‐PRP51	  pre-­‐
cursor	  was	  uninhibited	  by	  DRV	  and	  marginally	  inhibited	  by	  SQV,	  at	  150	  μM	  PI	  concentration	  (Louis	  et	  al.,	  
2011a).	  These	  properties	  of	  PRP51	  are	  consistent	  with	  the	  high	  antiviral	  resistance	  to	  DRV	  measured	  for	  
virus	  bearing	  this	  variant	  (>300-­‐fold	  increased	  EC50)	  relative	  to	  wild	  type	  (Koh	  et	  al.,	  2010).	  	  
We	  have	  reported	  recently	  the	  structural	  analysis	  of	  another	  extremely	  resistant	  variant,	  PR20,	  
which	   showed	  no	   inhibition	  of	  precursor	   autoprocessing,	   and	   KL	   values	   for	  mature	  PR20	   increased	  by	  
more	   than	  8000-­‐	  and	  2000-­‐fold,	   respectively,	   for	  DRV	  and	  SQV	   (Louis	   et	  al.,	  2011a,	  Agniswamy	   et	  al.,	  
2012).	  Crystallographic	  analysis	  of	  PR20	  showed	  fewer	  interactions	  with	  inhibitors	  and	  widely	  separated	  
flaps	  in	  the	  absence	  of	  inhibitors	  with	  no	  contact	  of	  the	  flap	  with	  residues	  from	  the	  other	  subunit	  unlike	  
interactions	   in	  the	  corresponding	  structures	  of	  wild-­‐type	  PR	  (Spinelli	  et	  al.,	  1991,	  Heaslet	  et	  al.,	  2007).	  
An	  increased	  separation	  of	  the	  flaps	  in	  the	  dimer	  may	  be	  typical	  of	  many	  resistant	  variants,	  as	  seen	  also	  
for	  variant	  MDR769	  (Logsdon	  et	  al.,	  2004)	  and	  in	  solution	  studies	  using	  Double	  Electron-­‐Electron	  Reso-­‐
nance	  (DEER)	  spectroscopy	  (de	  Vera	  et	  al.,	  2012).	  	  
In	  order	   to	   further	   investigate	   the	  molecular	  mechanisms	  of	  high-­‐level	   resistance	  we	  have	  de-­‐
termined	   the	   crystal	   structures	   of	   PRP51	   bearing	   the	   inactivating	   mutation	   D25N	   to	   abolish	   self-­‐
degradation	  (autoproteolysis)	   for	  sample	  handing	  during	  crystallization.	  When	  the	  D25N	  mutation	  was	  
introduced	  into	  wild-­‐type	  PR,	  the	  affinity	  for	  DRV	  was	  decreased	  by	  about	  106	  fold,	  while	  no	  substantial	  
changes	  were	  observed	  in	  the	  crystal	  structures	  (Sayer	  et	  al.,	  2008).	  Two	  structures	  were	  obtained	  for	  
PRP51:	  a	  DRV	  bound	  structure	  and	  a	  ligand	  free	  structure.	  Structural	  analysis	  revealed	  an	  unusual	  binding	  
site	  for	  DRV	  and	  the	  widely	  separated	  flaps	  that	  characterize	  the	  ligand-­‐free	  structures	  of	  many	  highly	  
resistant	  variants	  (Arpino	  et	  al.,	  2012,	  Logsdon	  et	  al.,	  2004,	  Agniswamy	  et	  al.,	  2012).	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3.3 Results	  and	  Discussion	  
3.3.1 Crystal	  Structures	  of	  Ligand-­‐free	  and	  DRV	  Bound	  PRP51.	  	  
Repeated	  attempts	  with	  active	  PRP51	  did	  not	  yield	  crystals	  likely	  due	  to	  its	  enhanced	  autoprote-­‐
olysis.	   Consistent	   with	   this	   observation	   even	   storage	   of	   the	   protein	   in	   12	   mM	   HCl	   prior	   to	   folding	  
showed	  degradation	  products	  unlike	  the	  optimized	  wild-­‐type	  PR.	  The	  optimized	  wild-­‐type	  PR	  bears	  the	  
mutations	   L33I	   and	   L63I	   shown	   to	   significantly	   restrict	   autoproteolysis	   of	   wild-­‐type	   PR	   in	   addition	   to	  
Q7K,	  which	  exists	  in	  PRP51	  (Louis	  et	  al.,	  1999a,	  Mildner	  et	  al.,	  1994).	  Also,	  as	  DRV	  interactions	  with	  PRD25N	  
are	  nearly	  identical	  to	  those	  in	  wild-­‐type	  PR/DRV	  complex	  (Sayer	  et	  al.,	  2008),	  we	  resorted	  to	  using	  PRP51	  
for	  our	  studies.	  
Crystal	  structures	  of	  mutant	  PRP51	  in	  complex	  with	  DRV	  and	  SQV	  were	  determined	  to	  identify	  the	  
structural	  changes	  associated	  with	  high	  level	  resistance.	  Electron	  density	  was	  observed	  within	  the	  ligand	  
binding	  cavity	  only	  in	  the	  structure	  of	  PRP51/DRV.	  No	  inhibitor	  was	  visible	  in	  the	  PRP51	  structure	  obtained	  
from	  crystals	  grown	  in	  the	  presence	  of	  SQV.	  Similar	  results	  were	  obtained	  when	  the	  mutant	  was	  crystal-­‐
lized	  in	  the	  presence	  of	  amprenavir	  or	  tipranavir.	  The	  two	  crystal	  structures	  designated	  PRP51/DRV	  and	  
PRP51	  were	  refined	  with	  X-­‐ray	  data	  at	  resolutions	  of	  1.66	  and	  1.50	  Å	  and	  R-­‐factors	  of	  18.9%	  and	  15.9%,	  
respectively.	  The	  crystallographic	  statistics	  are	  listed	  in	  Table	  3.1.	  PRP51/DRV	  was	  refined	  in	  space	  group	  
P41212	  with	  a	  monomer	  of	  residues	  numbered	  1-­‐99	   in	  the	  asymmetric	  unit,	  while	  PRP51	  was	  refined	   in	  
space	  group	  P41	  and	  contained	  one	  dimer	  of	  residues	  numbered	  1-­‐99	  and	  1’-­‐99’	  in	  the	  asymmetric	  unit.	  
Alternate	   conformations	  were	   refined	   for	   3	   residues	   in	   PRP51/DRV	   and	   7	   residues	   in	   PRP51	   structures.	  
Residues	  34	   to	  36	   from	  each	  monomer	  of	   the	   two	  structures	   showed	  similar	  alternate	   conformations	  
with	  0.5	  relative	  occupancy.	  The	  crystallographic	  dimer	  of	  PRP51/DRV	  was	  generated	  for	  structural	  analy-­‐
sis.	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3.3.2 PRP51/DRV	  Exhibits	  Unusual	  Binding	  Conformations	  of	  DRV	  
DRV	  placed	  at	  the	  typical	  binding	  site	  (Figure	  3.2A)	  (Tie	  et	  al.,	  2004,	  Kovalevsky	  et	  al.,	  2006),	  did	  
not	  fit	  the	  electron	  density	  visible	  in	  the	  ligand	  binding	  cavity	  of	  PRP51/DRV	  and	  thus	  different	  locations	  
were	   evaluated	   for	   the	   inhibitor.	   After	  manual	   adjustment,	   the	   final	  monomer	   structure	  was	   refined	  
with	  full	  occupancy	  molecules	  of	  DRV	  oriented	  approximately	  perpendicular	  to	  DRV	  in	  the	  typical	  inhibi-­‐
tor-­‐binding	  site	  of	  wild-­‐type	  PR	  or	  most	  mutants	  (Figure	  3.2B),	  as	  indicated	  by	  the	  clear	  electron	  density	  
map	  (Figure	  3.3A).	  The	  two	  molecules	  of	  DRV	  are	  related	  by	  180-­‐degree	  rotation	  and	  interact	  with	  each	  
other	  in	  the	  binding	  cavity	  of	  the	  PRP51	  dimer (Figure	  3.3B).	  The	  polar	  interactions	  between	  the	  two	  DRV	  
molecules	   include	  a	  water	  mediated	  hydrogen	  bond	  connecting	  a	   sulfonyl	  oxygen	  and	  hydroxyl	  group	  
with	   the	   amino	   group	   on	   the	   aniline	   of	   the	   other	   DRV,	   and	   C-­‐H…water	   interactions	   with	   the	   phenyl	  
group	  and	  the	  bis-­‐THF	  of	  both	  DRVs.	  The	  bound	  DRV	  has	  relatively	  few	  hydrogen	  bonds	  and	  many	  hy-­‐
drophobic	  contacts	  with	  the	  protein	  (Figure	  3.3C	  and	  3.3D).	  These	  DRV	  molecules	  have	  a	  different	  con-­‐
formation	  and	  interactions	  from	  those	  for	  the	  regular	  binding	  mode	  of	  DRV,	  which	  has	  11	  direct	  hydro-­‐
gen	   bond	   interactions	   and	   4	  water-­‐mediated	   ones	  with	   PR	   in	   the	  wild-­‐type	   PR/DRV	   complex	   (PDB	   ID	  
2IEN)	   (Figure	  3.4A	  and	  3.4B)	   (Tie	   et	  al.,	   2004).	  Many	  van	  der	  Waals	   contacts	  were	  observed	  between	  
PRP51	  and	  DRV	  with	  distances	   ranging	   from	  3.6-­‐4.2	  Å.	   In	   the	  crystal	   structure	  of	  PRP51,	  DRV	   forms	   two	  
direct	  hydrogen	  bonds	  with	   the	  main	  chain	  amides	  of	  Gly49	  and	  Gly50,	   two	  hydrogen	  bonds	  with	   the	  
side	   chain	   of	   Gln61	   from	   a	   symmetry-­‐related	   dimer	   and	   three	  water-­‐mediated	   hydrogen	   bonds	  with	  
protein	   atoms.	   Van	   der	   Waals	   interactions	   occurred	   between	   DRV	   and	   PRP51	   residues	   Asn25,	   Ala28,	  
Ile47,	  Gly48,	  Gly49,	   Ile50,	  Gly52,	  Phe53,	  Met54,	  Thr80,	  Pro81’,	   Ile82	  and	  Val84.	  These	   interacting	  resi-­‐
dues	  include	  mutations	  of	  V32I,	  I54M,	  V82I	  and	  I84V	  from	  the	  selected	  P51	  isolate	  and	  the	  D25N	  muta-­‐
tion.	   It	   is	  probable	  that	  these	  mutations	  facilitate	  binding	  of	  DRV	  to	  this	  atypical	  site.	   In	  addition,	  DRV	  
forms	   interactions	  with	   residues	   from	   symmetry-­‐related	   dimers	   of	   PRP51	   as	   shown	   in	   Figure	   3.4B	   and	  
Figure	   3.9.	   The	   two	  DRV	  molecules	   have	   almost	   identical	   interactions	  with	   Ile72	   and	  Gln61	   from	   two	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different	   symmetry-­‐related	   PRP51	   dimmers	   (Figure	   3.9).	   The	   interactions	   include	   two	   direct	   hydrogen	  
bonds	  between	  the	  two	  oxygens	  of	  the	  bis-­‐THF	  and	  the	  amino	  group	  on	  the	  side	  chain	  of	  Gln61	  and	  van	  
der	  Waals	  contacts	  with	  Ile72	  and	  Gln61.	  The	  existence	  of	  DRV	  interactions	  with	  the	  symmetry	  related	  
PRP51	  raises	  the	  possibility	  that	  crystal	  lattice	  contacts	  influence	  the	  atypical	  binding	  of	  inhibitor.	  	  
The	   question	   of	  whether	  DRV	  might	   bind	   at	   this	   atypical	   site	   in	  wild-­‐type	   enzyme	   can	   be	   ad-­‐
dressed	  by	  structural	  comparisons.	  The	  PRP51/DRV	  monomer	  shares	  an	  almost	  identical	  wide	  open	  con-­‐
formation	  (RMSD	  of	  0.33	  Å	  on	  equivalent	  Cα	  atoms)	  with	  the	  wild-­‐type	  PR	  crystallized	  with	  Mg2+	  coordi-­‐
nated	  at	  the	  active	  site	  (PDB	  ID	  2PC0)	  (Heaslet	  et	  al.,	  2007).	  Superposition	  of	  the	  two	  monomers	  reveals	  
that	  rotations	  of	  three	  side	  chains	  in	  each	  subunit	  would	  be	  required	  for	  DRV	  to	  bind	  in	  this	  atypical	  site	  
in	  wild-­‐type	  enzyme	  (Figure	  3.5).	  The	  side	  chain	  of	  Ile54	  in	  wild	  type	  PR	  would	  hinder	  binding	  of	  the	  sec-­‐
ond	  THF	  of	  the	  bis-­‐THF	  group	  of	  DRV	  due	  to	  short	  interatomic	  distances	  of	  2.0-­‐3.1	  Å	  (Figure	  3.5).	  Also,	  
the	  side	  chains	  of	  Val82	  and	  Ile84	  in	  wild	  type	  PR	  extend	  closer	  to	  the	  aniline	  group	  of	  DRV	  compared	  to	  
the	  good	  hydrophobic	  contacts	  formed	  by	  Ile82	  and	  Val84	  in	  PRP51/DRV.	  However,	  rotated	  conformers	  
of	  the	  side	  chains	  of	  Ile54,	  Val82	  and	  Ile84	  could	  allow	  the	  possible	  binding	  of	  DRV	  in	  the	  atypical	  site.	  
The	  affinity	  of	  DRV	  for	  binding	  in	  the	  typical	  location	  is	  expected	  to	  be	  decreased	  drastically	  by	  the	  mu-­‐
tations.	  The	  PRP51	  variant	  showed	  7400-­‐fold	  lower	  affinity	  for	  DRV	  (Louis	  et	  al.,	  2011a)	  while	  the	  D25N	  
mutation	  alone	  produces	  about	  106	  decreased	  affinity	  for	  DRV	  as	  measured	  by	  ITC	  (Sayer	  et	  al.,	  2008).	  
Therefore,	  the	  combination	  of	  D25N	  plus	  the	  14	  mutations	  in	  PRP51	  is	  expected	  to	  compromise	  the	  affin-­‐
ity	  to	  low	  µM	  levels	  (Sayer	  et	  al.,	  2008).	  Consequently,	  DRV	  may	  favor	  the	  weaker	  atypical	  binding	  loca-­‐
tion	  observed	  in	  PRP51.	  
It	  is	  not	  the	  first	  time	  that	  DRV	  has	  been	  observed	  to	  bind	  at	  an	  unusual	  site	  in	  HIV-­‐1	  protease	  
variants.	  A	  second	  binding	  site	  was	  observed	  in	  an	  ultra-­‐high	  resolution	  (0.84	  Å)	  structure	  of	  PRV32I/DRV	  
in	   addition	   to	   the	   typical	   active	   site	   binding.	   The	   second	  DRV	   bound	   in	   a	   groove	   on	   one	   flap	   surface	  
where	   the	   residues	   Glu35’,	   Lys45’,	   Lys55’,	   Val56’,	   and	   Arg57’	   participated	   in	   the	   major	   interactions	  
78 
(Kovalevsky	  et	  al.,	  2006).	  A	  similar	  DRV	  binding	  site	  occurred	  in	  the	  crystal	  structures	  of	  PRM46L/DRV	  and	  
PR20/DRV	  (Kovalevsky	  et	  al.,	  2006,	  Agniswamy	  et	  al.,	  2012).	  Also	  for	  SQV,	  a	  second	  molecule	  was	  found	  
in	   a	   location	   adjacent	   to	   the	   usual	   active	   site	   location	   in	   PR20/SQV	   and	   PRV32I/I47V/V82I/SQV	   structures	  
(Agniswamy	  et	  al.,	  2012,	  Tie	  et	  al.,	  2012).	  Another	  unique	  binding	  mode	  was	  found	  for	  GB-­‐18,	  specifi-­‐
cally	   [3-­‐cobalt	   bis(1,2-­‐dicarbollide)]-­‐ion,	  which	   belongs	   to	   a	   novel	   class	   of	   inorganic	   cobaltacarborane	  
inhibitors,	  in	  the	  active	  site	  cavity	  of	  the	  wild-­‐type	  PR	  (PDB	  ID	  1ZTZ)	  (Kozisek	  et	  al.,	  2008).	  This	  binding	  
mode	   involves	   two	  molecules	   of	   GB-­‐18	   positioned	   asymmetrically	   inside	   the	   pseudosymmetric	   active	  
site	   cavity	   (Kozisek	   et	   al.,	   2008).	   These	   binding	   pockets	   for	   GB-­‐18	   are	   formed	   by	   the	   residues	   Pro81,	  
Ile84,	  and	  Val82	  and	  covered	  by	  the	  flap	  residues	  Ile47,	  Gly48,	  and	  Ile54	  forming	  a	  semi-­‐open	  conforma-­‐
tion	  of	  the	  PR	  dimer	  (Kozisek	  et	  al.,	  2008).	  
3.3.3 Flaps	  of	  PRP51/DRV	  and	  PRP51	  Display	  Different	  Intersubunit	  Interactions	  
	  Both	  DRV	  bound	  and	  ligand-­‐free	  PRP51	  dimers	  have	  flaps	  separated	  by	  a	  large	  distance	  between	  
their	  tips.	  The	  flaps	  of	  PRP51/DRV	  had	  a	  larger	  separation	  of	  8.7	  Å	  between	  the	  closest	  atoms,	  while	  the	  
flaps	  were	  separated	  by	  4.4	  Å	  for	  PRP51.	  Superposition	  of	  the	  monomer	  of	  PRP51/DRV	  with	  each	  subunit	  
of	  PRP51	  gave	  the	  overall	  RMSD	  value	  of	  0.97	  Å	  and	  0.41	  Å	  on	  Cα	  atoms,	  respectively,	  with	  large	  differ-­‐
ences	  in	  the	  conformation	  of	  the	  two	  flaps	  and	  80’s	  loops	  (residues	  79/79’	  to	  83/83’) (Figure	  3.6A).	  One	  
of	  the	  two	  flaps	  (residues	  47/47’	  to	  54/54’)	  of	  the	  PRP51/DRV	  dimer	  is	  further	  away	  from	  the	  catalytic	  site	  
than	  seen	  for	  the	  equivalent	  flap	  of	  PRP51	  as	  indicated	  by	  the	  distance	  of	  5.6	  Å	  between	  the	  equivalent	  
Cα	  atoms	  of	  Ile50	  in	  these	  two	  structures,	  while	  the	  other	  flap	  conformation	  is	  more	  similar	  in	  the	  two	  
structures	  with	  only	  1.5	  Å	  distance	  between	  the	  Cα	  atoms	  of	  Ile50’	  residues	  (Figure	  3.6B).	  	  
The	  two	  PRP51	  structures	  were	  compared	  with	  open	  conformation	  structures	  of	  PR	  and	  PR20	  as	  
well	  as	  their	  DRV-­‐bound	  complexes.	  The	  open	  conformations	  of	  ligand-­‐free	  PR20	  have	  two	  unusual	  fea-­‐
tures	   relative	   to	  other	   reported	  dimer	   structures:	  widely	   separated	   flaps	   and	  no	   intersubunit	   van	  der	  
Waals	   contacts	   between	   the	   flap	   tip	   and	   residues	   from	   the	   other	   subunit	   (Agniswamy	   et	   al.,	   2012).	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Therefore,	   the	  conformations	  were	  assessed	  by	  measuring	   the	  closest	  distance	  between	  atoms	  at	   the	  
tip	  of	  the	  two	  flaps	  within	  one	  dimer	  structure	  and	  the	  closest	   intersubunit	  contact	  of	   Ile50/50’	  at	  the	  
flap	  tip	  with	  Pro81’/81.	  The	  shortest	   interatomic	  distances	  between	  the	  flap	  tips	  were	  4.0	  Å	   in	   ligand-­‐
free	  PRP51,	  compared	  to	  3.0	  Å	  in	  a	  typical	  open	  conformation	  of	  wild-­‐type	  PR	  (PDB	  ID	  1HHP),	  7.7	  Å	  in	  an-­‐
other	  wild-­‐type	  PR	  with	  Mg2+	  coordinated	  at	  the	  active	  site	  (PDB	  ID	  2PC0),	  and	  6.0	  Å	  in	  ligand-­‐free	  PR20	  
(PDB	  ID	  3UF3)	  (Agniswamy	  et	  al.,	  2012,	  Heaslet	  et	  al.,	  2007,	  Spinelli	  et	  al.,	  1991).	  The	  various	  flap	  con-­‐
formations	  in	  wild-­‐type	  PR	  (PDB	  ID	  1HHP),	  ligand-­‐free	  PRP51	  and	  ligand-­‐free	  PR20	  are	  compared	  in	  Figure	  
3.10A.	   For	   the	  DRV	  complexes,	   the	   shortest	   interflap	  distance	  was	  8.7	  Å	   in	  PRP51/DRV	  compared	  with	  
about	   3.3	   Å	   for	   typical	   closed	   conformation	   dimers	   of	   PR/DRV	   (PDB	   ID	   2IEN)	   and	   PR20/DRV	   (PDB	   ID	  
3UCB)	  (Figure	  3.10B)	  (Agniswamy	  et	  al.,	  2012,	  Tie	  et	  al.,	  2004).	  Ile50/50’	  at	  the	  flap	  tips	  has	  intersubunit	  
van	  der	  Waals	  contacts	  of	  about	  4.0	  Å	  with	  Pro81’/81	  in	  PRP51/DRV	  as	  observed	  for	  closed	  conformation	  
inhibitor-­‐bound	   dimers.	   The	   majority	   of	   dimers	   show	   intersubunit	   van	   der	   Waals	   contacts	   between	  
Ile50/50’	  and	  Pro81’/81,	  except	  for	  the	  ligand-­‐free	  PR20	  where	  these	  two	  side	  chains	  are	  separated	  by	  
about	  7	  Å.	  Moreover,	   this	   intersubunit	  contact	  was	   lost	   in	   ligand-­‐free	  PRP51	  since	  the	  closest	  atoms	  of	  
Ile50	  and	  Pro81’	  were	  separated	  by	  8.5	  Å.	  The	  ligand-­‐free	  PRP51	  has	  asymmetric	  flap	  conformations	  like	  
another	  open	  conformation	  dimer	  of	  PR20	   (PDB	   ID	  3UHL),	  which	  had	  van	  der	  Waals	  contact	  between	  
the	  flap	  tips,	  and	  asymmetric	  flaps	  with	  12.2	  and	  5.4	  Å	   intersubunit	  separation	  between	  Ile50/50’	  and	  
Pro81’/81	  (Figure	  3.7).	  Therefore,	  the	  large	  separation	  (~7-­‐12	  Å)	  between	  side	  chain	  atoms	  of	  Ile50	  and	  
Pro81’	  from	  the	  other	  subunit	  is	  conserved	  in	  the	  ligand-­‐free	  dimers	  of	  the	  two	  highly	  resistant	  mutants	  
PR20	  and	  PRP51.	  
3.3.4 Multiple	  Mutations	  Contribute	  to	  the	  Structural	  Changes	  in	  PRP51	  
PRP51	   bears	   14	  mutations	   (L10I,	   I15V,	   K20R,	   L24I,	   V32I,	   L33F,	  M36I,	  M46L,	   I54M,	   L63P,	   K70Q,	  
V82I,	   I84V	   and	   L89M)	   relative	   to	   the	   standard	   “wild-­‐type”	   PR	   sequence.	   Four	  mutations,	   V32I,	  M46I,	  
V82I	  and	  I84V,	  alter	  residues	  in	  the	  active	  site	  cavity	  where	  substrates	  and	  inhibitors	  usually	  bind.	  Addi-­‐
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tionally,	  “second	  shell”	  mutations	  L10I,	  L24I,	  L33F,	  I54M	  alter	  residues	  that	  form	  direct	  interactions	  with	  
residues	   in	   the	  active	   site	   cavity.	  Our	   crystallographic	   and	  biochemical	   analysis	   has	  demonstrated	   the	  
changes	   due	   to	   the	   individual	   single	   mutations	   of	   L24I,	   V32I,	   M46L,	   I54M,	   and	   I84V,	   as	   reviewed	   in	  
(Weber	  et	  al.,	  2009a).	  Several	  of	  the	  other	  substitutions	  in	  PRP51	  are	  shared	  by	  the	  highly	  resistant	  multi-­‐
ple	  mutant	  PR20	  and	  their	  coordinated	  effects	  have	  been	  described	  previously	  (Agniswamy	  et	  al.,	  2012).	  	  
The	  mutations	  of	  residues	  V32I,	  V82I	  and	  I84V	  in	  the	  active	  site	  cavity	  are	  assumed	  to	  contribute	  
to	  the	  poor	  affinity	  of	  PRP51	  for	  inhibitors	  and	  the	  observed	  unusual	  binding	  site	  for	  DRV	  (Figure	  3.3).	  The	  
side	  chains	  of	  these	  residues	  form	  hydrophobic	  interactions	  with	  each	  other	  and	  with	  Val47	  in	  all	  struc-­‐
tures.	  Mutations	  V32I	  and	  I47V	  have	  altered	  interactions	  with	  inhibitors	  DRV	  and	  SQV	  (Agniswamy	  et	  al.,	  
2012,	  Weber	   et	  al.,	  2009a),	  however,	  V82I	   in	   the	   triple	  mutant	  V32I/I47V/V82I	  bearing	   the	  active	  site	  
residues	  of	  HIV-­‐2	  PR	  does	  not	  significantly	  alter	  direct	  contacts	  with	  inhibitor	  (Tie	  et	  al.,	  2012).	  Further	  
comparison	  of	  inhibitor	  interactions	  is	  limited	  since	  the	  crystal	  structures	  of	  the	  PRP51	  mutant	  are	  in	  the	  
open	  conformation	  without	  inhibitors	  bound	  in	  the	  standard	  active	  site	  location.	  	  
Mutations	  M46L	  and	  I54M	  alter	  residues	  in	  the	  flaps	  and	  are	  proposed	  to	  have	  small	  indirect	  ef-­‐
fects	   on	   inhibitor	   binding	   and	   may	   alter	   the	   flap	   dynamics	   (Shen	   et	   al.,	   2010,	   Zhang	   et	   al.,	   2013a,	  
Kovalevsky	   et	  al.,	   2006).	   In	  PRP51/DRV,	   the	   I54M	  mutation	   introduced	  new	  van	  der	  Waals	   interactions	  
with	  DRV	   (Figures	  3.3C	  and	  3.5),	  while	  M46L	  had	  no	  contacts	  with	   the	   ligand.	  The	  changes	   in	   interac-­‐
tions	  of	  mutated	   residue	   L24I	   are	   similar	   in	   PRP51	   and	   the	   single	  mutant	  PRL24I	   (Liu	   et	   al.,	   2005).	   Ile24	  
gains	  two	  good	  van	  der	  Waals	  contacts	  with	  Leu90	  and	  loses	  or	  elongates	  contacts	  (4.7	  and	  4.2	  Å	  in	  the	  
two	  subunits	  compared	  to	  3.8	  Å	  distance	  in	  wild-­‐type	  PR)	  with	  Phe99’	  from	  the	  other	  subunit.	  Unlike	  the	  
mutated	  side	  chain	  of	  L10F	  in	  PR20/DRV,	  in	  which	  a	  new	  hydrophobic	  contact	  was	  formed	  between	  the	  
side	  chains	  of	  Phe10	  and	  mutated	  Ile82	  (Agniswamy	  et	  al.,	  2012),	  mutated	  residue	  L10I	  in	  PRP51	  yields	  no	  
new	  interactions	  with	  nearby	  residues.	  Mutation	  L33F	  introduces	  the	  large	  bulky	  Phe	  side	  chain,	  which	  
maintains	   hydrophobic	   contacts	   of	   the	   wild-­‐type	   enzyme,	   including	   contacts	   with	   mutated	   residues	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I15V,	  M36I	  substituting	  shorter	  side	  chains	  as	  reported	  for	  L33F	  in	  PR20	  (Agniswamy	  et	  al.,	  2012).	  Also,	  
the	  flap	  hinge	  region	  comprising	  residues	  34	  to	  43	  shares	  a	  very	  similar	  conformation	  in	  PRP51	  and	  in	  the	  
ligand	  free	  conformation	  of	  PR20,	  which	  is	  likely	  due	  to	  the	  presence	  of	  mutations	  M36I	  and	  I33F	  in	  both	  
highly	  drug-­‐resistant	  variants.	  The	  mutations	   in	   the	   flap	  hinge	  and	   flaps	  are	   likely	   to	  contribute	  to	   the	  
extended	  flap	  conformations	  observed	  in	  PRP51	  and	  in	  inhibitor-­‐free	  PR20	  structures.	  	  
Mutation	  L89M	  has	  not	  been	  analyzed	  previously	  in	  structures.	  The	  side	  chain	  of	  Leu89	  in	  wild-­‐
type	  PR	  forms	  hydrophobic	  contacts	  with	  the	  side	  chains	  of	  Ile64,	  Ile66,	  Ala71,	  Gly73,	  Ile85	  and	  Asn88,	  
as	  well	  as	  van	  der	  Waals	  and	  C-­‐H…O	  interactions	  with	  the	  side	  chain	  of	  Thr31	  (Figure	  3.8).	  The	  mutated	  
Met89	  forms	  very	  similar	  contacts	  in	  PRP51,	  except	  for	  an	  additional	  van	  der	  Waals	  contact	  with	  the	  side	  
chain	  of	  Val75.	  Mutation	  K20R	  alters	  a	  residue	  near	  the	  protein	  surface	  showing	  varied	  interactions	  with	  
other	  surface	  side	  chains.	  Mutations	  L63P	  and	  K70Q	  also	  alter	  surface	  side	  chains	  that	  form	  a	  hydropho-­‐
bic	  contact	  in	  the	  wild-­‐type	  PR,	  which	  is	  eliminated	  in	  the	  mutant	  PRP51.	  
Two	  crystal	  structures	  were	  analyzed	  for	  the	  PRP51	  variant	  that	  was	  selected	  for	  high	  levels	  of	  re-­‐
sistance	  to	  DRV.	  These	  structures	  confirm	  the	  increased	  separation	  of	  the	  two	  flaps	  in	  the	  dimer	  and/or	  
loss	  of	  intersubunit	  contacts	  between	  the	  flap	  tip	  and	  Pro81	  in	  comparison	  to	  the	  open	  conformations	  
seen	  for	  the	  ligand	  free	  wild-­‐type	  PR,	  as	  previously	  described	  for	  the	  MDR769	  (Logsdon	  et	  al.,	  2004)	  and	  
PR20	  (Agniswamy	  et	  al.,	  2012)	  highly	  resistant	  variants.	  Other	  highly	  resistant	  PR	  mutants	  have	  shown	  
greater	   flap	  mobility	   in	   studies	  employing	  various	   techniques	   (Agniswamy	   et	  al.,	   2012,	   Logsdon	   et	  al.,	  
2004,	  de	  Vera	  et	  al.,	  2012,	  Cai	  et	  al.,	  2012)	  and	  decreased	  interactions	  with	  inhibitors	  or	  substrate	  ana-­‐
logs	   in	  crystal	  structures	  (Liu	  et	  al.,	  2013,	  Agniswamy	  et	  al.,	  2012,	  Saskova	  et	  al.,	  2009).	   In	  PRP51,	  how-­‐
ever,	  DRV	  showed	  a	  unique	  mode	  of	  binding	  within	  the	  open	  conformation	  flaps	  and	  lying	  almost	  per-­‐
pendicular	  to	  the	  typical	  active	  site	  position.	  Importantly,	  this	  new	  binding	  site	  for	  DRV	  may	  hint	  at	  de-­‐
signs	  for	  novel	  types	  of	  antiviral	  inhibitors	  that	  capture	  the	  open,	  inactive	  conformation	  of	  the	  protease.	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3.4 Methods	  
3.4.1 Construction,	  Expression	  and	  Purification	  
The	  HIV-­‐1	  PR	  from	  Group	  M	  (Genbank	  HIVHXB2CG)	  is	  designated	  as	  PR.	  The	  PRP51	  construct	  con-­‐
tains	  14	  mutations	  (L10I,	   I15V,	  K20R,	  L24I,	  V32I,	  L33F,	  M36I,	  M46L,	   I54M,	  L63P,	  K70Q,	  V82I,	   I84V,	  and	  
L89M)	  plus	  three	  other	  mutations	  Q7K	  to	  minimize	  autoproteolysis	  and	  C67A	  and	  C95A	  to	  prevent	  cys-­‐
teine-­‐induced	  aggregation	  (Wlodawer	  et	  al.,	  1993,	  Louis	  et	  al.,	  2011a,	  Louis	  et	  al.,	  1999a).	  The	  mutant	  
DNA	  was	   constructed	   by	   oligonucleotide	   synthesis	   and	   cloned	   into	   the	   pET11a	   vector	   between	  Nde1	  
and	  BamH1	  restriction	  sites.	  To	  eliminate	  autoproteolysis,	  the	  inactivating	  mutation	  of	  D25N	  was	  intro-­‐
duced	   using	   the	  QuikChange	   II	   Site-­‐Directed	  Mutagenesis	   Kit	   and	   confirmed	   by	  DNA	   sequencing.	   The	  
protein	  was	   expressed	   in	  Escherichia	   coli	   BL21(DE3),	   purified	   and	   folded	  using	   the	  protocol	   described	  
previously	  (Sayer	  et	  al.,	  2010,	  Louis	  et	  al.,	  2009).	  
3.4.2 Crystallization	  and	  Data	  Collection	  
Crystals	  of	  PRP51	  complexed	  with	  clinical	  inhibitors	  DRV	  and	  SQV	  were	  obtained	  by	  the	  hanging-­‐
drop	  vapor-­‐diffusion	  method	  at	  room	  temperature	  using	  24	  well	  VDX	  plates	  (Hampton	  Research,	  Aliso	  
Viejo,	  CA,	  USA).	  PRP51	  with	  a	  monomer	  concentration	  of	  1.29	  mg·∙ml
-­‐1	  was	  mixed	  with	  the	  inhibitors	  at	  5-­‐
10	  fold	  molar	  excess.	  Screening	  Kit	  I	  solutions	  (Hampton	  Research,	  Aliso	  Viejo,	  CA,	  USA)	  gave	  good	  crys-­‐
tals	  of	  PRP51	  complexed	  with	  DRV	  (0.1	  M	  HEPES	  sodium	  pH	  7.5,	  0.8	  M	  Potassium	  sodium	  tartrate	  tetra-­‐
hydrate),	  and	  crystals	  of	  PRP51	  grown	  in	  the	  presence	  of	  SQV	  (0.1	  M	  imidazole	  pH	  6.5,	  1.0	  M	  sodium	  ace-­‐
tate	  trihydrate).	  The	  crystals	  were	  frozen	  in	  liquid	  nitrogen	  using	  25%	  (v/v)	  glycerol	  as	  a	  cryoprotectant.	  
X-­‐ray	  diffraction	  data	  were	  collected	  at	  100K	  by	  remote	  access	  on	  the	  beamline	  BM-­‐22	  of	  the	  Southeast	  
Regional	  Collaborative	  Access	  Team	  (SER-­‐CAT),	  the	  Advanced	  Photon	  Source,	  Argonne	  National	  Labora-­‐
tory,	  Chicago.	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3.4.3 Data	  Processing	  and	  Structure	  Determination	  
The	  X-­‐ray	  data	  were	  indexed,	  integrated	  and	  scaled	  with	  HKL2000	  (Otwinowski	  et	  al.,	  1997).	  The	  
structures	   were	   solved	   by	   molecular	   replacement	   with	   MOLREP	   in	   the	   CPP4i	   suite	   of	   programs	  
(Murshudov	   et	   al.,	   1997)	   using	   the	   PR20	   complex	   with	   Yb+	   (PDB	   ID	   3UF3)	   as	   the	   starting	   model	  
(Agniswamy	  et	  al.,	  2012).	  The	  structures	  were	  refined	  by	  REFMAC	  5.2	  in	  the	  CCP4	  program	  suite	  6.1.13	  
(Murshudov	  et	  al.,	  1997)	  and	  refitted	  using	  COOT	  0.6.1	   (Emsley	  et	  al.,	  2004).	  Alternate	  conformations	  
were	  modeled	  for	  PR	  residues,	  inhibitors	  and	  solvent	  molecules	  based	  on	  the	  observed	  electron	  density	  
maps.	   Anisotropic	   B	   factor	   refinement	   was	   applied	   for	   the	   higher	   resolution	   structure,	   and	   TLS	   re-­‐
strained	  refinement	  was	  used	  for	  the	  lower	  resolution	  structure.	  Structural	  figures	  were	  prepared	  with	  
PyMol	  (DeLano,	  2002).	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Table	  3.1	  Crystallographic	  data	  collection	  and	  refinement	  statistics	  
Complex	  name	   PRP51/DRV	   PRP51	  
X-­‐ray	  source	   APS_22BM	   APS_22BM	  
Wavelength	  (Å)	   1.0	   1.0	  
Space	  group	   P41212	   P41	  
Unit	  cell	  dimensions	  (Å)	  
a	  =	  b	  
c	  









Unique	  reflections	   13867	   34414	  
Redundancya	   8.3	  (4.6)	   8.0	  (3.4)	  
Rmerge	  (%)	  overall
a	   8.1%	  (42.2%)	   6.7%	  (27.7%)	  
<I/sigma>	  overalla	   18.5	  (3.3)	   23.2	  (4.6)	  
Completeness	  (%)	  overalla	   99.4%	  (98.3%)	   99.4%	  (95.5%)	  
Refinement	  resolution	  range	   22.16-­‐1.66	   23.64-­‐1.50	  
Rwork	   18.9%	   15.9%	  
Rfree	   22.6%	   19.7%	  






RMSD	  from	  ideality	  
Bonds	  (Å)	   0.021	   0.023	  
Angle	  distance	  (degrees)	   2.326	   2.070	  
Average	  B-­‐factors	  (Å2)	  
Main	  chain	  atoms	   26.33	   23.17	  
Side	  chain	  atoms	   31.10	   27.88	  
Ligand	   33.10	   -­‐	  
Solvent	   35.35	   32.43	  
aValues	  in	  parentheses	  are	  given	  for	  the	  highest	  resolution	  shell	  




Figure	  3.1	  PRP51	  mutations.	  (A)	  Sites	  of	  the	  14	  drug	  resistant	  mutations	  are	  mapped	  onto	  the	  PRP51	  dimer	  
(cyan	  cartoon	  representation).	  The	  mutations	  located	  in	  the	  active	  site	  cavity	  are	  shown	  as	  red	  spheres,	  
while	  the	  flap	  mutations	  are	  shown	  as	  blue	  spheres	  and	  the	  mutations	  distal	  from	  the	  active	  site	  are	  in-­‐
dicated	  as	  green	  spheres.	  (B)	  Amino	  acid	  sequence	  of	  HIV-­‐1	  PR	  (upper	   line)	  and	  PRP51	  (lower	  line).	  The	  
amino	  acids	  are	  colored	  as	   in	  (A).	  Note	  that	  the	  wild	  type	  PR	  sequence	  used	  for	  structural	  comparison	  
includes	  mutations	  Q7K,	  L33I,	  and	  L63I	  to	  prevent	  autoproteolysis,	  and	  both	  proteins	  include	  C67A	  and	  
C95A	  to	  eliminate	  potential	  cysteine-­‐thiol	  oxidation.	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Figure	  3.2	  DRV	  binds	  to	  different	  sites	  in	  PR	  and	  PRP51.	  (A)	  The	  structure	  of	  wild	  type	  PR	  (grey	  color)	  has	  
two	  conformations	  of	  DRV	  (red	  sticks)	  bound	  perpendicular	  to	  the	  dimer	  interface.	  (B)	  A	  different	  posi-­‐
tion	  and	  conformation	  was	  seen	  for	  the	  two	  molecules	  of	  DRV	  (red	  sticks	  and	  pink	  sticks)	  bound	  sym-­‐
metrically	  in	  the	  PRP51	  dimer	  (green	  color).	  The	  black	  two-­‐sided	  arrows	  indicate	  approximately	  the	  dimer	  
interface	  in	  PR-­‐DRV	  and	  PRP51.	  On	  the	  right	  side,	  the	  chemical	  structure	  of	  DRV	  is	   indicated	  in	  approxi-­‐
mately	  the	  same	  orientation	  for	  PR	  and	  PRP51.	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Figure	   3.3	   Unique	   binding	   site	   for	   DRV	   in	   PRP51.	   (A)	   Fo-­‐Fc	   omit	  map	   contoured	   at	   2.0σ	   showing	   one	  
molecule	  of	  DRV	  (yellow	  sticks)	   in	  the	  crystal	  structure	  of	  PRP51/DRV.	  (B)	  Interaction	  between	  two	  DRV	  
molecules.	  Water	  molecules	  are	  shown	  as	  red	  spheres.	  The	  dotted	  lines	  represent	  the	  hydrogen	  bonds	  
and	  the	  dashed	  lines	  represent	  potential	  CH…O	  interactions	  with	  the	  interatomic	  distances	  ranging	  from	  
3.0-­‐3.8	  Å.	  The	  numbers	  beside	  the	  lines	  indicate	  the	  distances.	  (C-­‐D)	  Interactions	  of	  one	  DRV	  with	  PRP51	  
(green	  sticks).	  The	   interactions	  with	   two	  parts	  of	  DRV	  are	  shown	   in	   (C)	  and	   (D)	   for	  clarity.	  The	  dotted	  
lines	   show	   the	  hydrogen	  bond	   interactions	  and	   the	  double-­‐sided	  arrows	   represent	   the	  van	  der	  Waals	  




Figure	  3.4	  DRV	  has	  distinct	  hydrogen	  bonding	  interactions	  with	  wild	  type	  PR	  (A)	  and	  PRP51	  (B).	  DRV	  is	  
represented	   in	  grey	  sticks	  and	  yellow	  sticks	   in	  PR	  and	  PRP51,	  respectively.	  The	  dotted	   lines	   indicate	  hy-­‐
drogen	  bond	   interactions.	  Water	  molecules	  are	   represented	  by	  W.	  NH	   is	   the	  main	  chain	  amide	  group	  





Figure	  3.5	  Comparison	  of	  dimers	  of	  PRP51/DRV	  and	  wild	   type	  PR	  (PDB	   ID	  2PC0).	  Superposition	  of	  the	  
overall	  structures	  of	  PRP51/DRV	  (green)	  and	  wild	  type	  PR	  (grey).	  The	  double-­‐sided	  arrows	  represent	  the	  
close	  contacts	  between	  DRV	  and	  side	  chains	  of	  Ile54,	  Val82	  and	  Ile84	  in	  wild-­‐type	  PR.	  The	  close	  distance	  




Figure	   3.6	   Comparison	  of	   two	   structures	   of	   PRP51.	   (A)	  Superposition	  of	   the	  overall	   structures	  of	  PRP51	  
(pink)	  and	  PRP51/DRV	  (green).	  (B)	  The	  interactions	  of	  flap	  residues	  47	  to	  54	  are	  shown	  in	  the	  blue	  box;	  
the	  numbers	  beside	  the	  black	  arrows	  show	  the	  distance	  between	  corresponding	  Cα	  atoms	  of	  Ile50/50’in	  
the	  two	  structures.	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Figure	  3.7	  Comparison	  of	   dimers	  of	   PRP51	   and	  PR20/p2-­‐NCopen.	   (A)	  Superposition	  of	   the	  overall	   struc-­‐
tures	  of	  PRP51	  (pink)	  and	  PR20/p2-­‐NCopen	  (PDB	  ID	  3UHL,	  blue).	  (B)	  The	  flap	  residues	  47	  to	  53	  and	  Pro81	  of	  
PRP51	  and	  PR20/p2-­‐NCopen	  are	  shown	  below.	  The	  numbers	  beside	  the	  black	  arrows	  show	  the	  distance	  in	  
Å	  between	  the	  flap	  tips	  on	  Ile50	  and	  Pro81’	  of	  PR20/p2-­‐NCopen	  and	  PRP51.	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Figure	  3.8	   Interactions	  of	   Leu89	   in	  PR/DRV	   (grey)	  and	  Met89	   in	  PRP51/DRV	   (green)	  with	  neighboring	  
residues	   in	   stick	   representation.	  The	  double-­‐sided	  arrows	  and	  the	  dashed	   lines	  represent	  the	  van	  der	  
Waals	  contacts	  and	  putative	  C-­‐H…O	  interactions,	  respectively,	  and	  are	  colored	  grey	  and	  green	  to	  match	  
the	  structures	  when	  differences	  occur,	  while	  black	   lines	   indicate	   identical	  numbers	  of	  contacts	   in	  both	  






Figure	  3.9	  DRV	   interactions	  with	  symmetry-­‐related	  monomer	  of	  PRP51.	  The	  dotted	  lines	  show	  the	  hy-­‐
drogen	  bond	  interactions	  and	  the	  double-­‐sided	  arrows	  represent	  the	  van	  der	  Waals	  contacts.	  The	  num-­‐
bers	  of	  van	  der	  Waals	  contacts	  are	  indicated.	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Figure	  3.10	  Comparison	  of	  PRP51,	  PR20	  and	  wild	  type	  PR	  structures.	  (A)	  Superposition	  of	  ligand-­‐free	  PR	  
(PDB	   ID:	  1HHP)	   (grey),	  PR20	   (PDB	   ID:	  3UF3)	   (blue)	  and	  PRP51	   (pink)	   in	   ribbon	   representation	  with	  per-­‐
pendicular	   view	   of	   flap	   residues	   46-­‐54.	   (B)	   Superposition	   of	   PR/DRV	   (PDB	   ID:	   2IEN)	   (grey),	   PR20/DRV	  
(PDB	   ID:	  3UCB)	   (blue)	  and	  PRP51/DRV	   (green)	   in	   ribbon	   representation	  and	  perpendicular	   view	  of	   resi-­‐












4 STRUCTURAL	  BASIS	  FOR	  HAND-­‐LIKE	  SITE	  IN	  CALCIUM	  SENSOR	  CATCHER	  WITH	  FAST	  KINETICS	  
(Published:	  Zhang,	  Y.,	  Reddish,	  F.,	  Tang,	  S.,	  Zhuo,	  Y.,	  Wang,	  Y.-­‐F.,	  Yang,	  J.J.,	  Weber,	  I.T.,	  Acta	  Cryst.	  D60,	  
doi:	  )	  
4.1 Abstract	  
Calcium	  ions,	  which	  are	  important	  signalling	  molecules,	  can	  be	  detected	  in	  the	  endoplasmic	  re-­‐
ticulum	  by	  an	  engineered	  mutant	  of	  green	   fluorescent	  protein	   (GFP)	  designated	  CatchER	  with	   fast	  off	  
rate.	  Crystal	  structures	  at	  high	  resolution	  (1.78	  to	  1.20	  Å)	  were	  analyzed	  for	  CatchER	  in	  the	  apo	  form	  and	  
in	  the	  complexes	  with	  calcium	  or	  gadolinium	  to	  probe	  the	  binding	  site	  for	  metal	  ions.	  While	  CatchER	  ex-­‐
hibits	   1:1	   binding	   stoichiometry	   in	   solution,	   two	   positions	   were	   observed	   for	   each	   of	   the	  metal	   ions	  
bound	   within	   the	   hand-­‐like	   site	   formed	   by	   the	   carboxylate	   side	   chains	   of	   mutated	   residues	   S147E,	  
S202D,	  Q204E,	  F223E	  and	  T225E	  that	  may	  be	  responsible	  for	   its	  fast	  kinetic	  properties.	  Comparison	  of	  
the	  structures	  of	  CatchER,	  wild	  type	  GFP	  and	  enhanced	  GFP	  confirmed	  that	  different	  conformations	  of	  
T203	  and	  E222	  are	  associated	  with	  the	  two	  forms	  of	  Y66	  of	  the	  chromophore,	  which	  are	  responsible	  for	  
the	  absorbance	  wavelengths	  of	  the	  different	  proteins.	  Calcium	  binding	  to	  CatchER	  may	  shift	  the	  equilib-­‐
rium	   for	   conformational	   population	   of	   the	   E222	   side	   chain,	   and	   lead	   to	   further	   changes	   in	   its	   optical	  
properties.	  
4.2 Introduction	  
The	  calcium	  ion	  Ca2+	  acts	  as	  a	  ubiquitous	  signalling	  molecule	  in	  the	  regulation	  of	  numerous	  bio-­‐
logical	  functions	  including	  heart	  beat,	  muscle	  contraction,	  cell	  development	  and	  proliferation	  (Berridge	  
et	  al.,	  1998,	  Bers	  et	  al.,	  2005).	  Ca2+	  signals	  exhibit	  different	  amplitude	  and	  duration	  as	  the	  ions	  flow	  be-­‐
tween	   subcellular	   compartments.	  Ca2+	   functions	  as	   first	  messenger	   in	   the	   central	  nervous	   system	  and	  
works	  as	  an	  extracellular	  ion	  source	  for	  postsynaptic	  ligand	  gated	  channels	  (Berridge,	  1998).	  The	  endo-­‐
plasmic	  reticulum	  (ER)	  functions	  as	  an	  intracellular	  Ca2+	  store	  and	  the	  release	  of	  ER	  Ca2+	  triggers	  a	  series	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of	  biological	  processes	  via	  binding	  to	   intracellular	  Ca2+-­‐sensing	  proteins	   like	  calmodulin	   (CaM)	  and	  tro-­‐
ponin	  C	  (TnC)	  (Zhang	  et	  al.,	  2001).	  The	  Ca2+	  signalling	  events	  are	  controlled	  by	  the	  basal	  ER/SR	  Ca2+	  level,	  
as	  well	  as	  the	  amplitude	  and	  the	  kinetics	  of	  Ca2+	  release	  from	  the	  calcium	  stores.	  Hence,	  the	  determina-­‐
tion	  of	  the	  concentration	  of	  free	  Ca2+	  in	  the	  ER	  is	  of	  extensive	  interest,	  which	  has	  stimulated	  the	  devel-­‐
opment	  of	  tractable	  intracellular	  Ca2+	  sensors.	  
Many	  efforts	  have	  been	  devoted	  to	  green	  fluorescent	  protein	  (GFP)-­‐based	  Ca2+	  fluorescent	  indi-­‐
cators,	  such	  as	  the	  cameleons	  (Miyawaki	  et	  al.,	  1997,	  Miyawaki	  et	  al.,	  1999),	  pericams	  (Persechini	  et	  al.,	  
1997),	  and	  TN-­‐XL	  (Mank	  et	  al.,	  2006),	  and	  TN-­‐XXL	  (Mank	  et	  al.,	  2008).	  Their	  detection	  is	  based	  on	  either	  
fluorescence	  resonance	  energy	  transfer	  (FRET)	  between	  two	  different	  GFP	  variants	  or	  the	  pH-­‐dependent	  
change	   in	   ionization	   state	   of	   the	   chromophore	   in	   circularly	   permutated	   GFP	   (Miyawaki	   et	   al.,	   1997,	  
Persechini	  et	  al.,	  1997,	  Nagai	  et	  al.,	  2001,	  Baird	  et	  al.,	  1999).	  One	  common	  property	  of	  these	  sensors	  is	  
that	  they	  involve	  the	  insertion	  of	  naturally	  occurring	  Ca2+-­‐sensing	  proteins	  like	  CaM	  and	  its	  target	  bind-­‐
ing	  peptide	  and	  are	  capable	  of	  sensing	  cytosolic	  calcium	  responses	  in	  the	  nM	  to	  μM	  range	  (Takahashi	  et	  
al.,	  1999,	  Solovyova	  et	  al.,	  2002,	  Tsien,	  1998).	  Several	  ER/SR	  sensors	  with	  lower	  metal	  binding	  affinities	  
have	   been	   developed	   by	  modifying	   the	   Ca2+	   binding	   loops	   or	   the	   peptide	   interaction	   surface	   of	   CaM 
(Ohkura	  et	  al.,	  2005,	  Miyawaki	  et	  al.,	  1997,	  Palmer	  et	  al.,	  2004,	  Evanko	  et	  al.,	  2005,	  Palmer	  et	  al.,	  2006).	  
These	  sensors	  exhibit	  some	  limitations	  such	  as	  off	  rates,	  which	  are	  not	  fast	  enough	  to	  detect	  the	  calcium	  
release	  during	  action	  potentials.	   In	  addition	  only	  ~50%	  of	  the	  skeletal	  muscle	  cells	  show	  a	  response	  to	  
calcium	  stimulation.	  For	  the	  FRET	  pair	  involved	  sensors,	  their	  highly	  variable	  basal	  CFP	  (cyan	  fluorescent	  
protein)/YFP	  (yellow	  fluorescent	  protein)	  ratio	  and	  poor	  signal-­‐to-­‐noise	  ratio	  also	  limit	  quantitative	  de-­‐
termination	  of	   calcium	  concentration	  and	  calcium	  release	   (Rudolf	   et	  al.,	  2006,	   Jimenez-­‐Moreno	   et	  al.,	  
2010).	   Therefore,	   there	   is	  pressing	  need	   for	  new	  Ca2+	   sensors	   targeted	   to	   cellular	   compartments	  with	  
putative	  high	  Ca2+	  concentration	  as	  in	  the	  ER/SR	  to	  overcome	  these	  limitations.	  In	  a	  previous	  attempt	  to	  
meet	  this	  urgent	  need,	  our	  laboratory	  has	  engineered	  a	  Ca2+	  sensor,	  “G1”,	  by	  grafting	  an	  EF-­‐hand	  motif	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into	  enhanced	  green	  fluorescent	  protein	  (EGFP)	  (Zou	  et	  al.,	  2007).	  Unlike	  GFP	  that	  can	  be	  excited	  at	  395	  
nm	  and	  475	  nm,	  EGFP	  contains	  two	  mutations	  F64L	  and	  S65T	  and	  has	  one	  absorption	  maximum	  at	  488	  
nm	  (Tsien,	  1998,	  Ormo	  et	  al.,	  1996).	  Mutation	  F64L	  is	  responsible	  for	  improved	  folding	  efficiency	  at	  37	  
°C,	  while	  S65T	  is	  a	  critical	  mutation	  for	  suppressing	  the	  395	  nm	  absorbance	  peak	  (Tsien,	  1998,	  Ormo	  et	  
al.,	  1996,	  Arpino	  et	  al.,	  2012).	  This	  G1	  sensor	  has	  an	  apparent	  Kd	  of	  0.8	  mM	  and	  responds	  to	  Ca
2+	  with	  a	  
ratiometric	  fluorescence	  change,	  but	  with	  a	  slow	  kinetic	  response.	  
Recently, we	  reported	  a	  new	  strategy	  for	  creating	  Ca2+	  indicators	  by	  introducing	  a	  Ca2+-­‐binding	  
site	   into	   EGFP	   via	   site-­‐directed	  mutagenesis	   of	   selected	   residues	   in	   the	   fluorescent	   sensitive	   location	  
(Tang	  et	  al.,	  2011).	  The	  single	  EGFP-­‐based	  Ca2+	  biosensor	  termed	  CatchER	  was	  generated	  by	  the	  substi-­‐
tutions	  of	  S147E,	  S202D,	  Q204E,	  F223E	  and	  T225E	  of	  EGFP	  in	  the	  designed	  Ca2+	  binding	  site	  (Figure	  4.1).	  
CatchER	  provides	  multiple	  advantages	  for	  reliably	  monitoring	  Ca2+	  signalling	  in	  high	  [Ca2+]	  environments:	  
(1)	  it	  exhibits	  a	  unique	  calcium-­‐induced	  change	  in	  optical	  property.	  Calcium	  binding	  results	  in	  ratiometric	  
changes	  in	  absorption	  while	  fluorescence	  emission	  at	  510	  nm	  is	  increased	  when	  excited	  at	  either	  398	  or	  
490	  nm	  (Figure	  4.2(a));	  the	  high	  signal	  to	  noise	  ratio	  for	  fluorescent	  change	  in	  response	  to	  Ca2+	  as	  well	  as	  
avoidance	  of	  cooperativity	  associated	  with	  multiple	  binding	  sites	  allows	  an	  accurate	  detection	  of	  calcium	  
both	  in	  vitro	  and	  in	  vivo;	  (2)	  CatchER	  exhibits	  unprecedented	  dissociation	  kinetics	  with	  an	  off-­‐rate	  >100	  
s-­‐1	   and	   a	   fast	   kinetic	   response	   to	   Ca2+	   changes	  within	  milliseconds;	   recent	   work	   has	   also	   shown	   that	  
CatchER	  is	  able	  to	  detect	  multiple	  calcium	  spikes	  during	  muscle	  contraction	  and	  relaxation	  (Wang	  et	  al.,	  
2012);	  (3)	  the	  Kd	  of	  CatchER	  (around	  1	  mM)	  allows	  the	  accurate	  calibration	  of	  SR	  Ca
2+	  signalling;	  CatchER	  
is	  able	   to	  report	  considerable	  differences	   in	  SR/ER	  Ca2+	  concentration	  between	  epithelial	  HeLa,	  kidney	  
HEK293,	  and	  muscle	  C2C12	  cells;	   (4)	  no	   invasive	  methods	  are	   required	   for	  CatchER	  detection	   in	   living	  
organelles	  compared	  with	  current	  Ca2+	  dyes.	  Such	  cumulative	  advantages,	  especially	  fast	  kinetic	  proper-­‐
ties,	  allowed	  us	  to	  monitor	  SR	  luminal	  Ca2+	  in	  flexor	  digitorum	  brevis	  (FDB)	  muscle	  fibers	  to	  understand	  
the	  mechanism	  of	  diminished	  SR	  Ca2+	  release	  in	  aging	  mice	  (Tang	  et	  al.,	  2011,	  Wang	  et	  al.,	  2012).	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In	  this	  report,	  we	  describe	  crystallographic	  analysis	  of	  CatchER	  to	  understand	  the	  structural	  ba-­‐
sis	   for	   the	   calcium	   induced	   fluorescent	   and	   absorption	   changes	   and	   fast	   response.	   Crystal	   structures	  
were	  determined	  of	  CatchER	   in	   the	  absence	  of	  Ca2+	   (CatchER(apo)),	   in	   the	  presence	  of	  Ca2+	   (CatchER-­‐
Ca2+),	  and	  from	  crystals	  soaked	  with	  Gd3+	  (CatchER-­‐Gd3+).	  To	  overcome	  the	  challenges	  for	  visualizing	  Ca2+	  
binding	  sites	   in	  the	  proteins	  due	  to	  weak	  Ca2+	  binding	  affinity	  and	  high	  off	  rate	  and	  difficulty	   in	  distin-­‐
guishing	  calcium	  from	  water	   in	   the	  crystal	  structure,	  we	  used	  the	  heavier	  Gd3+	   ions	  with	  similar	  metal	  
binding	  coordination	  properties	  to	  calcium	  to	  identify	  the	  position	  of	  the	  metal	  ion.	  These	  X-­‐ray	  crystal	  
structures	  of	  CatchER	  and	  its	  complexes	  can	  assist	  the	  future	  development	  of	  protein-­‐ligand	  interaction	  
based	  biosensors	  for	  the	  detection	  of	  various	  physiological	  molecules.	  
4.3 Experiments	  and	  Methods	  
4.3.1 Expression	  and	  Purification	  
Protein	  was	  expressed	  by	  modification	  of	  the	  procedure	  described	  in	  (Zou	  et	  al.,	  2007).	  BL21DE3	  
cells	  transformed	  with	  pET28a	  vector	  containing	  the	  CatchER	  DNA	  were	  pre-­‐cultured	  in	  10	  mL	  of	  LB	  me-­‐
dia	  containing	  6	  μL	  of	  50	  mg/mL	  kanamycin	  (30	  mg/mL)	  and	  shaken	  overnight	  at	  37°C.	  	  The	  pre-­‐culture	  
was	  transferred	  to	  1	  L	  of	  Luria	  Bertani	  media	  containing	  30	  mg/mL	  of	  kanamycin	  and	  allowed	  to	  shake	  at	  
220	  rpm	  at	  37°C	  until	   the	  O.D.	   reached	  ~0.6	   followed	  by	   the	   induction	  of	  protein	  expression	  with	   the	  
addition	  of	  200	  μL	  of	  1	  M	  IPTG	  (0.2	  mM)	  and	  a	  reduction	  in	  temperature	  to	  25°C.	  Cells	  were	  collected	  by	  
centrifugation	  at	  7,000	  rpm	  for	  30	  min	  at	  4°C.	  	  Cell	  pellets	  were	  re-­‐dissolved	  in	  extraction	  buffer	  (20	  mM	  
Tris	  pH	  8.0,	  100	  mM	  NaCl,	  0.1%	  Triton	  X-­‐100)	  and	  sonicated.	  Cell	  lysate	  mixture	  was	  centrifuged	  for	  30	  
minutes	  at	  17,000	  rpm	  and	  4°C.	  	  Supernatant	  was	  filtered	  using	  a	  0.45	  μm	  Whattman	  filter	  and	  protein	  
purified	  by	  using	  a	  5	  mL	  Hitrap	  chelating	  column	  (Amersham	  Biosciences,	  Sweden)	  loaded	  with	  Ni2+.	  The	  
protein	  has	  a	  6	  histidine	  tag	  at	  the	  N-­‐terminal	  for	  Immobilized	  Metal	  Ion	  Affinity	  Chromatography.	  High	  
purity	  fractions	  were	  then	  concentrated	  to	  1-­‐2	  mL	  and	  purified	  further	  using	  size	  exclusion	  chromatog-­‐
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raphy	  with	  a	  Superdex	  75	  100	  mL	  column	  (Pharmacia	  Biotech)	  at	  a	  flow	  rate	  of	  1	  mL/min	  with	  10	  mM	  N-­‐
[2-­‐hydroxyethyl]piperazine-­‐N’-­‐2-­‐ethanesulfonic	  acid	  (HEPES)	  buffer	  pH	  7.4	  to	  ensure	  high	  purity	  for	  crys-­‐
tallization.	  The	  6XHis-­‐tag	  was	  not	  removed.	  The	  protein	  without	  the	  tag	  contains	  244	  amino	  acids	  and	  
has	  ~30	  kDa	  molecular	  mass.	  
4.3.2 Crystallization,	  X-­‐ray	  Data	  Collection	  and	  Structure	  Determination	  
Crystals	  of	  Ca2+	  free	  and	  Ca2+	  loaded	  CatchER	  were	  obtained	  via	  the	  hanging	  drop	  method	  of	  va-­‐
por	   diffusion	   using	   2	   μL	   protein:	   2	   μL	   reservoir	   solutions	   at	   room	   temperature	   in	   24-­‐well	   VDX	   plates	  
(Hampton	  Research,	  Aliso	  Viejo,	  CA).	  Ca2+	   free	  CatchER	  crystals	   (0.9	  mM	  protein,	  5	  μM	  EGTA)	  grew	   in	  
solutions	   containing	   51	  mM	   HEPES	   pH	   7.0,	   1	   mM	   β-­‐mercaptoethanol,	   50	  mM	  NaOAc,	   and	   17%	   PEG	  
4000.	  The	  Ca2+	  loaded	  CatchER	  complex	  was	  created	  by	  adding	  50	  mM	  CaCl2	  to	  a	  0.9	  mM	  protein	  solu-­‐
tion	  (final	  concentration	  of	  0.45	  mM).	  Crystals	  of	  Ca2+	  loaded	  CatchER	  grew	  in	  mother	  liquors	  containing	  
53	  mM	  HEPES	  pH	  7.0,	  1	  mM	  β-­‐mercaptoethanol,	  50	  mM	  NaOAc,	  and	  16%	  PEG	  3350.	  Crystals	  of	  Catch-­‐
ER-­‐Gd3+	  were	  obtained	  via	  the	  soaking	  technique.	  Crystals	  of	  apo	  CatchER	  were	  soaked	  for	  1	  to	  2	  days	  in	  
a	  solution	  of	  mother	   liquor	  with	  the	  final	  concentration	  of	  2	  mM	  GdCl3.	  The	  crystals	  were	  mounted	   in	  
liquid	  nitrogen	  with	  20%	  (v/v)	  glycerol	  as	  cryoprotectant	  in	  the	  mother	  liquor	  without	  added	  metal	  ions.	  
X-­‐ray	  diffraction	  data	  for	  the	  crystals	  were	  collected	  on	  the	  SER-­‐CAT	  beamline	  of	  the	  Advanced	  Photon	  
Source,	  Argonne	  National	   Laboratory,	  Argonne,	   IL.	  No	  anomalous	   scattering	  was	  detected	   for	  Gd3+	   or	  
Ca2+	  likely	  due	  to	  the	  short	  X-­‐ray	  wavelengths	  used.	  
X-­‐ray	   diffraction	   data	  were	   processed	   and	   scaled	  with	   HKL2000	   (Otwinowski	   &	  Minor,	   1997),	  
and	  the	  structures	  were	  solved	  by	  molecular	  replacement	  using	  MOLREP	  CPP4i	  suite	  of	  programs	  (Vagin	  
&	   Teplyakov,	   1997,	   Potterton	   et	   al.,	   2003)	   with	   the	   chain	   A	   of	   EGFP	   [Protein	   Data	   Bank	   (PDB)	   entry	  
2OKW]	  (Chapleau	  et	  al.,	  2008)	  as	  the	  starting	  model.	  The	  structures	  of	  CatchER(apo)	  and	  CatchER-­‐Gd3+	  
were	   refined	   with	   REFMAC5	   (Murshudov	   et	   al.,	   1997)	   and	   the	   near-­‐atomic	   resolution	   structure	   of	  
CatchER-­‐Ca2+	  was	  refined	  with	  SHELX	  (Sheldrick	  &	  Schneider,	  1997,	  Sheldrick,	  2008).	  Manual	  adjustment	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of	   the	  models	  used	  Coot	  0.5.2	   (Emsley	  &	  Cowtan,	  2004).	  The	   full	   length	  protein	  has	  238	  amino	  acids,	  
however,	  an	  N-­‐terminal	  methionine	  was	  observed	  in	  these	  structures	  and	  labelled	  residue	  0	  for	  consis-­‐
tency	  with	  other	  published	  GFP	  structures,	  and	  several	  C-­‐terminal	  residues	  were	  not	  visible	  in	  the	  elec-­‐
tron	  density	  maps.	  In	  the	  three	  structures,	  a	  single	  protein	  molecule	  were	  refined	  with	  the	  residues	  la-­‐
belled	  0-­‐231	  in	  CatchER(apo)	  and	  CatchER-­‐Gd3+	  and	  0-­‐229	  in	  CatchER-­‐Ca2+,	  respectively,	  while	  the	  chro-­‐
mophore	   is	   labelled	  CRO66	  as	   in	  other	  published	  GFP	   structures.	  Alternate	   conformations	  were	  mod-­‐
elled	  for	  CatchER	  residues	  where	  observed.	  The	  solvent	  was	  modelled	  with	  waters,	  metal	  ions	  and	  other	  
solvent	  molecules	  according	  to	  the	  observed	  electron	  density	  maps.	  Anisotropic	  B	  factors	  were	  applied	  
for	  the	  whole	  structures	  of	  CatchER-­‐Ca2+	  and	  only	  the	  Gd3+	  atoms	  in	  CatchER-­‐Gd3+.	  In	  the	  CatchER-­‐Ca2+	  
and	  CatchER(apo)	  structures,	  residues	  R73	  and	  E225	  were	  refined	  with	  the	  same	  free	  variable	  number	  in	  
SHELX	  or	   the	  same	  reasonable	  occupancy	  assignment	   in	  REFMAC5	  due	   to	   the	  short	  distance	  between	  
two	   alternative	   conformations.	   Residues	   155-­‐159	   that	   show	   two	   alternate	   conformations	   in	   all	   three	  
structures	  were	   refined	   in	   a	   similar	  manner.	   The	  mutant	   crystal	   structures	  were	   compared	  with	   each	  
other	  and	  also	  with	  the	  wild	  type	  EGFP	  (PDB	  entry	  4EUL),	  a	  recently	  published	  high	  resolution	  structure	  
(Arpino	  et	  al.,	  2012),	  by	  superimposing	  their	  Cα	  atoms	  using	  SUPERPOSE	  in	  the	  CPP4i	  suite	  of	  programs	  
(Krissinel	  &	  Henrick,	  2004,	  Potterton	  et	  al.,	  2003).	  Structural	   figures	  were	  made	  using	  PyMol	   (DeLano,	  
2002).	  The	  atomic	  coordinates	  and	  structure	  factors	  have	  been	  deposited	  in	  the	  Protein	  Databank	  (PDB)	  
with	  PDB	  codes	  of	  4L13,	  4L1I	  and	  4L12	  for	  CatchER(apo),	  CatchER-­‐Ca2+	  and	  CatchER-­‐Gd3+,	  respectively.	  
4.3.3 Absorbance	  Spectrum	  of	  CatchER	  and	  Metal	  Binding	  Affinity	  via	  Fluorescence	  
Spectroscopy	  
The	  absorbance	  spectra	  of	  CatchER	  and	  EGFP	  were	  obtained	  using	  a	  Shimadzu	  UV-­‐1601	  spec-­‐
trophotometer.	  Samples	  were	  prepared	  using	  20	  µM	  protein	  in	  10	  mM	  Tris	  pH	  7.4.	  To	  the	  CatchER	  sam-­‐
ple,	  5	  µM	  of	  ethyleneglycoltetraacetic	  acid	  (EGTA)	  was	  added	  to	  get	  the	  Ca2+	  free	  spectrum.	  To	  get	  the	  
Ca2+	  loaded	  CatchER	  spectrum,	  5	  mM	  CaCl2	  was	  added	  to	  the	  sample.	  The	  absorbance	  spectrum	  of	  Gd
3+	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loaded	  CatchER	  was	  obtained	   in	   the	   same	  manner	  with	   the	  addition	  of	  200	  μM	  GdCl3	   to	   the	  CatchER	  
sample	  prepared	   in	  20	  mM	  PIPES	  pH	  6.8.	  The	   fluorescence	   response	  of	  CatchER	   to	  Gd3+	  and	  Ca2+	  was	  
analyzed	  using	  a	  Photon	  Technology	   International	   (PTI)	   (Canada)	  spectrofluorimeter.	  The	  spectra	  were	  
collected	  with	  Felix32	  fluorescence	  analysis	  software.	  Slit	  widths	  were	  set	  at	  0.35	  mm	  for	  excitation	  and	  
emission.	  Samples	  of	  10	  μM	  CatchER	  with	  2	  μM	  EGTA	  were	  prepared	  in	  triplicate	  in	  20	  mM	  PIPES	  pH	  6.8	  
for	  Gd3+	  titrations	  and	  in	  10	  mM	  Tris	  pH	  7.4	  for	  Ca2+	  titrations.	  Samples	  were	  excited	  at	  395	  and	  488	  nm	  
with	  emission	  recorded	  from	  500-­‐600	  nm.	  To	  determine	  the	  Kd,	  the	  following	  1:1	  binding	  equation	  was	  
used,	  
[PM]/[PT]	  =	  [MT]/	  Kd	  +	  [MT]	  
where	  Kd	  is	  the	  dissociation	  constant,	  PM/PT	  is	  the	  fractional	  change	  of	  complex	  formation,	  and	  MT	  is	  the	  
total	  metal	  concentration.	  The	  equation	  was	  derived	  as	  follows:	  	  
[PT]	  =	  [PF]	  +	  [PM]	  
[MT]	  =	  [MF]	  +	  [PM]	  
[PF]	  =	  [PT]	  –	  [PM]	  
Kd	  =	  [PF][MF]/[PM]	  
Kd	  =	  (([PT]-­‐[PM])([MF]))/([PM])	  
([PM])(Kd	  +	  [MF])	  =	  ([MF][PT])	  	  
([PM]/[PT])	  =	  [MT]/Kd	  +	  [MT]	  
Dividing	  by	  [PT]	  gives	  the	  fractional	  saturation	  of	  the	  protein.	  	  Because	  [MF]	  =	  [MT],	  we	  can	  replace	  [MF]	  
with	  [MT].	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4.4 Results	  and	  Discussion	  
4.4.1 Metal	  Binding	  Properties	  of	  CatchER	  
The	  absorption	  and	  fluorescence	  response	  of	  CatchER	  to	  Ca2+	  and	  Gd3+is	  shown	  in	  Figures	  4.2(a)-­‐
(f)	  with	  fluorescence	  monitored	  at	  510	  nm	  upon	  excitation	  at	  488	  nm.	  The	  normalized	  response	  shows	  
an	   excellent	   fit	  with	   the	   1:1	   binding	   equation.	   Figure	   4.8(a)-­‐(d)	   shows	   the	   fluorescence	   response	   and	  
normalization	  for	  Gd3+	  and	  Ca2+	  at	  395	  nm	  excitation.	  From	  these	  results,	  the	  Kd	  of	  CatchER	  for	  Gd
3+	   is	  
53.0	  ±	  4.0	  µM	  and	  177.0	  ±	  13.6	  µM	  excited	  at	  395	  and	  488	  nm,	  respectively.	  The	  Kd	  of	  CatchER	  for	  Ca
2+	  
was	  determined	  to	  be	  315.4	  ±	  40.0	  µM	  and	  227.0	  ±	  3.3	  µM	  excited	  at	  395	  and	  488	  nm,	  respectively.	  The	  
addition	  of	  Ca2+	  or	  Gd3+	  greatly	  enhances	  fluorescence	  emission	  of	  CatchER	  at	  510	  nm	  while	  excited	  at	  
395	  or	  488	  nm.	  	  	  
The	  stoichiometric	  interaction	  of	  CatchER	  with	  Gd3+	  was	  investigated	  and	  determined	  using	  the	  
Job	  Plot	  method	  (Figure	  4.2(f)).	  Figure	  4.8(c)	  lists	  the	  calculated	  relative	  amounts	  of	  Gd3+	  loaded	  CatchER	  
from	  the	  plot	   in	  Figure	  4.2(f).	   The	   largest	  amount	  of	  Gd3+	  bound	  CatchER	  was	  obtained	  at	  equi-­‐molar	  
amounts	  of	  CatchER	  and	  Gd3+	  (25	  μM).	  Thus,	  CatchER	  forms	  1:1	  complex	  with	  Gd3+	  (Table	  4.1).	  In	  (Tang	  
et	  al.,	  2011),	  CatchER	  was	  shown	  to	  exhibit	  1:1	  binding	  stoichiometry	  with	  Ca2+	  as	  well.	  Overall,	  CatchER	  
exhibits	  a	  1:1	  stoichiometric	  interaction	  with	  Gd3+	  and	  Ca2+.	  
4.4.2 Crystallographic	  Analysis	  of	  CatchER	  Structures	  
Crystal	  structures	  of	  CatchER	  in	  the	  apo	  form,	  Ca2+	  form	  and	  Gd3+	  loaded	  form	  were	  determined	  
to	  identify	  and	  analyze	  the	  Ca2+	  binding	  site	  in	  the	  designed	  sensor.	  The	  crystallographic	  data	  collection	  
and	  refinement	  statistics	  are	  summarized	  in	  Table	  4.2	  and	  the	  data	  statistics	  versus	  resolution	  for	  each	  
CatchER	  are	  listed	  in	  Table	  4.4.	  The	  crystal	  structures	  of	  CatchER(apo),	  CatchER-­‐Ca2+,	  and	  CatchER-­‐Gd3+	  
were	   refined	   to	  R	   factors	  of	   18.1%,	   15.0%	  and	  19.6%	  at	   resolutions	  of	   1.66,	   1.20	   and	  1.78	  Å,	   respec-­‐
tively.	  These	  three	  structures	  are	  in	  two	  different	  space	  groups:	  CatchER(apo)	  and	  CatchER-­‐Gd3+	  in	  C2221	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and	   CatchER-­‐Ca2+	   in	   P212121.	   Structure	   validation	   was	   performed	   and	   the	   Ramachandran	   plots	   are	  
shown	  in	  Figure	  4.10.	  The	  p-­‐hydroxylbenzylideneimidazolidinone	  chromophore	  (CRO66)	  is	  clearly	  visible	  
in	   the	  electron	  density	   for	  all	   structures,	  as	   shown	   in	  Figure	  4.3(a)	   for	  CatchER-­‐Ca2+.	   The	   three	  crystal	  
structures	  have	  very	  similar	  backbone	  conformation,	  as	  demonstrated	  by	  low	  RMSD	  values	  of	  0.09-­‐0.20	  
Å	   for	  each	  pair	  of	   structures.	  Slightly	  more	  variation	   is	   seen	  relative	   to	   the	  EGFP	  structure	   (PDB	  code:	  
4EUL)	  with	  RMSD	  values	  of	  0.39-­‐0.41	  Å.	  
Because	  of	  the	  high	  resolution	  of	  the	  diffraction	  data,	  the	  solvent	  was	  fitted	  with	  167	  waters	  for	  
CatchER(apo),	  197	  water	  molecules	  for	  CatchER-­‐Ca2+,	  and	  138	  for	  CatchER-­‐Gd3+.	  One	  acetate	  molecule	  
was	   refined	   with	   1.0	   occupancy	   in	   CatchER(apo),	   two	   Ca2+	   ions	   with	   0.5	   relative	   occupancy	   each	   in	  
CatchER-­‐Ca2+,	  and	  two	  Gd3+	  ions	  with	  the	  relative	  occupancy	  of	  0.7	  and	  0.3	  in	  CatchER-­‐Gd3+.	  These	  mole-­‐
cules	  were	  identified	  by	  the	  shape	  and	  peak	  height	  in	  the	  electron	  density	  maps,	  B-­‐factors	  and	  potential	  
interactions	  with	   other	  molecules,	   as	   described	   in	   the	   next	   section.	   The	   occupancies	  were	   calculated	  
with	  SHELX	  for	  CatchER-­‐Ca2+,	  and	  estimated	  with	  REFMAC5	  for	  the	  other	  structures.	  	  
Alternative	  conformations	  were	  modelled	  for	  a	  total	  of	  19,	  23,	  and	  13	  residues	  in	  CatchER(apo),	  
CatchER-­‐Ca2+	  and	  CatchER-­‐Gd3+	  structures,	  respectively.	  The	  surface	  loop	  of	  residues	  155-­‐159	  shows	  two	  
alternative	   conformations	   with	   about	   0.5/0.5	   relative	   occupancy	   in	   all	   three	   structures	   (Figure	   4.9),	  
while	  most	  other	  reported	  structures	  have	  a	  single	  conformation	  of	  these	  residues.	  This	  disordered	  loop	  
is	  located	  on	  the	  opposite	  side	  of	  the	  protein	  to	  the	  designed	  metal	  binding	  site.	  Notably,	  E222	  consis-­‐
tently	   shows	   two	  alternate	   conformations	   in	  CatchER-­‐Ca2+	   and	  CatchER-­‐Gd3+	   structures	   (Figure	  4.3(b))	  
and	  a	  single	  conformation	  in	  CatchER(apo).	  Among	  the	  five	  designed	  mutations	  located	  on	  three	  neigh-­‐
boring	  β-­‐strands,	  the	  side	  chain	  of	  E225	  has	  two	  alternate	  conformations	  in	  CatchER(apo)	  and	  CatchER-­‐
Ca2+	  that	  interact	  with	  the	  two	  alternative	  conformations	  of	  R73	  side	  chain.	  Due	  to	  the	  surface	  location	  
of	   the	   five	   mutated	   residues	   and	   the	   potential	   for	   radiation	   damage	   to	   the	   carboxylate	   side	   chains,	  
E204,	  E223	  and	  E225	  showed	  relatively	  poor	  electron	  density	  in	  the	  different	  CatchER	  complexes.	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4.4.3 Identification	  of	  Metal	  Ions	  in	  Designed	  Binding	  Site	  of	  CatchER	  
CatchER	  was	  designed	  with	  five	  mutated	  residues	  S147E,	  S202D,	  Q204E,	  F223E,	  and	  T225E	  com-­‐
pared	   to	   EGFP.	   The	  mutations	   are	   located	  on	   three	  β-­‐strands,	   pointing	  out	   of	   the	  protein	  β-­‐barrel	   to	  
form	  a	  penta-­‐carboxylate	  ionic	  environment	  suitable	  for	  binding	  Ca2+	  (Figure	  4.1).	  In	  CatchER(apo),	  one	  
of	  the	  carboxyl	  oxygen	  atoms	  of	  E147	  forms	  close	  interactions	  with	  the	  carboxylate	  of	  D202,	  suggesting	  
possible	  protonation	  of	  the	  carboxylates	  (Figure	  4.4(a)).	  Protonated	  carboxylates	  have	  been	  reported	  in	  
other	  protein	  crystal	  structures	  (Tie	  et	  al.,	  2005).	  The	  E147	  and	  D202	  carboxylates	  are	  further	  apart	  with	  
no	  direct	  interaction	  in	  the	  CatchER	  structures	  with	  Ca2+	  and	  Gd3+	  and	  additional	  solvent	  peaks	  were	  ob-­‐
served	  in	  this	  region	  of	  the	  electron	  density	  maps.	  	  
Identification	  of	  Ca2+	  in	  the	  designed	  binding	  site	  of	  CatchER	  was	  not	  trivial	  partly	  because	  of	  the	  
fast	  off	  rate	  related	  to	  its	  weak	  calcium	  binding	  affinity.	  Crystals	  of	  CatchER	  were	  grown	  in	  high	  concen-­‐
trations	  of	  50	  mM	  Ca2+	  to	  ensure	  saturation	  of	  CatchER	  molecules;	  however,	   the	  non-­‐protein	  peaks	   in	  
the	  electron	  density	  maps	  near	  the	  mutated	  residues	  were	  indistinguishable	  from	  those	  assigned	  to	  wa-­‐
ter	  elsewhere	   (Figure	  4.4(b)).	  Therefore,	   the	  presence	  of	  Ca2+	  was	  deduced	  from	  the	   interactions	  with	  
nearby	  protein	  residues	  and	  water	  molecules.	  Two	  possible	  locations	  for	  Ca2+	  were	  identified,	  mostly	  by	  
the	  presence	  of	  shorter	  distances	  of	  1.8-­‐2.5	  Å	  to	  interacting	  oxygen	  atoms	  of	  E147	  and	  water	  molecules	  
and	  further	  interactions	  with	  D202	  and	  other	  water	  molecules	  in	  the	  designed	  site	  (Figure	  4.4(b);	  Table	  
4.3).	  These	  interatomic	  distances	  are	  within	  the	  range	  observed	  in	  high	  resolution	  crystal	  structures	  of	  
proteins	   (Harding,	   2001).	   The	   two	   locations	   were	   fitted	   with	   Ca2+	   ions	   refined	   at	   partial	   occupancy	  
(0.5/0.5).	  However,	   this	  deduction	   for	  Ca2+	  cannot	  exclude	   the	  possible	  binding	  of	  Na+	  or	  water	  mole-­‐
cules	  from	  the	  crystallization	  solution.	  No	  significant	  electron	  density	  was	  present	  in	  the	  apo	  structure	  at	  
the	  positions	  assigned	  to	  Ca2+	  near	  E147	  and	  D202.	  
In	  order	  to	  pinpoint	  the	  metal	  binding	  site	  more	  definitively,	  the	  structure	  of	  CatchER-­‐Gd3+	  was	  
obtained	   from	  apo	   crystals	   soaked	   in	  high	   concentrations	  of	  GdCl3.	   Ca
2+	   has	  18	  electrons	  orbiting	   the	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nucleus,	  while	  the	  Gd3+	  has	  61	  orbital	  electrons.	  Therefore,	  it	  is	  easier	  to	  locate	  Gd3+	  with	  increased	  dif-­‐
fraction	  over	  Ca2+	  since	  X-­‐ray	  atomic	  scattering	  factor	  increases	  with	  atomic	  number.	  The	  major	  0.7	  oc-­‐
cupancy	  Gd3+	  ion	  was	  identified	  unambiguously	  from	  the	  very	  high	  peak	  at	  22	  σ	  in	  the	  electron	  density	  
indicative	  of	  a	  heavy	  metal	  ion	  (Figure	  4.4(c)).	  This	  Gd3+	  ion	  is	  located	  between	  the	  side	  chains	  of	  E147,	  
D202	  and	  E204,	  forming	  four	  ionic	  interactions	  with	  these	  three	  residues	  at	  2.2	  Å,	  and	  2.5	  Å,	  2.6	  Å	  and	  
2.6	  Å	  distance	  and	  one	  with	  a	  nearby	  water	  molecule	  at	  2.1	  Å	  (Figure	  4.4(c))	  and	  Table	  4.3.	  The	  second	  
Gd3+	   ion	   with	   0.3	   occupancy	   was	   deduced	   from	   positive	   difference	   density	   observed	   in	   (Fo-­‐Fc)	   maps	  
when	  a	  water	  molecule	  or	  a	  partial	  occupancy	  Na+	  ion	  was	  refined	  at	  this	  site.	  Overall,	  the	  Gd3+	  ions	  co-­‐
ordinate	  with	  the	  side	  chains	  of	  residues	  E147,	  D202	  and	  E204	  of	  the	  designed	  Ca2+	  binding	  site	  as	  well	  
as	  the	  water	  molecules.	  	  
Superposition	  of	  CatchER-­‐Ca2+	  and	  CatchER-­‐Gd3+	  structures	   revealed	   that	   the	  major	  occupancy	  
site	  for	  the	  Gd3+	  ion	  is	  identical	  to	  one	  of	  the	  sites	  deduced	  for	  the	  Ca2+	  ion	  (Figure	  4.4(d)).	  This	  Ca2+	  ion	  
coordinates	  with	  the	  side	  chains	  of	  E147	  and	  D202	  and	  3	  water	  molecules.	  No	  Gd3+	  ion	  was	  visible	  at	  the	  
other	  site	  where	  the	  Ca2+	  ion	  coordinates	  with	  the	  carboxylate	  side	  chains	  of	  E147	  and	  D202	  and	  4	  water	  
molecules	  (Figure	  4.4(b)).	  It	  is	  possible	  that	  the	  presence	  of	  the	  high	  occupancy	  Gd3+	  ion	  at	  the	  adjacent	  
site	  precludes	  binding	  to	  the	  inner	  site	  occupied	  by	  a	  Ca2+	  ion	  in	  the	  CatchER-­‐Ca2+	  structure.	  	  
The	   extended	   binding	   site	   formed	   by	   the	   carboxylate	   side	   chains	   of	   mutated	   residues	   E147,	  
D202,	  E204,	  E223	  and	  E225	  traps	  metal	   ions	  at	   three	  possible	  positions,	  as	  shown	  by	  superposition	  of	  
CatchER-­‐Ca2+	  and	  CatchER-­‐Gd3+	  (Figure	  4.4(d)).	  The	  metal	  ions	  mainly	  interact	  with	  side	  chains	  of	  E147,	  
D202	  and	  E204.	  No	  direct	  interactions	  of	  designed	  metal	  ligand	  residues	  E223	  and	  E225	  with	  the	  metal	  
ions	  are	  visible,	  and	  their	  side	  chains	  are	  not	  well	  defined	  in	  the	  electron	  density	  maps,	  possibly	  due	  to	  
radiation	  damage.	  Nevertheless,	  both	  Ca2+	  and	  Gd3+	  ions	  are	  well	  situated	  at	  the	  designed	  Ca2+	  binding	  
site	  in	  CatchER,	  which	  suggests	  that	  these	  X-­‐ray	  structures	  provide	  snapshots	  for	  steps	  in	  the	  likely	  dy-­‐
namic	  metal	  binding	  process.	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4.4.4 Structural	  Changes	  around	  the	  Chromophore	  
The	   chromophore	   interactions	   were	   compared	   for	   the	   CatchER	   structures,	   EGFP	   (PDB	   code:	  
4EUL)	   (Arpino	  et	  al.,	  2012)	  and	  GFP	  (PDB	  code:	  1EMB)	   (Brejc	  et	  al.,	  1997).	  The	  chromophore	   is	  buried	  
centrally	   in	   the	   protein	  molecule	   and	  well	   protected	   from	   solvent.	   It	   can	   exist	   as	   neutral	   and	   anionic	  
forms,	  which	  are	  responsible	  for	  the	  absorbance	  at	  395	  nm	  and	  475	  nm,	  respectively	  (Yang	  et	  al.,	  1996)	  
(Figure	  4.5).	  The	  spectroscopic	  characterization	  of	  CatchER	  and	  its	  response	  to	  Ca2+	  shows	  two	  absorp-­‐
tion	  maxima	  with	  a	  major	  peak	  at	  398	  nm	  and	  a	  smaller	  peak	  at	  490	  nm,	  and	  thus,	  it	  resembles	  GFP	  with	  
two	   similar	   excitation	  wavelengths	  unlike	   EGFP	  with	   the	  one	   single	   excitation	  peak	   at	   488	  nm	   (Tsien,	  
1998)	   (Figure	   4.2(e)).	   Comparisons	   of	   the	   chromophore	   environment	   in	   the	   three	   CatchER	   structures	  
and	  currently	  solved	  EGFP	  and	  GFP	  structures	  have	  shed	  light	  on	  the	  relationship	  between	  the	  spectro-­‐
scopic	  properties	   and	   structures.	   The	   intricate	  hydrogen	  bond	  networks	   around	   the	   chromophores	  of	  
CatchER(apo),	   CatchER-­‐Ca2+	   or	   Gd3+,	   EGFP	   and	   GFP	   are	   shown	   in	   Figures	   4.6(a)-­‐4.6(d)	   (Arpino	   et	   al.,	  
2012,	  Brejc	  et	  al.,	  1997).	  Most	  hydrogen	  bond	  interactions	  are	  conserved	  in	  the	  vicinity	  of	  the	  carbonyl	  
group	  of	  the	   imidazolidinone	  ring	  of	  the	  chromophore	  (Arpino	  et	  al.,	  2012,	  Brejc	  et	  al.,	  1997,	  Ormo	  et	  
al.,	  1996).	  Two	  residues,	  T203	  and	  E222,	  show	  a	  critical	  role	   in	  the	  chemical	  environment	  for	  chromo-­‐
phore.	   T203	  has	  been	  observed	  with	   two	  different	   conformations:	   in	  one,	   the	   side	   chain	  of	   T203	   can	  
have	  direct	  contact	  with	  the	  tyrosyl	  group	  of	  the	  chromophore;	  in	  the	  other,	  the	  side	  chain	  of	  T203	  ro-­‐
tates	  away	  from	  the	  tyrosyl	  group	  and	  the	  main	  chain	  moves	  towards	  the	  chromophore	  resulting	  in	  the	  
elimination	  of	  direct	  hydrogen	  bond	  interactions	  but	  permitting	  a	  water-­‐mediated	  interaction	  between	  
the	  main	  chain	  carbonyl	  group	  and	  the	  chromophore	  tyrosyl	  group.	  In	  addition,	  the	  side	  chain	  of	  E222	  
has	   shown	   two	   alternate	   conformations	   in	   some	   EGFP	   structures	   (Royant	   et	   al.,	   2011,	   Arpino	   et	   al.,	  
2012).	  	  	  
In	  our	  structural	  analysis	  and	  comparisons,	  CatchER-­‐Ca2+	  and	  CatchER-­‐Gd3+	  have	  similar	  interac-­‐
tions	  around	  the	  chromophore	  as	  shown	  schematically	  in	  Figure	  4.6(b),	  while	  CatchER(apo)	  has	  different	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interactions	  for	  E222	  (Figure	  4.6(a)).	  In	  all	  the	  three	  CatchER	  structures,	  T203	  formed	  a	  water-­‐mediated	  
hydrogen	  bond	  with	   the	  chromophore	   tyrosyl	   via	   the	   second	   type	  of	   conformation	  mentioned	  above.	  
The	  representative	  omit	  map	  of	  D202-­‐D206	  adjacent	  to	  CRO66	  and	  the	  mediating	  water	   for	  hydrogen	  
bond	  in	  CatchER(apo)	  is	  shown	  in	  Figure	  4.3(c).	  This	  type	  of	  interaction	  between	  the	  carbonyl	  group	  of	  
T203	   and	   chromophore	   was	   also	   found	   in	   the	   GFP	   structure	   (PDB	   code:	   1EMB)	   (Figure	   4.6(d)),	   even	  
though	  it	  also	  has	  an	  alternate	  side	  chain	  conformation	  with	  0.15	  occupancy	  which	  can	  form	  the	  direct	  
hydrogen	  bonds	  with	   chromophore	   (Brejc	   et	   al.,	   1997).	   In	   contrast,	   in	   the	   EGFP	   structure	   (PDB	   code:	  
4EUL),	  T203	  only	  forms	  the	  first	  type	  of	  interaction	  (Figure	  4.6(c)).	  	  
Regarding	   the	   side	   chain	   of	   E222,	   the	   conformational	   population	   differs	   in	   the	   three	   CatchER	  
structures:	  only	  one	  conformation	  of	  E222	  was	  observed	  in	  CatchER(apo)	  and	  its	  side	  chain	  is	  considered	  
to	  be	  deprotonated	  and	  forms	  a	  hydrogen	  bond	  with	  S205	  and	  another	  one	  with	  the	  hydroxyl	  group	  of	  
chromophore	  (Figure	  4.6(a));	  in	  CatchER-­‐Ca2+	  and	  CatchER-­‐Gd3+,	  one	  additional	  alternative	  conformation	  
of	  E222	  was	  determined	  which	   lacks	   interactions	  with	  chromophore;	   instead	   it	  participates	   in	   interac-­‐
tions	  with	  a	  network	  of	  water	  molecules	  linking	  to	  Q69	  (Figure	  4.6(b)).	  Recent	  crystallographic	  study	  of	  
EGFP	   has	   revealed	   two	   alternate	   conformations	   for	   E222	   not	   only	   in	   the	   EGFP	   structure	   (PDB	   code:	  
4EUL)	  used	  here	   for	  comparison	  but	   in	  another	   reported	  structure	   (PDB	  code	  of	  2Y0G)	   (Royant	   et	  al.,	  
2011).	   In	   both	   the	   published	   structures,	   E222	   shows	   similar	   interactions	   with	   chromophore	   and	  
surrounding	  environment	  as	  in	  Figure	  4.6(c),	  which	  is	  quite	  similar	  to	  the	  arrangement	  in	  CatchER-­‐Ca2+	  
and	   CatchER-­‐Gd3+.	   However,	   in	   the	   GFP	   structure	   (PDB	   code:	   1EMB),	   one	   conformation	   of	   E222	  was	  
defined	  forming	  hydrogen	  bond	  interactions	  like	  in	  CatchER(apo).	  
Previously,	   the	   profound	  but	   opposite	   effects	   of	   residues	   T203	   and	   E222	  were	   reported	   from	  
mutagenesis	  and	  analysis	  of	  crystal	  structures	  (Heim	  et	  al.,	  1994,	  Ehrig	  et	  al.,	  1995,	  Brejc	  et	  al.,	  1997).	  
Introduction	  of	  T203I	  in	  GFP	  retains	  the	  395	  nm	  peak	  but	  eliminates	  the	  475	  nm	  peak,	  whereas	  GFP	  with	  
E222G	  retains	  the	  475	  nm	  peak	  but	  lacks	  the	  395	  nm	  peak	  (Heim	  et	  al.,	  1994,	  Ehrig	  et	  al.,	  1995).	  Crystal	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structures	  of	  GFP	  and	  EGFP	  revealed	  that	  the	  side	  chain	  of	  T203	  can	  stabilize	  a	  negative	  charge	  on	  the	  
chromophore	  (anionic	  form	  chromophore)	  as	  a	  hydrogen	  bond	  donor	  through	  a	  direct	  hydrogen	  bond	  
with	   the	   chromophore	   tyrosyl,	   but	   the	   carboxylate	  of	   charged	  E222	   can	  maintain	   the	  neutral	   form	  of	  
chromophore	   through	   electrostatic	   repulsion	   and	   the	   hydrogen-­‐bonding	   network	   via	  water	   and	   S205	  
(Brejc	  et	  al.,	  1997).	  In	  the	  CatchER	  structures,	  the	  conformation	  of	  T203	  preferred	  the	  proposed	  proto-­‐
nated	  form	  of	  the	  chromphore.	  The	  hydrogen-­‐bond	  network	  via	  water	  and	  S205	  is	  achieved	  by	  one	  con-­‐
formation	  of	  E222	  in	  deprotonated	  or	  negatively	  charged	  states	  and	  helps	  maintain	  the	  neutral	  form	  of	  
chromophore.	  In	  CatchER-­‐Ca2+	  and	  CatchER-­‐Gd3+,	  even	  though	  the	  other	  conformation	  of	  E222	  does	  not	  
interact	  with	  the	  chromophore	  threonine	  as	   in	  EGFP	  (Ormo	  et	  al.,	  1996,	  Royant	  et	  al.,	  2011,	  Arpino	  et	  
al.,	  2012),	  this	  alternate	  conformation	  with	  almost	  half	  occupancy	  is	  proposed	  to	  be	  protonated	  and	  can	  
no	  longer	  maintain	  the	  neutral	  form	  of	  chromophore.	  Therefore,	  although	  there	  is	  only	  one	  conforma-­‐
tion	  of	  E222	  in	  CatchER(apo),	  we	  suggest	  that	  the	  chromophore	  of	  CatchER	  has	  a	  mixture	  of	  neutral	  and	  
negatively	  charged	  states,	  as	  observed	  in	  wild	  type	  GFP,	  which	  has	  two	  conformations	  of	  T203	  (Brejc	  et	  
al.,	  1997).	  	  
The	   ratio	  of	  neutral	  and	  negatively	   charged	  chromophore	  can	  differ	   in	   the	  CatchER	  structures	  
based	  on	  the	  spectroscopic	  properties.	   In	  the	  absorbance	  spectra,	  addition	  of	  Ca2+	  results	   in	  a	  concur-­‐
rent	   increased	   intensity	  around	  490	  nm	  (increase	  of	  deprotonated	  chromophore)	  and	  a	  decreased	  ab-­‐
sorption	   intensity	   around	   398	   nm	   (decrease	   of	   protonated	   chromophore	   state),	   exhibiting	   an	   optical	  
spectral	  feature	  more	  closely	  resembling	  that	  of	  EGFP,	  as	  shown	  in	  Figure	  4.2(a).	  Tang	  et	  al.	  has	  also	  re-­‐
ported	   that	   the	   presence	   of	   calcium	   results	   in	   a	   decrease	   in	   the	   pKa	   value	   of	   the	   chromophore	   of	  
CatchER	   (Tang	   et	   al.,	   2011),	   suggesting	   that	   the	   chromophore	   in	  CatchER	   is	  more	  deprotonated	  upon	  
calcium	  binding.	  This	  change	  could	  be	  related	  to	  the	  observed	  equilibrium	  shift	  in	  conformational	  popu-­‐
lations	  of	  E222	  in	  CatchER:	  the	  increase	  of	  deprotonated	  chromophore	  on	  calcium	  binding	  is	  likely	  due	  
to	   the	   stabilizing	   capability	   of	   E222	   as	   a	   hydrogen	   bond	   donor	   with	   the	   hydrogen	   bond	   acceptor	   of	  
deprotonated	   T65	   in	   the	   chromophore	   (Figure	   4.6(b)).	   Such	   stabilizing	   effect	   is	   manifested	   by	   the	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protonated	  T65	  in	  the	  chromophore	  (Figure	  4.6(b)).	  Such	  stabilizing	  effect	  is	  manifested	  by	  the	  changes	  
in	  the	  proton	  wire	  network	  between	  apo-­‐	  and	  calcium-­‐loaded	  forms	  of	  CatchER	  and	  EGFP	  as	  shown	  in	  
Figures	  4.6(a)-­‐(c).	  Thus,	  binding	  of	  calcium	  induces	  an	  equilibrium	  shift	  in	  conformational	  populations	  of	  
the	  E222	  side	  chain	  and	   its	  network	  of	   interactions	   through	  two	  water	  molecules	   to	  Q69.	  Overall,	   the	  
crystal	   structures	   of	   CatchER	   have	   reinforced	   support	   for	   the	   proposed	   excited-­‐state	   photon	   transfer	  
pathway	   for	   the	  photoisomerization	  of	  GFP,	  which	  was	  based	  on	   structural	   and	   spectroscopic	   studies	  
(Chattoraj	  et	  al.,	  1996,	  Brejc	  et	  al.,	  1997).	  The	  similar	  observation	  and	  proposed	  interpretation	  apply	  to	  
Gd3+	  induced	  change	  (Figure	  4.2(b)	  and	  Figure	  4.6(b)).	  
No	  significant	  difference	  was	  observed	  for	  L42,	  T43,	  Y143	  and	  T153	  in	  the	  structural	  comparison	  
of	  CatchER(apo)	  with	  CatchER-­‐Ca2+,	  despite	  the	  chemical	  shift	  changes	  related	  to	  Ca2+	  binding	  	  (Tang	  et	  
al.,	  2011)	  shown	  in	  dynamic	  NMR.	  The	  addition	  of	  Ca2+	  leads	  to	  splitting	  of	  one	  resonance	  gradually	  into	  
two	  for	  Q69,	  which	   is	  buried	   inside	  the	  protein	  (Tang	  et	  al.,	  2011).	   In	  both	  CatchER-­‐Ca2+	  and	  CatchER-­‐
Gd3+,	  Q69	   forms	  a	  hydrogen	  bond	  network	   through	   two	  water	  molecules	  with	  E222	  and	   this	  network	  
was	  also	  found	  in	  EGFP	  (PDB	  code:	  4EUL)	  (Figure	  4.6(b)).	  	  However,	  this	  network	  was	  interrupted	  due	  to	  
a	  missing	  water	  molecule	  in	  CatchER(apo)	  (Figure	  4.6(a)).	  Therefore,	  here	  we	  propose	  that	  the	  calcium	  
induced	  change	  in	  optical	  properties	  could	  be	  also	  associated	  with	  the	  Q69	  hydrogen	  bond	  network.	  
4.4.5 Relationship	  between	  Mutations	  of	  the	  Novel	  Metal	  Binding	  Site	  and	  Optical	  
Properties	  
CatchER	  was	  selected	  from	  a	  series	  of	  Ca2+	  sensors	  designed	  by	  introducing	  different	  mutations	  
around	  the	  desired	  Ca2+	  binding	  site,	  designated	  D8,	  D9,	  D10,	  D11	  (CatchER)	  and	  D12	  (Tang	  et	  al.,	  2011).	  
These	  mutants	  all	   show	  an	   increase	   in	   the	  peak	  at	  398	  nm	  and	  a	  decrease	  at	  490	  nm	  to	  different	  ex-­‐
tents.	  D8	  has	  only	  two	  mutations	  of	  S202D	  and	  F223E,	  while	  the	  other	  variants	  have	  additional	  muta-­‐
tions,	  which	   indicated	   that	  S202D	  and/or	  F223E	  might	  play	  an	   important	   role	   in	   the	  conserved	  absor-­‐
bance	   changes	   for	   the	   designed	   proteins.	   Based	   on	   the	   structural	   changes	   around	   the	   chromophore,	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T203	  and	  E222	  are	  two	  key	  residues	  that	  account	  for	  the	  altered	  chemical	  environment	  of	  the	  chromo-­‐
phore.	  The	  effects	  of	  these	  two	  residues	  might	  be	  modified	  by	  the	  mutations	  of	  adjacent	  residues	  S202D	  
and	  F223E.	  However,	  F223E	  has	  no	  direct	  interaction	  with	  Ca2+	  in	  CatchER-­‐Ca2+,	  although	  it	  forms	  a	  wa-­‐
ter-­‐mediated	  hydrogen	  bond	  with	  one	  Gd3+	  in	  CatchER-­‐Gd3+	  structure.	  Instead,	  mutation	  S147E	  appears	  
to	  function	  as	  the	  anion	  for	  interacting	  with	  metal	  cations,	  while	  S202D	  is	  also	  involved	  in	  metal	  coordi-­‐
nation	  based	  on	  our	  crystal	  structures.	  The	  main	  chain	  of	  residues	  202	  to	  206	  has	  shifted	  by	  0.7	  to	  0.9	  Å	  
in	  association	  with	  the	  rotation	  of	  T203	  in	  CatchER	  relative	  to	  EGFP,	  which	  leads	  to	  the	  ionization	  change	  
of	  the	  chromophore	  (Figure	  4.7).	  
4.5 Conclusions	  
The	  binding	  of	  metal	  ions	  Ca2+	  and	  Gd3+	  to	  the	  designed	  calcium	  sensor	  CatchER	  has	  been	  inves-­‐
tigated	   by	   spectroscopic	   methods	   and	   X-­‐ray	   crystallography.	   Both	   the	   kinetic	   assays	   and	   structures	  
demonstrated	  binding	  of	  the	  two	  types	  of	  metal	  ions	  to	  CatchER,	  however,	  there	  were	  unexpected	  dif-­‐
ferences.	  Crystal	  structures	  of	  CatchER	   in	  the	  apo	  form	  and	   in	   its	  complexes	  with	  Ca2+	  and	  Gd3+	  reveal	  
snapshots	   of	   the	   dynamic	   binding	   of	  metal	   ions	   to	   the	   designed	   site	   comprising	   five	   carboxylate	   side	  
chains.	   Both	  Ca2+	   and	  Gd3+	   ions	  were	  observed	   in	   two	   locations	  within	   the	  designed	  binding	   site.	   The	  
high	  (mM)	  concentrations	  of	  Ca2+	  and	  Gd3+	  used	  to	  obtain	  the	  crystal	  structures	  of	  their	  CatchER	  com-­‐
plexes	  resulted	  in	  two	  alternative	  binding	  sites	  for	  each	  metal	  ion	  with	  one	  central	  common	  binding	  site.	  
In	  solution,	  however,	  these	  two	  metal	  ions	  bind	  CatchER	  with	  1:1	  stoichiometry	  and	  micromolar	  affinity.	  
These	  structures	  suggest	  that	  the	  ability	  of	  Ca2+	  ions	  to	  jump	  between	  two	  possible	  binding	  sites	  may	  be	  
partly	  responsible	  for	  the	  fast	  kinetics	  of	  metal	  ion	  binding	  to	  CatchER.	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Abs	  493	  nm	  
[CatchER-­‐Gd]	  
Fluo	  395	  nm	  
[CatchER-­‐Gd]	  
Fluo	  488	  nm	  
[CatchER]/[Gd3+]	  
40	   10	   11.1±2.3	   6.7	  ±	  4.4	   6.5±3.7	   4.0	  
35	   15	   18.0±1.4	   17.5±1.2	   16.4±1.0	   2.3	  
30	   20	   23.0±0.3	   22.8±1.0	   20.5±0.7	   1.5	  
25	   25	   30.8±3.5	   32.7±0.5	   20.0±1.7	   1.0	  
20	   30	   15.7±2.2	   23.6±0.0	   14.4±0.5	   0.6	  
15	   35	   10.4±0.3	   19.5±0.8	   11.4±0.5	   0.4	  


































Table	  4.2	  Crystallographic	  data	  and	  refinement	  statistics	  
Complex	  Name	   CatchER	  (apo)	   CatchER-­‐Ca2+	   CatchER-­‐Gd3+	  	  
X-­‐ray	  source	   APS_22ID	   APS_22ID	   APS_22BM	  
Wavelength	  (Å)	   0.8	   0.8	   1.0	  
Temperature	  (K)	   100	   100	   100	  













Protein	  molecules	  per	  asymmetric	  unit	   1	   1	   1	  
Unique	  reflections	   38048	   70,349	   30,260	  
Rmerge	  (%)	  overall
a	   6.8%	  (22.8%)	   8.1%	  (39.2%)	   8.5%	  (18.5%)	  
<I/sigma>	  overalla	   22.6	  (7.7)	   19.9	  (6.1)	   14.2	  (8.7)	  
Resolution	  range	  	  (Å)	   31.08	  –	  1.66	   50	  –	  1.20	   27.13	  –	  1.78	  
Completeness	  (%)	  overalla	   99.1%	  (93.6%)	   99.2%	  (100%)	   98.3%	  (93.8%)	  
Rwork	   0.181	   0.150	   0.196	  
Rfree	  	   0.203	   0.191	   0.219	  
No.	  of	  protein	  atoms	  	  
(includes	  alternative	  conformations)	  
1956	   1967	   1922	  
No.	  of	  H2O	  molecules	  	  
(total	  occupanciesb)	  
167	  (151)	   197	  (191.5)	   138	  (128.5)	  
No.	  of	  ions	  (occupancy)	   1	  (1.0)	   2	  (0.5/0.5)	   2	  (0.7/0.3)	  
RMS	  deviation	  from	  ideality	   	  
Bonds	  (Å)	   0.012	   0.012	   0.014	  
Angle	  distance	  	   1.527d	   0.031c	   1.594d	  
Average	  B-­‐factors	  (Å2)	   	  
Main	  chain	  atoms	   17.46	   16.60	   20.40	  
Side	  chain	  atoms	   19.34	   20.52	   22.01	  
H2O	   25.47	   28.80	   25.79	  
Ions	   43.74	   35.67	   37.56	  
Ramachandran	  plots	  results	   	  
Number	  of	  residues	  in	  favored	  region	  







aValues	  in	  parentheses	  are	  given	  for	  the	  highest	  resolution	  shell	  
bTotal	  occupancies	  are	  the	  sum	  of	  calculated	  occupancies	  of	  all	  the	  atoms	  or	  ions.	  
cThe	  angle	  rmsd	  in	  SHELX97	  is	  indicated	  by	  distance	  in	  Å	  

















Ca2+(1)	   Ca2+(2)	  
E147/OE2	   30.76/1.0	   1.9	   2.1	  
D202/OD1	   18.84/1.0	   3.0	   3.2	  
D202/OD2	   27.29/1.0	   2.6	   2.8	  
H2O1	   35.36/1.0	   3.1	   	  
H2O2	   31.95/1.0	   2.5	   	  
H2O3	   25.38/1.0	   1.8	   	  
H2O4	   44.32/0.5	   2.5	   3.0	  
H2O5	   25.02/1.0	   	   2.1	  







Gd3+(1)	   Gd3+(2)	  
E147/OE2	   30.51/1.0	   2.2	   	  
D202/OD1	   22.52/1.0	   2.6	   	  
D202/OD2	   30.51/1.0	   2.5	   	  
E204/OE1	   32.69/1.0	   2.6	   3.1	  
E204/OE2	   29.53/1.0	   	   3.1	  
H2O1	   33.89/1.0	   2.1	   	  
H2O2	   24.74/1.0	   	   2.3	  






























50.00	   3.58	   5088.0	   187.5	   37.2	   0.971	   0.052	   0.064	  
3.58	   2.84	   2732.9	   116.4	   21.1	   0.968	   0.066	   0.076	  
2.84	   2.48	   1118.7	   50.3	   13.5	   0.974	   0.072	   0.081	  
2.48	   2.25	   754.5	   33.6	   12.6	   1.050	   0.076	   0.081	  
2.25	   2.09	   584.7	   32.0	   12.6	   0.931	   0.088	   0.091	  
2.09	   1.97	   427.2	   25.7	   12.3	   0.960	   0.103	   0.107	  
1.97	   1.87	   277.3	   19.7	   11.7	   0.956	   0.123	   0.119	  
1.87	   1.79	   176.9	   14.8	   11.3	   1.041	   0.156	   0.147	  
1.79	   1.72	   120.3	   13.2	   11.2	   1.015	   0.197	   0.183	  
1.72	   1.66	   95.3	   12.4	   10.9	   0.987	   0.228	   0.224	  

















50.00	   2.59	   15117.6	   803.1	   245.3	   0.901	   0.060	   0.071	  
2.59	   2.05	   4838.3	   172.0	   34.5	   1.098	   0.074	   0.084	  
2.05	   1.79	   2084.5	   106.1	   23.6	   0.955	   0.098	   0.110	  
1.79	   1.63	   811.5	   39.3	   11.3	   1.094	   0.128	   0.147	  
1.63	   1.51	   448.4	   23.4	   9.4	   1.124	   0.157	   0.175	  
1.51	   1.42	   262.5	   16.1	   8.6	   1.122	   0.210	   0.224	  
1.42	   1.35	   163.4	   12.6	   8.5	   1.077	   0.281	   0.295	  
1.35	   1.29	   120.5	   11.3	   8.8	   1.108	   0.317	   0.331	  
1.29	   1.24	   87.4	   10.7	   9.2	   1.063	   0.351	   0.370	  
1.24	   1.20	   64.1	   10.5	   9.5	   1.013	   0.392	   0.408	  

















50.00	   3.83	   2142.8	   130.3	   21.5	   0.951	   0.065	   0.071	  
3.83	   3.04	   1484.5	   109.5	   15.9	   0.980	   0.086	   0.088	  
3.04	   2.66	   611.6	   47.1	   8.3	   0.951	   0.091	   0.094	  
2.66	   2.42	   379.2	   29.5	   6.3	   0.912	   0.093	   0.092	  
2.42	   2.24	   283.8	   22.6	   5.9	   0.930	   0.102	   0.101	  
2.24	   2.11	   217.9	   16.8	   5.3	   1.048	   0.115	   0.107	  
2.11	   2.00	   171.4	   13.7	   5.0	   0.973	   0.118	   0.108	  
2.00	   1.92	   122.6	   10.2	   4.7	   0.989	   0.131	   0.114	  
1.92	   1.84	   78.8	   7.1	   4.4	   1.004	   0.162	   0.149	  
116 
1.84	   1.78	   52.8	   6.1	   4.7	   1.008	   0.185	   0.156	  
All	  reflections	   572.3	   40.4	   8.4	   0.974	   0.085	   0.079	  












Figure	   4.1	   Structure	   of	   CatchER	   (green	   cartoon)	   indicating	   the	   locations	   of	   mutated	   residues	   (red	  




Figure	  4.2	  Absorbance	  spectra	  of	  CatchER	  and	  metal	  binding	  analysis	  via	   fluorescence	  spectroscopy.	  
(a)	  Absorbance	  response	  of	  CatchER	  to	  5	  mM	  Ca2+.	  20	  µM	  CatchER	  with	  5	  µM	  EGTA	  (dashed	  line)	  in	  10	  
mM	  Tris	  pH	  7.4	  and	  the	  same	  CatchER	  sample	  with	  5	  mM	  Ca2+	  added	  (solid	  line).	  Addition	  of	  Ca2+	  pro-­‐
duces	  more	  of	  the	  anionic	  chromophore	  (increase	  in	  488	  nm	  absorbance	  peak)	  and	  less	  of	  the	  neutral	  
chromophore	   (decrease	   in	   the	  395	  nm	  absorbance	  peak).	   (b)	  Absorbance	   response	  of	  CatchER	   to	  200	  
μM	  Gd3+.	  A	  20	  μM	  sample	  of	  CatchER	  was	  prepared	  in	  20	  mM	  PIPES	  pH	  6.8.	  	  The	  dashed	  line	  represents	  
the	  sample	  with	  5	  μM	  EGTA	  and	  the	  solid	   line	   is	   the	  same	  sample	  with	  200	  μM	  Gd3+	  added.	   (c	  and	  d)	  
Fluorescence	  response	  of	  CatchER	  to	  Ca2+	  and	  Gd3+	  excited	  at	  488	  nm	  with	  emission	  at	  510	  nm	  with	  inset	  
binding	  curves.	  Normalized	  fluorescence	  response	  for	  Ca2+	  and	  Gd3+	  was	  fitted	  with	  a	  1:1	  binding	  equa-­‐
tion	  producing	  Kd	  values	  of	  227.0	  ±	  3.3	  µM	  and	  177.0	  ±	  13.6	  µM	  for	  Ca
2+	  and	  Gd3+,	  respectively.	  (e)	  Over-­‐
lay	  of	  the	  absorbance	  spectrum	  of	  20	  µM	  CatchER	  with	  5	  µM	  EGTA	  (dashed	  line)	  and	  20	  µM	  EGFP	  (solid	  
line)	  in	  10	  mM	  Tris	  pH	  7.4.	  (f)	  Binding	  stoichiometry	  of	  CatchER	  to	  Gd3+	  via	  Job	  Plot.	  The	  relative	  amount	  
of	  CatchER	  bound	  to	  Gd3+	  was	  determined	  using	  fluorescence	  and	  absorbance	  intensity	  changes	  in	  the	  
absence	  and	  presence	  of	  Gd3+.	  Concentrations	  of	  CatchER	  were	  40,	  35,	  30,	  25,	  20,	  15,	  and	  10	  µM	  (actual	  
concentrations	  via	  280	  nm	  absorbance	  peak	  were	  38,	  35,	  30,	  24,	  20,	  15,	  and	  10.5	  µM).	  The	  total	  molar	  




Figure	  4.3	  Selected	  Fo-­‐Fc	  omit	  map	  in	  CatchER-­‐Ca
2+	  CatchER-­‐Gd3+	  and	  CatchER(apo).	  (a)	  Fo-­‐Fc	  omit	  map	  
showing	  the	  chromophore	  from	  CatchER-­‐Ca2+	  contoured	  at	  4.0σ.	  (b)	  Fo-­‐Fc	  omit	  maps	  showing	  two	  con-­‐
formations	  of	  E222	  from	  CatchER-­‐Gd3+	  and	  two	  water	  molecules	  contoured	  at	  3.0σ.	  (c)	  Fo-­‐Fc	  omit	  map	  
showing	  residues	  from	  D202	  to	  A206	  from	  CatchER(apo)	  and	  one	  water	  molecule	  contoured	  at	  3.0σ	  with	  
chromophore	  (CRO66).	  The	  dotted	  lines	  represent	  hydrogen	  bond	  interactions.	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Figure	  4.4	  Hydrogen	  bond	  interactions	  at	  the	  designed	  Ca2+	  binding	  site	  in	  CatchER	  structures	  and	  su-­‐
perposition	  of	  CatchER-­‐Ca2+	  and	  CatchER-­‐Gd3+.	  (a)-­‐(c)	  The	  hydrogen	  bond	  interactions	  at	  the	  designed	  
Ca2+	  binding	  site	  in	  CatchER	  strucures.	  The	  protein	  is	  represented	  as	  yellow,	  light	  blue	  and	  cyan	  sticks	  in	  
CatchER(apo),	  CatchER-­‐Ca2+,	  and	  CatchER-­‐Gd3+,	  respectively.	  Ca2+,	  Gd3+	  and	  water	  molecules	  are	  repre-­‐
sented	  as	  spheres.	  The	  numbers	  (0.5/0.5,	  0.7/0.3)	  give	  the	  relative	  occupancy	  of	  the	  alternate	  positions	  
of	  the	  Ca2+,	  Gd3+	  ions,	  respectively.	  The	  interatomic	  (non-­‐hydrogen)	  distance	  range	  of	  2.6-­‐3.2	  Å	  was	  used	  
for	  hydrogen	  bonds	   (black	  dotted	   lines).	   Shorter	  distances	   in	   the	   range	  of	  2.0-­‐2.4	  Å	   (red	  dotted	   lines)	  
suggest	  coordination	  with	  a	  metal	  ion.	  The	  coordinating	  waters	  are	  numbered	  as	  in	  Table	  3.	  (d)	  Super-­‐
position	  of	  CatchER-­‐Ca2+	  and	  CatchER-­‐Gd3+;	  the	  protein	  backbones	  are	  shown	  as	  grey	  cartoons	  and	  the	  
chromophore	  (CRO66)	  is	  represented	  as	  green	  sticks.	  The	  five	  mutated	  residues	  and	  ions	  are	  shown	  in	  
sticks	  and	  spheres	  in	  lightblue	  for	  CatchER-­‐Ca2+	  and	  cyan	  for	  CatchER-­‐Gd3+.	  The	  cyan	  arrow	  points	  to	  the	  
major	  site	  for	  Gd3+.	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Figure	   4.6	   Scheme	   of	   the	   hydrogen	   bond	   interactions	   around	   chromophore	   in	   CatchER	   structures,	  
EGFP	  and	  GFP.	  (a)-­‐(d)	  Scheme	  of	  the	  hydrogen	  bond	  interactions	  between	  chromophore	  and	  surround-­‐
ing	  residues	  and	  water	  molecules	  (W)	  in	  CatchER(apo),	  CatchER-­‐Ca2+	  or	  Gd3+,	  EGFP	  and	  GFP.	  Hydrogen	  
bonds	  are	  shown	  as	  dashed	  lines.	  The	  interatomic	  (non-­‐hydrogen)	  distance	  range	  of	  2.6-­‐3.2	  Å	  was	  used	  
for	  hydrogen	  bonds.	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Figure	  4.7	  Comparison	  of	  EGFP	  and	  CatchER(apo)	  at	  the	  chromophore	  and	  nearby	  residues.	  Residues	  
202	  to	  206	  of	  EGFP	  and	  CatchER(apo)	  are	  shown	  as	  sticks	   in	  grey	  and	  yellow,	  respectively.	  S202/D202	  
and	   Q204/E204	   label	   mutated	   residues	   in	   EGFP/CatchER(apo).	   The	   main	   chain	   from	   residues	   202	   to	  




Figure	  4.8	  Fluorescence	  response	  of	  CatchER	  to	  Ca2+	  and	  Gd3+	  excited	  at	  395	  nm	  (a	  and	  c)	  and	  fitted	  
normalized	   intensity	   (b	   and	  d).	  CatchER	  experiences	  a	   large	   fluorescence	   increase	  when	  titrated	  with	  
Ca2+	   and	  with	   Gd3+.	   The	   normalized	   fluorescence	  was	   fitted	  with	   the	   1:1	   binding	   equation	   to	   give	   Kd	  




Figure	  4.9	  (a-­‐b)	  Flexible	  loop	  region	  comprising	  residues	  155-­‐159.	  CatchER-­‐Gd3+	  is	  shown	  in	  a	  cyan	  car-­‐
toon	   representation	   with	   the	   mutated	   residues	   of	   the	   designed	   Ca2+	   binding	   site	   in	   red	   sticks	   and	  
chromophore	  colored	  by	  CPK.	  The	  alternative	  conformations	  of	  residues	  155-­‐159	  are	  indicated	  in	  cyan	  
and	  orange	  by	  CPK.	   In	  the	  circle,	  Fo-­‐Fc	  omit	  map	  (in	  green)	  for	  the	  two	  conformations	  of	  residues	  155-­‐
159	  contoured	  at	  2.0σ.	   In	  EGFP	  (PDB	  code:	  4EUL)	  and	  GFP	  structure	   (PDB	  code:	  2WUR),	  only	  the	  con-­‐




Figure	   4.10	   Structure	   validation	   by	   Ramachandran	   plots	   for	   the	   three	   CatchER	   structures,	   as	   per-­‐
formed	  by	  PROCHECK	  CCP4i	  suite	  program.	  (Potterton	  et	  al.,	  2003)	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Appendix	  A:	  List	  of	  Crystal	  Structures	  
Protein	   ligand	   PDB	  accession	  code	   Resolution	  (Å)	  
PRL76V	   darunavir	   3PWM	   1.46	  
PRL76V	   saquinavir	   3PWR	   1.45	  
PRP51	   darunavir	   4NPT	   1.66	  
PRP51	   	   4NPU	   1.50	  
CatchER	   Gd3+	   4L12	   1.78	  
CatchER	   	   4L13	   1.66	  
CatchER	   Ca2+	   4L1I	   1.20	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